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Background, Rationale and General Purpose: Several seminal observations suggest that AMPK 
mediates vascular tone: 1) in endothelial cell culture and in vitro isolated protein experiments, activation 
of AMPK stimulates nitric oxide (NO) production via phosphorylation of endothelial nitric oxide 
synthase (eNOS), 2)  stimuli associated with AMPK activation relax isolated vascular smooth muscle 
preparations from healthy animals, and 3) acute activation of AMPK in vivo induces hypotension in 
normotensive animals, an effect that could be indicative of reduced vascular tone. Together these findings 
prompt the logical hypothesis that acute activation of AMPK induces relaxation that is both endothelium-, 
NO-dependent and also vascular smooth muscle dependent; however the direct effects of AMPK 
activation on the regulation of vascular tone in the context of intact healthy arteries in vitro or in situ have 
not been tested. AMPK activation is dysregulated in essential hypertension and aging, conditions both 
characterized by vasomotor dysfunction. The integrity of AMPK-mediated vasomotor effects has not 
been evaluated in any model of vascular dysfunction or in the presence of AMPK dysregulation, and so it 
is unknown if or to what extent, activation of AMPK alters vascular tone in vessels with these 
impairments. The mechanisms of AMPK-mediated vasomotor effects have also not been delineating in 
healthy or dysfunctional arteries. Studying basic vascular signalling mechanisms in both healthy and 
dysfunctional models is important for understanding physiological function and regulation of vascular 
tissue, as well as to understand vascular pathology and aid in the development of therapeutic 
interventions. Collectively these considerations present compelling reasons to investigate the role of 
AMPK in vasomotor function in health and disease. The unifying purpose of this thesis was therefore to 
investigate the role of AMP-activated protein kinase in regulating vascular tone in arteries of healthy, 
hypertensive and aged rats. 
Experimental Approach and Main Findings:  The global objective of the thesis is satisfied by four 




function, biochemical analyses and in vivo hemodynamic assessments. In Study 1, we characterize the 
basic nature of the vasomotor response generated acutely by the pharmacological AMPK activator 
AICAR in vitro in isolated aorta of normotensive (Wistar-Kyoto rats; WKY) and hypertensive rats 
(Spontaneously Hypertensive rats; SHR), and the mechanisms mediating these responses. In these 
experiments, acute activation of AMPK using AICAR induced dose-dependent relaxation of isolated, 
precontracted arteries from WKY and SHR that was dependent in part on both the endothelium and 
vascular smooth muscle, and vasorelaxation to AICAR was enhanced in aortic rings of SHR versus those 
of WKY. In WKY, the endothelium-dependent component of relaxation to AICAR was solely NO-
mediated, while in SHR it was dependent on both elevated NO-bioactivity and blunted COX-dependent 
contraction. In Study 2, we investigate the mechanisms responsible for AMPK-mediated inhibition of 
endothelium- and cyclooxygenase-dependent vasocontraction in aorta from WKY and SHR (a response 
enhanced in arteries of hypertensive rats that contributes to vasomotor dysfunction). Pre-activation of 
AMPK blunted endothelium-dependent contractions to acetylcholine in isolated, non-precontracted WKY 
and SHR aortic rings. The mechanisms accounting for this effect of AICAR were endothelium-specific, 
occurring via inhibition of the ACh-stimulated production/release of 6-keto-prostaglandin F1α, the major 
product of prostacyclin, which is the key prostanoid responsible for endothelium-dependent contractions 
in aorta of WKY and SHR. AMPK activation had no effect on vascular smooth muscle responsiveness to 
TP-receptor agonists, ruling out a contribution of vascular smooth muscle mechanisms. In Study 3, we 
examine responses and mechanisms associated with acute pharmacological AMPK activation on vascular 
tone of isolated mesenteric resistance arteries in vitro, and on in vivo hemodynamics in WKY and SHR. 
These experiments revealed that administration of AICAR acutely in vivo acutely reduced blood pressure 
by ~70mmHg in SHR and this effect was partly NO-dependent. In contrast, AICAR had no effect on 
blood pressure in WKY. Activation of AMPK also produced vasodilation of isolated, precontracted WKY 
and SHR resistance mesenteric arteries in vitro, and this was dependent on NO to a greater extent in SHR 
than in WKY. Together, the parallel reductions in blood pressure in vivo and relaxation of isolated arteries 




effects. Finally, Study 4 characterizes the basic vasodilatory responses to acute AMPK activation and 
mechanisms associated with these responses in aorta from aged animals and their young counterparts 
(male Sprague Dawley rats) to glean insight using an additional model of vasomotor dysfunction. In this 
study, acute activation of AMPK using AICAR generates relaxation in a dose-dependent manner that is 
partly endothelium-, NO-dependent and partly reliant on vascular smooth muscle in precontracted aorta of 
both young and aged rats. Similar to the findings of Study 1 in SHR versus WKY, vasodilatory response 
to AICAR were also enhanced in dysfunctional aorta of aged rats versus healthy aorta of young animals. 
Other agents shown to activate AMPK in other tissues and models, the anti-diabetic drug metformin and 
the polyphenol resveratrol, generated varying amounts of relaxation in vascular smooth muscle of young 
and aged aortic rings. These effects were only associated with AMPK activation in rings treated with 
metformin but not resveratrol. 
Conclusions and Perspectives: These findings are the first to characterize the vasomotor responses 
generated by acutely activating AMPK in intact arteries of any hypertensive or aging model, and to 
delineate mechanisms mediating these responses in healthy and dysfunctional vessels. Despite vasomotor 
dysfunction and dysregulated AMPK activity in arteries of hypertensive and aged rats, acute AMPK 
activation still generates robust relaxation responses via endothelium- and NO-dependent relaxation, 
inhibition of enhanced endothelium-dependent contractions in SHR, and direct relaxation of the vascular 
smooth muscle; effects that would aid in reversing the dysfunctional characteristics of arteries from these 
animals, and may recommend AMPK as a useful therapeutic target for interventions aimed at improving 
vasomotor function. Future studies will be necessary to reveal whether AMPK plays a role in generating 
acute changes in vessel tone induced by AMPK-activating physiological stimuli in situ (i.e. such as shear 
stress during exercise). Together these data continue to support AMPK as a novel regulator of vascular 
tone, yield valuable, novel, mechanistic insight into AMPK-mediated regulation of vasomotor function in 
arteries during health, disease and aging, and highlight the need for continued investigation into a 
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1.1 Orientation to the thesis 
1.1.1 Global Purpose and Approach 
The unifying purpose of this thesis is to investigate the role of AMPK in regulating arterial vascular 
tone in models of health and dysfunction (essential hypertension and aging). Our primary experimental 
approach employs in vitro isolated artery preparations to evaluate vasomotor function while 
pharmacologically manipulating AMPK activation and vasomotor pathways of interest. These measures 
are complimented with biochemical analyses and in vivo hemodynamic assessments. 
1.1.2 Thesis Organization 
The thesis begins with background information, rationale for the thesis topic, an overview of the 
thesis studies (the specific objectives and hypotheses for each study), and descriptions of the major 
models and methods chosen for the experiments. The thesis is comprised of four main studies that are 
each presented in manuscript form. In Study 1, entitled Endothelium-dependent vasorelaxation to the 
AMPK activator AICAR is enhanced in aorta from hypertensive rats and is NO- and EDCF-dependent 
(published in the American Journal of Physiology Heart and Circulatory Physiology), we investigate the 
vasomotor responses generated by acutely activating AMPK in isolated aorta of normotensive and 
hypertensive rats in vitro, and the mechanisms associated with these responses. In Study 2, entitled 
Activation of AMP-activated protein kinase blunts contractions to acetylcholine by endothelium-
dependent mechanisms in aorta of normotensive and hypertensive rats, we explore mechanisms 
mediating the effects of AMPK activation on endothelium-dependent contractions (a hallmark feature of 
vasomotor dyfunction in hypertension), using isolated aorta of normotensive and hypertensive rats. Study 
3 is entitled AMPK activator AICAR acutely lowers blood pressure and relaxes resistance arteries of 




blood pressure in response to acute AMPK activation in vivo in normotensive and hypertensive animals, 
and the acute vasomotor effects of AMPK activation on isolated mesenteric resistance arteries of these 
animals in vitro. The final study (Study 4), entitled Vasomotor responses generated by acute exposure to 
AMP-activated protein kinase activators in isolated aorta of young and aged rats, mirrors Study 1 in that 
we evaluate the vasodilatory effects of acute AMPK activation, but in this study we use isolated aorta 
from young and aged rats. Each experimental chapter is also succeeded by an addendum containing 
related data that is not part of the manuscript. The thesis concludes with a general summary of the main 
findings, conclusions, overall interpretation, potential implications, future directions, limitations, and 
perspectives derived from the collective body of work.    
 
1.2 Preface: The physiological and pathological big picture -- the importance of studying vascular 
signalling systems in health and disease  
The arterial wall is a dynamic tissue that is capable of sensing, integrating and responding to 
complex patterns of environmental signals to serve many important physiological functions. It consists of 
three distinct layers that include (moving from the lumen to vessel wall exterior): 1) the tunica intima, a 
single layer of endothelial cells anchored to a connective tissue matrix, 2) the tunica media, composed of 
vascular smooth muscle (VSM) cell layers aligned circumferentially around the vessel lumen, and 3) the 
tunica adventia, a membrane of collagen and elastin fibers overlayed by perivascular fat, nerves and 
fibroblasts
[158]
. Arteries play an essential role in maintaining homeostatic control of hemostasis, 
thrombogenesis and fibrinolysis, vascular permeability, tissue perfusion, and vascular resistance
[62,65,89]
. 
The endothelium is the central orchestrator of many of these functions, and accordingly, dysregulation of 
the endothelial function is particularly debilitating. Endothelial dysfunction is a hallmark feature of 













, and contributes to the progression and 
exacerbation of a host of overt cardiovascular diseases including atherosclerosis
[231]








, and peripheral vascular disease
[84]
 (Figure 1-1). Cardiovascular disease is 
a major health concern, accounting for ~ 30% of the human mortality rate in Canada
[105]
  and globally
[255]
, 
and represents a substantial societal financial burden that costs the Canadian economy more that 22 
billion dollars annually
[106]. 
Since the signalling systems within and between vascular cells are the underlying mechanisms 
that dictate the capacity of the vasculature to perform its physiological functions, it is not surprising that 
investigations aimed at understanding the basic mechanisms that govern vascular function in health and 
disease have become an important research priority. Substantial progess has been made towards 
understanding vascular signalling processes in physiological and pathophysiological circumstances, and 
in the translation of this knowledge into treatment strategies; however even with these advancements,  
existing therapeutic interventions still do not completely restore proper endothelial function, or only 
address some of the contributing factors [62]. Therefore, continuing to study novel and existing vasomotor 
signalling mechanisms is important for moving forward, to both expand our comprehension of the 
normal physiological function of the vasculature, and to uncover how vascular signalling processes are 
compromised in disease to facilitate the development of more efficacious therapeutic strategies. The aim 
of this thesis is to understand how a novel signalling pathway contributes to the regulation of vascular 
tone in healthy and in dysfunctional arteries, with the greater goal of ultimately enhancing our 
comprehension of vascular function in physiological and pathophysiological conditions.  
 
1.3 Thesis focus: the regulation of vascular tone 
Although vascular tissue has many important functions, the focus of this thesis is on regulation of 
vascular tone. The ability of arteries to properly regulate vessel tone is also indicative of the health of 
vascular signalling systems, and thus provides some insight regarding their ability to carry out other 
functions (such as anti-thrombotic, anti-inflammatory, anti-proliferative roles). Vascular tone is the net 




capacity to tightly regulate vascular tone is important, because it confers upon the arterial system the 
ability to divert and direct blood flow to meet metabolic demand, and to contribute to the homeostatic 
regulation of blood pressure by maintaining appropriate levels of vascular resistance
[158]
. The net level of 
vascular tone is ultimately determined by the balance between the multiple vasodilatory and 
vasoconstrictory signals that converge on the contractile machinery of the VSM 
[89]
 (Figure 1-1). In situ, 
signal input to the VSM originates from the vessel lumen via the endothelium (i.e. the endothelium senses 
physical, hormonal, and chemical signals in the blood stream and generates signal output to the 
underlying VSM) and from other sources that act on the VSM directly (i.e. neural input, pressure 
changes; Figure 1-1). In vitro, vascular tone of isolated arteries can be manipulated using endothelium-
dependent and endothelium-independent (VSM dependent) agonists to study endothelial and VSM 
vasomotor signalling pathways in isolation. The following section describes the vascular signalling 
systems of the endothelium and VSM that are involved in regulating vascular tone in healthy arteries, and 
then describes how these become dysfunctional in essential hypertension and aging. 
 







Figure 1-1. Regulation and function of the vascular wall, and its dysregulation in cardiovascular 
disease. The arterial wall is comprised of endothelial and vascular smooth muscle cell layers. External 
signals act via the endothelium or directly on the VSM to influence vessel tone, which is important for 
regulating vascular resistance, tissue perfusion and contributes to the maintenance of blood pressure. The 
endothelium is also a central regulator of other important functions of the vascular wall, such as 
thrombosis and fibrinolysis, vascular inflammatory responses, VSM growth and proliferation and barrier 
function. Dysregulation of vascular function is a hallmark feature that co-exists in the presence of 
cardiovascular disease risk factors, and ultimately contributes to the development of cardiovascular 
disease. See text for further details. 
 
1.3.1 Endothelium-derived vasomotor signals 
In 1980, Furchgott and Zawadski performed a seminal experiment that demonstrated for the first 
time the importance of endothelium in directing VSM tone 
[76]
. Extensive research in endothelial biology 
over the 30 years since then has revealed that endothelial cells sense and respond to signals including 
physical factors (shear stress, changes in pressure), substances released from nerves (autonomic, sensory) 
and platelets, pH changes, circulating hormones, vasoactive drugs, and cytokines
[62]
. Exposure to these 




(endothelium derived relaxing factors; EDRFs)
[55]
 and vasoconstrictory (endothelium-derived contracting 
factors; EDCFs)
[62]
 signalling intermediates that act on the VSM. EDRFs produced and released by the 
endothelium include nitric oxide (NO), COX-derived prostacyclin (PGI2), adenosine, hydrogen peroxide, 
epoxyeicosatrienoic acids (EETs), C-natriuretic peptide (CNP) and endothelium-derived hyperpolarizing 
factors (EDHFs; a broad term for substances including H2S, CO etc)
[62,216]
.  EDCFs generated by the 
endothelium can include substances such as angiotensin II, endothelin-1, uridine adenosine 
tetraphosphate, superoxide anion, 20-hydroxyeicosatetraenoic acid (20-HETEs) and other COX-derived 
endoperoxides and prostanoids (prostaglandin H2 (PGH2), prostacyclin (PGI2), thromboxane A2 (TxA2), 
prostaglandin F1α, prostaglandin E2 and others)
[62]
. EDRFs and EDCFs diffuse in a paracrine fashion to the 
underlying VSM to stimulate relaxation or contraction respectively, and maintaining a proper balance 
between EDRF and EDCF signalling is important for healthy vasomotor function and regulation of 
vascular tone. The particular compliment of vasoactive factors generated by the endothelium varies and is 
dependent upon the agonist/stimulus applied, on the arterial bed involved (i.e. heterogeneity exists in 
vasoactive factors generated to the same stimulus across vascular beds) and on the health status of the 
vessel (diseased endothelium generate a different compliment of vasoactive factors compared to their 
health counterparts) 
[229]
. For example: of the EDRFs, NO is the major contributor to vasorelaxation in 
large conduit arteries 
[64,144,231]
, where as this predominance is offset by the contribution of EDHFs in 
resistance vasculature 
[216]
; although the production and release of vasoconstrictor COX-derived 
prostanoids are observed in healthy blood vessels and likely play a role in the physiological regulation of 




Of the EDRFs and EDCFs that contribute to vascular tone, the signalling systems regulating NO 
and COX-derived prostanoids will be the focus of this thesis. These two systems are of particular interest 
because reduced NO bioavailability and enhanced endothelium-COX-EDCF-TP-receptor mediated 




hypertension and aging 
[62,65]
, and these are the main pathways of interest in terms of their potential 
interaction with our enzyme of interest (AMPK). Thus for clarity and brevity, only the vasomotor 
signalling systems pertaining to NO and COX-derived prostanoids will be described in detail in the 
following section. Although mechanical forces like fluid shear stress and hormonal stimuli play a major 
role in the physiological regulation of vascular tone in vivo via activation of endothelium-dependent 
signalling mechanisms, G-protein coupled receptor agonists also contribute to the regulation of vascular 
tone, and are useful for studying common endothelial signalling systems in vitro (which was the approach 
used to evaluate vasomotor pathways in the thesis experiments). Therefore the following discussion also 
focuses on how these systems are modulated by G-protein coupled receptor agonists. 
1.3.2 Endothelium-derived vasomotor signals: a focus on nitric oxide and cyclooxygenase-
derived prostanoids 
The production of NO and COX-derived prostanoids by arterial endothelium can be initiated by 
agonists such as acetylcholine, bradykinin, adenine nucleotides (ATP and ADP) and others that stimulate 
specific G-coupled protein receptors (i.e. M3-muscarinic, B2- bradykinin, P2Y-purigenic receptors 
respectively) on the endothelial cell surface 
[55,190,230]. G-proteins exist as several different subtypes, and 
the receptor/G-proteins combination determines the downstream signalling processes initiated. These 
downstream effects typically include activation of protein kinase signalling cascades and/or the release of 
calcium from intracellular stores. Gi (pertussis toxin-insenstive, coupled to serotonin, thrombin, 
sphingosine-1-phosphate receptors) initiate PI3K-Akt/PKB kinase signalling cascades
[55,190,230]
; Gs 
(responsive to shear stress) activate PI3K-Akt/PKB cascade as well as adenylate cyclase-cAMP mediated 
activation of protein kinase A (PKA)
[190]
; and Gq (pertussis toxin-sensitive, coupled to bradykinin, 
purigenic, muscarinic receptors) activate phospholipase Cβ-mediated production of IP3 and DAG from 
membrane phospholipids. In the case of Gq stimulation, IP3 acts on IP3-sensitive receptors on the 
endoplasmic reticulum (ER) to trigger Ca
2+
 release from intracellular stores 
[55,190,230]
. Elevation of 
endothelial [Ca
2+




COX-derived prostanoids, where as the protein kinase signalling cascades contribute to production of 
NO. 
Nitric oxide 
NO is produced by endothelial nitric oxide synthase (eNOS) from L-arginine, oxygen, and 
NADPH in the presence of heat shock protein 90, and FMN, FAD and BH4 co-factors 
[55,190]
. eNOS is 
activated by increases in [Ca
2+





calmodulin binds to eNOS and stimulates NO production by increasing the efficiency of electron flow 
through the eNOS active complex
[55]
. eNOS can also be activated covalently upon phosphorylation at its 
serine 1177 and serine 633 residues by upstream kinases such as PI3K-Akt/PKB, CaMKII, PKA, or 
AMPK 
[55,190]
. NO presumably diffuses across the intracellular space or through gap junctions to the VSM 
where it stimulates relaxation via activation of soluble guanylate cyclase (sGC) in the VSM
[190,230,231].  NO 
can also contribute to relaxation via other mechanisms independently of sGC, such as by direct activity on 
potassium channels (BKCa, Kv, KATP; promoting K
+









 and SERCA (to promote re-uptake of intracellular Ca
2+
 and relaxation) via protein 
nitrosylation 
[34]
 in the VSM (mechanisms of VSM relaxation will be discussed in more detail below). The 







Figure 1-2. Endothelium- and nitric oxide-dependent regulation of vascular tone. See text for details. 
 
Cyclooxygenase-derived endoperoxides and prostaglandins 
Elevation of endothelial [Ca
2+
]i by agonist-mediated mechanisms, or via compounds that bypass 
agonist-dependent machinery to facilitate the entrance of extracellular Ca
2+
 (i.e. calcium ionophores like 
A23187), stimulate the production and release of COX-derived prostanoids. The current working 
hypothesis for the signalling mechanisms mediating agonist-stimulated prostanoid production by the 
endothelium is depicted in Figure 1-3. Briefly, stimulation of Gq-coupled receptors (by ACh, bradykinin, 
adenine nucleotides) results in IP3-mediated release of Ca
2+
 from the ER (described above). Although not 
yet demonstrated in endothelial cells, results from experiments in other cell types suggest that depletion of 
ER Ca
2+
 content triggers the release of Ca
2+
 influx factor (CIF) from the ER 
[177]
, and that CIF displaces 
calmodulin from its inhibitory association with Ca
2+






Activated endothelial iPLA2 then releases lysophospholipids from membrane lipids that interact with 
store-operated Ca
2+
 channels on the endothelial cell membrane to permit the entrance of extracellular Ca
2+
 
into the cytoplasm 
[12,195,250]
. This influx of Ca
2+
 actives cytosolic phospholipase A2 α (cPLA2; a Ca
2+
-
dependent isoform), which liberates arachondonic acid from lipid membranes to act as a substrate for 
COX 
[63,250]
. COX-1 and COX-2 isoforms both generate endoperoxides such as PGH2 from arachadonic 
acid. PGH2 is the central substrate for the family of prostaglandin (PG) synthases (i.e. prostacyclin, 
thromboxane, PGD, PGE and PGF sythnase) that convert this compound into a number of specific 
prostanoid by-products (PGI2, TxA2, PGD2, PGE2 and PGF2α respectively). These substances (PGH2 and 
prostanoids) subsequently exert vasomotor effects by their interaction with VSM receptors 
[63]
.  
At the VSM, endoperoxides and prostaglandins interact with prostanoid receptors, which are part 
of the seven transmembrane G-protein coupled receptor family 
[63]
. Although there are five subtypes of 
these receptors that function to preferentially interact with specific prostanoids mentioned above, 
prostaglandin I2/prostacyclin (IP)- and thromboxane prostanoid (TP)- are the two main types important 
for understanding the current work. IP-receptors have a preferential affinity for PGI2 and initiate 
vasorelaxation, where as TP-receptors may be activated by PGH2, PGI2, TxA2 and others (i.e. not only by 
TxA2; order of affinity for prostanoids is TxA2 > U46619 >> 8-isoprostane = PGF2α = PGH2 > PGE2 = 
PGD2 > PGI2) and initiate VSM contraction
[65]
. In healthy arteries, PGI2 acts predominantly on IP-
receptors to function as a vasodilator; however, under circumstances in which PGI2 concentrations are 
supra-normal, in the absence of functional IP-receptors, or hyper-sensitivity of TP-receptors (as can occur 
in dysfunctional arteries, discussed below in section 1.4 Dysregulation of vascular tone in essential 








Figure 1-3. Cyclooxygenase-derived endoperoxide and prostanoid mediated regulation of vascular 
tone. See text for details. 
 
1.3.3 Convergence of EDRFs and EDCFs on the contractile machinery: signalling systems of the 
vascular smooth muscle 
Relaxation and contraction of the VSM can be initiated by either receptor-mediated signalling 
pathways (i.e. sGC by NO, TP and IP receptors by prostanoids, α-adrenergic receptors by phenylephrine) 
or by inducing changes in the VSM membrane potential (i.e. EDHFs, potassium chloride etc.). These 
mechanisms are coupled to one or both of the two main signalling axes within VSM cells that govern 






-sensitization) signalling pathways 
[164,198]
. 




the 20 kDa myosin light chain regulatory subunit on smooth muscle myosin (MLC20), which is the final 
step required to promote cross bridge cycling and contraction 
[164,198]
 (Figure 1-4).  
Ca
2+
-dependent contraction is induced by agonists, stretch or depolarization of the VSM resting 
membrane potential. Depolarization (by agents like potassium chloride or action potentials) initiates 
elevated [Ca
2+
]i by triggering an influx of extracellular Ca
2+
 through voltage dependent L-type Ca
2+
 
channels (VGCC) that may be augmented by the release of Ca
2+
 from intracellular SR stores
[164]
. Agonists 
(like EDCFs or phenylephrine) stimulate receptors coupled to Gq/11 proteins activate phospholipase C to 
produce IP3 and DAG; IP3 acts on IP3-sensitive Ca
2+
 release channels on the SR to initiate the release of 
Ca
2+




]i by either mechanism interacts with calmodulin to activate Ca
2+
-
sensitive myosin light chain kinase (MLCK), which is responsible for phosphorylating MLC20 of VSM 





-sensitization pathways are activated by agonist stimulation of receptors coupled to the G12/13 
subtypes of the G-protein super-family (i.e. TP-receptors), which stimulate mobilization of Rho-GEFs to 
activate RhoA-Rho kinase
[198]
. Agonist receptors coupled to Gq/11 proteins can also activate Ca
2+
 
sensitization in addition to stimulating Ca
2+
 release, as DAG generated by PLC activates PKC that in turn 
activates the kinase CP1-17
[198]
. These kinases (Rho kinase and CPI-17) phosphorylate the regulatory 
subunit (MYPT1) of myosin light chain phosphatase (MLCP), to inhibit its activity; since MLCP is 
responsible for dephosphorylation of MLC20, inhibition of MLCP ultimately leads to contraction by 
allowing phosphorylation of MLC20 by MLCK to persist/increase (in essence enhancing the sensitivity of 





Vasorelaxation can be achieved by: 1) decreasing activity of MLCK via reduced VSM [Ca
2+
]i 
and/or 2) inhibition of the Ca
2+
 sensitization pathway, reversing the suppression of MLCP activity to 
allow de-phosphorylation at MLC20. One of the main ways in which both of these effects are initiated is 
via central coordinate activity of VSM PKA and PKG
[198]




(resulting in the production of cGMP from GTP) by NO or activation of IP-receptors by PGI2 (coupled to 
Gs proteins and adenylate kinase that generates cAMP from ATP) both stimulate PKA and/or PKG 
(activated by cAMP and cGMP respectively)
[198]
. PKA and PKG exert multiple functions that result in 
lower [Ca
2+
]i (by activating SERCA, extrusion by plasma membrane Ca
2+
-ATPase, inhibiting SR Ca
2+
 





 efflux channels, inward rectifying K
+






 and decreased 
Ca
2+
 sensitization (via phosphorylation of an inhibitory site on MLCK and MLCK regulatory protein 
telokin)
[198]
. A simplified representation of the signalling pathways modulating VSM tone is depicted in 
Figure 1-4. 
 
Figure 1-4. The signalling pathways of the vascular smooth muscle that dictate vascular tone. See 





1.4 Dysregulation of vascular tone in essential hypertension and aging 
In both hypertension and aging, homeostatic regulation of vascular tone is impaired, resulting in 
vascular dysfunction. Vasomotor dysfunction results from an imbalance between vasodilatory and 
vasoconstrictory signals that converge on the VSM contractile apparatus, and can be exacerbated by both 
dysregulation of the endothelium-dependent signals reaching the VSM (endothelial dysfunction is a major 
contributor to vasomotor dysfunction), and by altered VSM responsiveness. Endothelial dysfunction is 
characterized by impaired vasorelaxation and enhanced vasocontraction responses to vasoactive stimuli 
[64]
. Reduced NO bioavailability, enhanced production of prostanoids (such as prostacyclin, thromboxane 
A2, etc.), impaired EDHF responses, and increased release of endothelin-1 are some of the common 
mechanisms that can individually or co-ordinately contribute to endothelial dysfunction; however the 
extent to which each of these contribute to the dysfunctional phenotype varies markedly depending on the 
pathological state, vascular bed and stimulus studied
[62]
. In arteries of both hypertensive and aging animals 
and humans, the major mechanisms contributing to the impaired ability of the endothelium to generate 
endothelium-dependent relaxation in vitro and in vivo  include both reduced NO bioavailability 
[42,62,89,93,101,115,183,196,200,209,211,221,224,225,228]
 and enhanced COX-dependent contraction 
[48,49,63,86,112,191,230,237,240,251]
. 
The vasoreactivity of the VSM is also altered with age 
[5,46,149,228]
 and hypertension 
[111,133,148,233]
, although 
the specific nature of the alterations varies depending on the stimulus and vascular bed examined. 
Endothelial dysfunction (rather than dysregulation of the VSM) is the major focus of this thesis, and since 
reduced NO bioavailability and enhanced COX-derived EDCFs are the main mechanism contributing to 
endothelial dysfunction in conduit arteries of Spontaneously hypertensive rats (SHR) and aged rats (the 
two models of dysfunction used in the experimental chapters), these mechanisms will be the focus of the 






Reduced NO bioavailability 
The bioavailability of NO is determined by three main factors: 1) NO production, 2) the 
degradation of NO by reactions involving reactive oxygen species (ROS; i.e. superoxide anion) and 3) the 
sensitivity of the target VSM to NO
[183]
. Of the three factors, elevated levels of ROS primarily contribute 
to reduced NO bioavailability in the vascular wall 
[62,249,260]
. ROS (superoxide anion in particular) 
originate from a number of sources, although in vascular tissue enhanced production is accounted for 






 and uncoupled 
eNOS (resulting from deficiency of necessary co-factors, oxidation or substrate deficiency) 
[94]
. In the 
vasculature of SHR, the production of NO is generally not affected or enhanced; however elevated levels 
of superoxide anion interact with NO to generate peroxynitrite and thus quench NO bioavailability and 
vasodilatory potential
[91,222]
. In aging arteries, reduced NO bioavailability is generated by an increase in 
arginase activity (reducing L-arginine bioavailability and competing with eNOS for a common 
substrate)
[7]
, reduced tetrahydrobiopterin bioavailability
[193]
, augmented production of free 
radicals
[54,224,225,228]




 of eNOS. The sensitivity to NO is 
generally unaltered (in some examples it is slightly enhanced or depressed), in arteries of 
hypertensive
[47,85,86]
 and aged animals
[46,49,86,252,253]
. 
Enhanced endothelium-dependent contractions 
Alterations that contribute to enhanced endothelium- and COX-dependent contractions can 
include dysregulation of endothelial [Ca
2+
]i in response to agonist stimulation (i.e. exaggerated elevations 
in intracellular calcium following exposure to agonists), elevated levels of ROS (which activate COX-
mediated prostanoid production), increased expression of COX-1 and/or COX-2 (COX-1 and COX-2 can 
both contribute to endothelium-dependent contractions depending on the model and artery bed studied, 
although COX-1 is the mainly responsible for enhanced EDCF production/release observed in aorta of 
hypertensive rats
[229]




impaired IP-receptor function, and increased TP-receptor sensitivity in dysfunctional vessels from 
compared to those of healthy arteries
[65,232,233]
. These observations have been derived largely from arteries 
of hypertensive rats (SHR) compared to their normotensive control strain (Wistar-Kyoto rats; WKY). The 
mechanisms that account for enhanced endothelium- and COX-dependent contractions with age are less 
well defined, but increases in COX-1 and/or COX-2 protein expression have been documented in arteries 
of aged rats
[112,191,251]
. Since the studies that deal predominantly with the COX-prostanoid pathway in this 
thesis are performed using SHR and WKY, the examples given below will focus on how these alterations 
contribute to enhanced contractions in arteries from this model. 
Dysregulated endothelial calcium content is a major contributor to enhanced endothelium-
dependent contractions in aorta of SHR. The production of COX-derived EDCFs is triggered by 
abnormally high concentrations of intracellular calcium (i.e. under normal circumstances, regular levels 
of calcium do no initiate production of COX-derived EDCFs to the same extent) 
[213,216]
. Stimulation of 
SHR aortic endothelial cells results in greater accumulation of intracellular Ca
2+
 (from intracellular stores) 
than that observed in endothelial cells of WKY 
[213,216]
, suggesting that dysfunctional Ca
2+
 handling is an 
important upstream impairment contributing to the elevated production of EDCFs 
[216]
. All other 




The compliment of vasoconstrictor prostanoids released by the endothelium to generate 
contractions varies depending on the vascular bed, stimulus applied, age and disease condition. 
Endothelium-dependent contractions are usually evoked by a combination of these compounds rather than 
exclusively due to one particular substance
[216]
. However, there are instances where it is likely that one 
prostanoid in particular is a predominant contributor to the enhanced contractions observed in 
dysfunctional vessels. In conduit arteries of SHR and WKY rats, contractions to acetylcholine are 
accompanied by the release of PGI2, PGE2, PGF2α, and TxA2 
[65]




important observations that support PGI2 as the prodominant EDCF responsible for enhanced contraction 
in SHR aorta (these have been reviewed in detail previously by others 
[65]
): 1) prostacyclin synthase is by 
far the most abundant prostanoid synthase expressed in the endothelium 
[215]
, and expression is greater in 
aorta of SHR versus WKY 
[161,215]
, 2) the release of prostacyclin is 10 to 100 times greater than all other 
prostanoids, and is ~2 times greater in aorta of SHR than WKY 
[79-81]
 3) in aorta of SHR and aging WKY, 
PGI2 acts predominantly as a constrictor and not a vasodilator, 4) PGI2 is a more potent constrictor in 
SHR than WKY
[65]
 5) at higher concentrations, PGI2 stimulates activation of the TP-receptor (to signal 
contraction), rather than that of the IP receptor (mediating relaxation) 
[65]
, and 6) the release of 
prostacyclin and endothelium-dependent contractions are affected similarly by COX inhibitors
[65]
. Thus 
PGI2 is likely the main factor accounting for enhanced endothelium- and COX-dependent contractions in 
aorta of SHR rats
[65]
.  
Altered components of VSM signalling mechanisms may also play a role in enhanced 
responsiveness to EDCFs. For example, the IP-receptor is not functional in aortic vascular smooth muscle 
of SHR as early as 12 weeks of age 
[65]
. Some experiments have also shown that IP-receptor gene 
expression decreases with age and is lower in arteries of SHR versus those of normotensive WKY, 
although this remains controversial
[65,161,215]
. Both of these effects could be responsible for greater 
activation of the TP-receptor by PGI2 (due to “spill-over”) in arteries of SHR versus WKY, and in arteries 
of aged versus young animals. TP-receptor expression is not altered between SHR and WKY arteries
[215]
, 
but TP-receptors are more sensitive to endoperoxides (generate greater contraction to the same stimulus) 
in SHR versus WKY aorta 
[78]
. Elevated activation of the RhoA-Rho kinase signalling axis (greater Rho-




Reactive oxygen species generated in the endothelium may amplify endothelium-dependent 




bioavailability and thus the functional, balancing, vasodilatory influence of NO 
[232]
. ROS are generated 
by COX in response to stimulation with ACh (ROS production to ACh is prevented by the COX-inhibitor 
indomethacin) and the burst of ROS is greater in aorta of SHR than WKY
[213]
. These ROS facilitate 
production of vasoconstrictor prostanoids by VSM COX
[259]
, and likely reach the VSM by travelling 
through myoendothelial gap junctions that exist between endothelial and VSM cells
[214]
. Thus although 
the production of ROS by COX seems to be a secondary event to that of PGH2 production, ROS do 
contribute to amplification of the vasoconstrictory response 
[232]
. The identity of the ROS that contribute 
to enhanced contractions could be superoxide anion, hydrogen peroxide and/or hydroxyl radicals (tiron 
and diethyldithiocarbamic acid (DETCA), intracellular scavengers of superoxide anion and hydrogen 




Figure 1-5. Pathological alterations in vascular signalling mechanisms that lead to vasomotor 
dysfunction. The left panel of the figure depicts the intact signalling processes of healthy arteries, leading 
to an appropriate balance between relaxation and contraction, and proper responses to vasoactive stimuli. 




vasomotor dysfunction depending on the model and artery bed observed. See text for a detailed 
description of the alterations depicted above.  
  
The preceding discussion provided a basic introduction to vasomotor signalling systems of 
interest in this thesis, their involvement in regulating vascular tone, and the dysregulation of these 
processes in vascular dysfunction. The focus of the following section will now shift to address the 
enzyme of interest, AMP-activated protein kinase, and its potential contribution to the regulation of 
vascular tone.   
 
1.5 AMP-activated protein kinase as a novel regulator of vascular tone in health and disease 
AMPK has only very recently been recognized as a potential mediator of arterial tone, and is 
therefore a new topic of study in the field of vascular biology.  Although it has been studied extensively in 
other capacities for the past 30-40 years, AMPK was not identified in endothelial cells until 1999 by 
Dagher et al
[40]
, and was reported in vascular smooth muscle in 2005 by Rubin and colleagues
[181]
. The 
first experiment associating AMPK activation and changes in vascular tone was published by Rubin et al 
in 2005 
[181]
. Therefore, at the onset of this thesis, the relationship between AMPK and vasomotor 
function was virtually unexplored. The sections that follow describe AMPK and the rationale for studying 
it as a novel regulator of vascular tone and function. 
 
1.6 A basic introduction to AMP-activated protein kinase  
1.6.1 The identification of AMPK and its multiplicity of functions 
The enzyme we now call AMPK was first described in the early 1970‟s as both acetyl-CoA 
carboxylase kinase-3
[23]
 and 3-hydroxy-3-methylglutaryl kinase
[6]
 and was part of the second protein 
kinase signalling cascade ever described 
[98,121]
 . In 1988, Munday, Campbell, Carling and Hardie 
described it as “AMP-activated protein kinase” 
[152]




be activated by AMP and inhibited by ATP. The sensitivity of AMPK to these substrates enabled it to 
sense changes in the [ATP]/[ADP][AMP] ratio, endowing upon it the capacity to sense and respond to 
changes in intracellular energy status 
[22,98,152,163]
. This property, coupled with its ubiquitous expression in 
eukaryotic cells, quickly made AMPK a promising research target as a central regulator and integrator of 
fundamental metabolic processes. As such, AMPK is most well-studied for its ability to sense changes in 
intracellular energy status (and has been famously labelled the “energy sensing” serine-threonine protein 
kinase), and for its ability to respond by activating energy producing pathways (fatty acid and glucose 
catabolism) and inhibiting energy consuming processes (glucose, glycogen and lipid biosynthesis) 
[98,99,205]
. However since this description, knowledge regarding the role of AMPK has expanded to include 
government of numberous cellular processes (such as cell growth and senescence, cell death, 
mitochondrial biogenesis, protein and nucleotide synthesis), and the regulation of whole body energy 
status through the neural control of appetite 
[56,57,98,205]
. In addition to responding to changes in intracellular 
energy status, we now know that AMPK activity can also be regulated by a variety stimuli beyond 







. It is also appreciated that AMPK exerts regulatory control not only acutely via 
phosphorylation signalling cascades, but also chronically through regulation of transcription factors and 
gene expression 
[99,205]
. Thus, our knowledge of AMPK is expanding beyond mere regulation of cellular 
energy metabolism, to encompass important roles in other vital cell and whole body functions, including 
the recently identified regulation of vascular tissue.  
1.6.2 The structure and expression of AMPK 
AMPK is comprised of three subunits: a catalytic alpha subunit, containing the serine-threonine 
protein kinase domain and a Thr
172
 regulatory residue; a beta subunit, which maintains the structural 
integrity of the enzyme via important contacts with the other subunits and also hosts a glycogen binding 
domain; and a regulatory gamma subunit, the site of two nucleotide binding sites (Bateman 
domains)
[98,99,205]
. Each subunit exists as multiple isoforms (α1, α2, β1, β2, λ1, λ2, λ3) 
[143,204]




possible isoform combinations for the expression of AMPK. The ability to express distinct subunit 
combinations affords variation in subcellular localization
[185,248]





 and general functional diversity of the enzyme.  
Endothelial and VSM cells both express AMPK
[20,40]
. The characterization of AMPK subunit 
isoform expression in vascular tissue is very limited, but the available data suggests that heterogeneity 
exists in AMPK subunit isoform expression patterns between endothelial and vascular smooth muscle 
cells, and within these cell types throughout the vascular tree. For example, cultured endothelial cells 
express predominantly AMPK α1 and much lower quantities of α2 
[35,145,267]
. Although vascular smooth 
muscle of porcine carotid
[181]
, and rat 3
rd
 order pulmonary arteries
[60]
 contain α1 almost exclusively, rat 
mesenteric and main pulmonary arteries expresses similar levels of both α1 and α2 
[60]
. In endothelial cells 
express predominantly β1
[35]
, whereas vascular smooth muscle contains both β1 and β2 (but β1 > β2, in 
porcine carotid arteries) 
[181]
 or solely β2 (rat pulmonary arteries) [60]. 
1.6.3 Regulation of AMPK enzymatic activity 
The regulation of AMPK activity is complicated and occurs by both allosteric and covalent 
mechanisms. AMPK is activated covalently by phosphorylation at its threonine 172 (Thr
172
) residue on 





 is phosphorylated mainly by upstream kinases LKB1
[29,256,257]
 and CaMKKβ 
[70,103,123,146,202]
 in 
vascular cells and is dephosphorylated by protein phosphatase 2C 
[186,208]
, such that the net phosphorylation 
at Thr
172
 is determined by the balance between upstream kinase and phosphatase activities. AMPK 
activity is also regulated allosterically by the competitive binding of AMP or ATP to the nucleotide 
binding sites (AMP stimulates activity where as ATP is inhibitory) 
[70,104,208]
. The role of AMP in enzyme 
regulation becomes complex, as in addition to functioning as an allosteric regulator when bound to the 
Bateman domains, AMP also promotes phosphorylation of Thr
172
 by facilitating conformational changes 




for upstream phosphatases (recent evidence is in favour of facilitated phosphatase rather than restricted 




. This dual role of AMP is important to the overall regulation of 
AMPK by AMP, because allosteric activation of AMPK upon binding of AMP produces only modest 
activation of < 10 fold, where as covalent phosphorylation at Thr
172
 produces a much more potent effect, 
increasing enzymatic activity by > 1000-fold 
[208]
.  
1.6.4 Assessment of AMPK activation 
Phosphorylation of AMPK at activation site Thr
172
, and of its well known downstream target, 
serine 79 on acetyl-CoA carboxylase (ACC)
[40,43,99]
, are commonly evaluated as reliable surrogate markers 
of AMPK activation (phosphorylation of the Ser
 
79 residue on ACC has been regarded as the “gold 
standard” target site for assessing AMPK activation status)
[99]
. Phosphorylation status at these sites can be 
easily evaluated by immunoblotting, providing a simple assay for AMPK activation using limited 
amounts of tissue. AMPK activity can also be measured using a SAMS peptide assay, whereby 
phosphorylation of the SAMS peptide substrate (engineered to mimic the sequence surrounding the serine 
79 sequence on ACC) is an indicator of AMPK activity level 
[99,127]
. However, this assay is inefficient in 
crude tissue extracts where there is a high level of background noise generated by other kinases and their 
substrates 
[127]
, and is not practical in experiments where sample matter is limited. 
 
1.7 Specific rationale for the thesis topic: evidence of a role for AMPK in the regulation of vascular 
tone  
Our hypothesis of a role for AMPK in regulating vascular tone developed from several seminal 
observations. These findings initiated our interested in investigating a potential acute vasomotor influence 
of AMPK, and provide the backbone on which the global and specific hypotheses of this thesis are based. 
A summary of these observations are as follows: 1) AMPK activator AICAR has hypotensive effects in 




in biochemical experiments and cultured endothelial cells, 3) factors that activate AMPK generate 
relaxation of vascular smooth muscle preparations of healthy animals in vitro, and 4) AMPK is activated 
by a multitude of factors that exert vasomotor effects. Our premise for extending the investigation of 
AMPK-mediated vasomotor effects to include dysfunctional arteries of hypertensive and aged animals is 
partly based on observations showing that 5) AMPK activation is dysregulated in dysfunctional arteries of 
cardiovascular disease models and with age, a characteristic which may result in an impairment in any 
AMPK-mediated vasomotor effects.  
1) AMPK activator AICAR has hypotensive effects in situ 
The first vague indication for a potential role of AMPK in regulating vascular tone was derived 
from metabolic studies that incidentally observed hypotensive effects following acute or chronic 
administration of the pharmacological AMPK activator AICAR to healthy and diabetic animals 
respectively 
[19,71]
. Similar observations were made in healthy, diabetic, and hypertensive models 





(TZDs), compounds later identified as possessing the ability to activate AMPK 
(at the time of the experiments, AMPK was not considered as a possible mediator of the effects observed 
in these studies). Although the hypotensive influence of these compounds could have resulted from 
sympathoinhibition of the central nervous system
[153,173]
, suppression of cardiac function
[113]
 or other 
factors regulating blood pressure, it is not possible to rule out decreased vascular resistance resulting from 
direct vasodilation of the vasculature as a potential contributor to these results. Furthermore, metformin 
and TZDs were able to stimulate vasodilation when administered directly to isolated rings in vitro
[18,175]
 
(although these studies did not assess AMPK activation), providing further support that the hypotensive 
effects of these compounds could be partially mediated by direct effects on vascular tone. Thus, although 
these data only provide loose, associated evidence for a link between AMPK and vasomotor effects, these 
observations initiated an interest in developing further studies to investigate a potential role for AMPK in 




2) AMPK stimulates the production of nitric oxide by eNOS in biochemical experiments and 
cultured endothelial cells  
In the late 1990‟s and early 2000‟s, in vitro biochemical and cell culture experiments revealed 
that AMPK is capable of stimulating NO production
[27,29,31,145]
 by phosphorylating endothelial nitric oxide 

















 and other stimuli has been associated 
with increased eNOS phosphorylation, activity and NO production in cell culture experiments. Since 
endothelium-derived NO is a major signalling intermediate responsible for vasodilatory responses 
generated in the vasculature, these data support the obvious hypothesis that AMPK may also be involved 
in mediating endothelium-dependent vasorelaxation though NO-dependent mechanisms. However, no 
data had been generated to test this hypothesis in the context of intact isolated vessel environment in vitro 
or in vivo, and the experiments of this thesis were designed to evaluate this question.  
3) Acute activation of AMPK in vitro relaxes isolated arteries of healthy animals 
The first study to directly investigate the association between AMPK activation and vascular tone 
was not presented until 2005 by Rubin and colleagues, who demonstrated that activation of AMPK by 
hypoxia/2-deoxyglucose is associated with vasodilation of isolated porcine carotid artery vascular smooth 
muscle in vitro (endothelium-independent relaxation, as their preparations were devoid of functional 
endothelium)
[181]
. Later, in 2007, Goirand et al. showed that AICAR dose-dependently produces 
vasodilation in isolated aortic rings of healthy mice, but that this response is largely blunted in aorta from 
AMPKα1
-/-
 animals, suggesting dependency of AICAR-mediated relaxation on the α1 subunit of 
AMPK
[82]
. These observations provided the first strong support that activation of AMPK within the VSM 





4) AMPK is activated by a multitude of vasoactive factors 
On-going investigations have revealed that AMPK can be activated by a wide array of vasoactive 


























. The ability of AMPK to be stimulated by an overwhelming number of 
vasoactive stimuli also imply a role for this enzyme in the regulation of vascular tone. 
5) AMPK activation is dysregulated in dysfunctional arteries of cardiovascular disease models 
and with age 
 Dysregulated AMPK activation (altered basal AMPK activation or responsiveness of the AMPK 
signalling axis to stimulation relative to that observed in healthy conditions) has been documented in 
tissues from a number of cardiovascular and metabolic pathologies as well as with age. AMPK activation 
is reduced in arteries of aged 
[132,179]
, streptozotocin-induced diabetic 
[243]
, Zucker diabetic fatty 
[10]
 and 
Otsuka Long-Evans Tokushima Fatty (OLETF)
[135]
 rodents. These are all models where vasomotor 
dysfunction also exists. Pilot work in our lab demonstrated that AMPK activation is reduced in thoracic 
aorta of 20-24 week old spontaneously hypertensive rats (SHR), a finding that is consistent with the lower 
AMPK activity observed in left ventricle of 15 week old SHR 
[50]
. However, it was unknown if AMPK-
mediated vasomotor effects are impaired in arteries that display vasomotor dysfunction and dysregulated 
AMPK activation. 
Summary of the evidence supporting a role for AMPK in the regulation of vascular tone 
 Together these observations provided a compelling reason to investigate the role of AMPK in the 
vasomotor control of healthy and dysfunctional arteries. Although a limited number of observations 
relating to the association between AMPK activation and vascular tone had been generated in healthy 




any model of vascular dysfunction. Continued support for our hypotheses have emerged in the literature 
over the duration of data collection for this thesis. Figure 1-6 demonstrates our basic hypotheses for the 
role of AMPK in mediating vasomotor function based on the evidence available when designing the 
thesis experiments. The two hypotheses were: 1) that acute activation of endothelial AMPK would 
generate endothelium-dependent relaxation mediated by NO and 2) acute activation of AMPK in the 
vascular smooth muscle would generate endothelium-independent relaxation, resulting the contribution of 
both mechanisms to relaxation of an intact artery preparation.  
 
Figure 1-6. The basic hypotheses for AMPK-mediated vasomotor effects in isolated vessels based on 
the literature available at the time of thesis design. Based on isolated biochemical experiments and cell 
culture experiments, we hypothesized that activation of endothelial AMPK would generated endothelium-
dependent relaxtion of isolated vessels by stimulating NO production via phosphorylation at eNOS 
activation site serine 1177 (indicated by circled 1). A limited number of isolated vessel experiments also 
suggest that direct activation of vascular smooth muscle AMPK also generates relaxation, resulting in 
endothelium-independent relaxation (indicated by circled 2). Thus we expected that exposure of isolated 
vessels to the pharmacological AMPK activator AICAR should generate vasorelaxation that has both an 




1.8 General purpose of the thesis and experimental approach 
Based on the supporting evidence gathered above, the general purpose of this thesis was to 
investigate the role of AMPK in the regulation of vasomotor function in arteries from models of health 
and vascular dysfunction. The studies herein are designed to characterize the vasomotor responses 
generated by acute AMPK activation, to evaluate mechanisms mediating these responses, and to compare 
these components in functional arteries of healthy animals to those of dysfunctional vessels obtained from 
hypertensive and aged rat models. We have chosen Spontaneously Hypertensive rats (SHR) and aged 
Sprague-Dawley rats as models of vascular dysfunction (see rationale below, section 1.10.3 Animal 
models of vasomotor dysfunction). To address these general objectives, we employed a combination of in 
vitro arterial vasomotor function, biochemical and in vivo hemodynamic assessments in the four distinct 
studies. 
 
1.9 Specific objectives, rationale and hypotheses of the thesis studies 
Overview of the relationship between thesis studies and progression through experiments 
In Study 1, we investigate the basic nature of the vasodilatory response generated to acute AMPK 
activation using AICAR in isolated aorta of normotensive and hypertensive rats in vitro, the endothelium-
dependent and endothelium-independency of AICAR-induced vasodilation, and potential mechanisms 
responsible for mediating these responses. This study begins the thesis by confirming the previous 
observations (i.e. the endothelium-independent vasodilatory response to AICAR in aorta of healthy 
rodents) and then extends this work by additionally investigating the endothelium-dependent component 
of relaxation in conduit aorta of normotensive WKY and hypertensive animals. A serendipidous finding 
of Study 1 demonstrated that AMPK may relax isolated aorta of SHR by inhibiting endothelium- and 
COX-dependent contraction; this finding served as the basis for developing Study 2, where we investigate 




normotensive rats and dissect mechanisms involved in mediating this response. Since our observations in 
Study 1 showed that acute AMPK activation with AICAR relaxes conduit arteries, in Study 3 we attempt 
to extend these findings to resistance arteries and demonstrate parallel effects of acute AICAR injections 
on hemodynamic parameters in vivo. After observing that relaxation initiated by AMPK activator AICAR 
was both endothelium-, NO-dependent and endothelium-independent in arteries of WKY and SHR, we 
wanted to examine whether these results could be duplicated in other conditions of vasomotor function, so 
we performed similar experiments in aorta of young and aged rats (Study 4). The specific purpose, 
objectives, explicit hypotheses, and a brief statement of methods for each study are outlined below (Note: 
if you would prefer to read these immediately prior to reviewing the individual studies, they have been 
replicated identically at the beginning of each study chapter). A more focussed introduction and rationale 
for each study is included as part of the manuscript material in the experimental chapters that follow. 
 
1.9.1 Study 1 (Chapter 2): 
Purpose: To characterize the vasomotor responses of isolated arteries from healthy and hypertensive rats 
to acute AMPK activation and to investigate mechanisms involved.  
Specific objectives and hypotheses: 
Objective 1: To characterize the state of AMPK activation in aorta from WKY and SHR rats. Hypothesis 
1: AMPK activation (as determined by phosphorylation of AMPK activation site threonine 172 and 
downstream target serine 79 of acetyl-CoA carboxylase) will be depressed in aorta of hypertensive versus 
normotensive rats. [Note: this data is actually included in the manuscript for Study 3, Chapter 4] 
Objective 2: To investigate whether relaxation to AICAR is comprised of both an endothelium-
dependent and an endothelium-independent component in WKY aortic rings. Hypothesis 2: Relaxation to 
AICAR will be only partly abolished in the absence of functional endothelium, demonstrating partial 




Objective 3: To assess if endothelium-dependent and –independent relaxation responses to AICAR are 
intact or altered in aortic rings from SHR compared to those of WKY. Hypothesis 3: The magnitude of 
relaxation to AICAR may be depressed in aorta from hypertensive rats. This hypothesis is based on 1) 
pilot work showing that basal AMPK activation is depressed in aorta of SHR versus WKY and 2) that 
vasomotor dysfunction exists in arteries from these animals; therefore it is reasonable to expect that 
vasomotor signalling through these pathways would be compromised. 
Objective 4: To confirm uptake of AICAR into aortic rings of WKY and SHR by assessing its 
intracellular metabolite ZMP, and adenine nucleotide content (ATP, AMP and ADP) in control versus 
AICAR treated rings by high performance liquid chromatography. Hypothesis 4: ZMP will be elevated in 
rings treated with AICAR but undetectable in those receiving no drug, and that ZMP content will be 
similar in aortic rings of WKY and SHR. AICAR treatment will not affect ATP and AMP content of 
WKY and SHR aortic rings. 
Objective 5: To evaluate dose-dependent AMPK activation in aortic rings of WKY and SHR over the 
increasing concentrations of AICAR used in the vasomotor function experiments. Hypothesis 5: AICAR 
will increase P(Thr172)-AMPK and P(Ser79)-ACC phosphorylation in a dose-dependent manner that 
mirrors the relaxation responses observed in the functional experiments. 
Objective 6: To pharmacologically dissect potential mechanisms responsible for AICAR-induced 
functional outcomes in WKY and SHR aortic rings. Hypothesis 6: The endothelium-dependent 
component of relaxation to AICAR will be NO-dependent in WKY and SHR aortic rings. 
Objective 7: To evaluate phosphorylation of eNOS at Ser1177 in aortic rings of WKY and SHR exposed 
to increasing doses of AICAR to determine if this may be a mechanism of enhanced NO-dependent 
relaxation. Hypothesis 7: AMPK will dose-dependently increase phosphorylation at eNOS serine 1177 





1.9.2 Study 2 (Chapter 3): 
Purpose: To evaluate the influence of AMPK activation status on endothelium-dependent contractions in 
dysfunctional arteries of hypertensive rats and to elucidate mechanisms responsible for this interaction. 
Specific objectives and hypotheses: 
Objective 1: To verify that endothelium-dependent contractions to ACh are enhanced in quiescent (non-
precontracted) aortic rings from SHR versus those of WKY, and that these contractions are COX-
dependent (as has been shown by others and previously in our own lab). Hypothesis 1: Contractions to 
ACh will be enhanced in aortic rings of SHR versus WKY, and will be abolished by inhibition of COX or 
removal of the endothelium. 
Objective 2: To determine the effect of the AMPK activator AICAR on endothelium-dependent 
contractions in SHR aortic rings. Hypotheses: Endothelium-dependent contractions to ACh will be 
blunted by AICAR pre-incubation in aortic rings of both WKY and SHR. 
Objective 3: To demonstrate reversibility the inhibitory effect of AICAR on endothelium-dependent 
contractions by co-incubating rings with the AMPK inhibitor Compound C. Hypothesis 3: Co-incubation 
of WKY and SHR aortic rings with Compound C will preserve the magnitude of endothelium-dependent 
contraction generated in these vessels to ACh (contractions to ACh will be no different from those in no 
drug control rings). 
Objective 4: To verify that AMPK is activated by AICAR but inhibited by AICAR-Compound C co-
incubation in aortic rings. Hypothesis 4: AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) will 
be elevated in rings treated with AICAR, but unaltered in rings treated with AICAR and CC compared to 
controls in vessels of both WKY and SHR. 
Objective 5: To evaluate the effect of the presence of AICAR on contraction to increasing doses of  TP-




stimulation. Hypothesis 5: Contraction to increasing concentrations of TP-receptor agonists U46619 and 
PGH2 will be blunted in aortic rings of WKY and SHR in the presence of AICAR 
Objective 6: To investigate the production/release of 6-keto-prostaglandin F1α (a stable metabolite of  
prostacyclin) by aortic rings of WKY and SHR stimulated with acetylcholine Hypothesis 6: 6-keto-
prostaglandin F1α levels will be blunted in buffer bathing aortic rings of WKY and SHR treated with 
AICAR, but unaltered in the presence of AICAR together with Compound C. 
Objective 7: To determine the effect of AICAR on dose-dependent relaxation/re-contraction of 
phenylphrine pre-contracted SHR aortic rings to increasing [ACh]. Since the vasomotor response of 
phenylephrine pre-contracted SHR aorta to increasing [ACh] is biphasic (relaxation at lower [ACh] is 
NO-dependent followed by COX-dependent recontraction at higher concentrations, this experiment will 
afford the opportunity to confirm the effect of AICAR on endothelium- and COX-dependent contraction, 
and also on NO-dependent relaxation. Hypothesis 7: The endothelium- and COX-dependent re-
contraction at higher concentrations will be abolished in SHR aortic rings pre-treated with AICAR, but 
NO-dependent relaxation will be enhanced with AICAR. 
 
1.9.3 Study 3 (Chapter 4) 
Purpose: To determine the effects of AMPK activation by an acute injection of AICAR on in vivo 
hemodynamic responses of normotensive and hypertensive rats, and to evaluate whether parallel 
relaxation responses occurs in isolated, pre-contracted resistance arteries of normotensive and 
hypertensive rats exposed to AICAR acutely in vitro. 
Specific objectives and hypotheses: 
Objective 1: To investigate the effect of acute AICAR injection on blood pressure responses of SHR and 




transducers. Hypothesis 1: Acute injections of AICAR will lower blood pressure in WKY and SHR, and 
that this effect will be partly NO-dependent. 
Objective 2: To investigate the effect of acute AICAR injection on heart rate response of SHR and WKY 
in vivo by carotid arterial catheter. Hypothesis 2: AICAR will have minimal to no influence on heart rate 
of WKY or SHR.  
Objective 3: To verify the efficacy of the AICAR treatment during the in vivo experiments by assessing 
AMPK activation in vascular tissue from these animals by immunoblotting. Hypothesis 3: Acute 
injections of AICAR will elevate P(Thr172)-AMPK levels in aortas of WKY and SHR rats. 
Objective 4: To characterize basal levels of AMPK activation and expression in mesenteric artery 
sections from SHR and WKY by immunoblotting. Hypothesis 4: AMPK activation (P(Thr172)-AMPK) 
will be depressed in mesenteric arteries of SHR versus those of WKY. 
Objective 5: To evaluate the vasomotor response of pre-contracted isolated mesenteric resistance artery 
segments to acute AICAR exposure, to determine the NO-dependency of this response, and to compare 
the responses generated in SHR versus WKY vessels using vascular myography. Hypothesis 5: 
Relaxation to AICAR will occur in mesenteric arteries of both WKY and SHR and will be partly NO-
dependent. 
Objective 6: To verify AMPK activation in mesenteric artery segments from SHR and WKY incubated 
with AICAR by immunoblotting. Hypothesis 6: AMPK activation (P(Thr172)-AMPK) will be elevated 
in mesenteric arteries of WKY and SHR following incubation with AICAR. 
Objective 7: To compare baseline levels of P(Ser1177)-eNOS and total eNOS protein content in aortas 
and mesenteric arteries of WKY and SHR rats. Hypothesis 7: P(Ser1177)-eNOS will be depressed in 
aorta and mesenteric arteries of SHR versus those of WKY, and total eNOS protein content will be 




Objective 8: To evaluate the effect of AICAR injections in vivo and AICAR incubation in vitro on 
P(Ser1177)-eNOS (and total eNOS protein content) by immunoblotting in aortas and mesenteric arteries 
respectively of WKY and SHR. Hypothesis 8: Acute exposure to AICAR will increase P(Ser1177)-
eNOS in both types of experiments (aorta and mesenteric arteries) but total eNOS protein content will not 
be altered by AICAR.  
 
1.9.4 Study 4 (Chapter 5) 
Purpose: To characterize the vasomotor responses of isolated arteries from young and aged rats to 
pharmacological AMPK activators and to investigate the mechanisms involved. 
Specific objectives and hypotheses: 
Objective 1: To assess basal AMPK activation in aorta of aged versus young male Sprague-Dawley rats. 
Hypothesis 1: Basal AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) will be depressed in 
arteries of aged versus those of young rats. 
Objective 2: To determine if vasorelaxation to AICAR is intact in isolated aortic rings from aged rats 
compared to those of young rats. Hypothesis 2: AMPK-mediated relaxation will be impaired in arteries 
of aged versus young rats.  
Objective 3: To evaluate the endothelium-dependency and/or –independency of vasodilatory responses to 
AICAR in aortic rings young and aged rats.  Hypothesis 3: AICAR will generate relaxation in aortic 
rings of young and aged rats that is partly endothelium-dependent and partly endothelium-independent. 
Objective 4: To pharmacologically dissect the mechanisms responsible for AMPK-mediated vasodilation 
in aortic rings of young and aged rats (i.e. NO- and COX-dependency). Hypothesis 4: The endothelium-
dependent component of relaxation to AICAR will be primarily NO-dependent in aortic rings of young 




dependent functional responses are typically reduced in arteries of aged rats, we expect NO-dependent 
relaxation to AICAR may be reduced in aged versus young aorta. Responsiveness to vasoactive agents is 
often impaired in arteries of aged rats, so endothelium-independent relaxation to AICAR may also be 
impaired in arteries of aged animals versus those of young. 
Objective 5: To biochemically confirm AMPK activation by AICAR in aortic rings of young and aged 
rats. Hypothesis 5: AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) will be elevated by 
treatment with AICAR to a similar extent in rings of young and aged animals. 
Objective 6: To investigate whether or not vasorelaxation of young and aged pre-contracted aortic rings 
also occurs in response to other known AMPK activators, metformin and resveratrol, and to compare 
these responses in vessels of young versus aged animals. Hypothesis 6: Metformin and resveratrol will 
each generate relaxation in aortic rings of young and aged rats and relaxation to both of these agonists 
will be impaired in aortic rings of aged versus young animals. 
Objective 7: To biochemically confirm AMPK activation by metformin and resveratrol in aortic rings. 
Hypothesis 7: AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) will be elevated by treatment of 
rings with either metformin or resveratrol. 
Objective 8: To evaluate total eNOS protein content in aortic rings of young and aged rats, and the effect 
of AICAR on P(Ser1177)-eNOS of these vessels in vitro. Hypothesis 8: Total eNOS content will be 
depressed in aortic rings of aged versus young rats, and P(Ser1177)-eNOS will be enhanced in aorta rings 
of young and aged rats treated with AICAR. 
 
1.10 Overview of the experimental approaches and models used in the thesis studies 
The following section overviews the main experimental method used across the thesis studies to 
assess vasomotor function (vascular myography), and provides additional rationale for the choice of 




methods specific to the experiments described therein, this general orientation is provided to appreciate 
the overall experimental approach. 
1.10.1 Isolated vessel preparations to assess vasomotor function in vitro 
 Vascular myography is a technique commonly used to assess vasomotor responses of isolated 
vessel preparations to vasoactive agents in the context of a controlled environment (i.e. in the absence of 
of multiple vasoactive influences present in vivo like mechanical, neural input etc.). This approach 
enables clear dissection of vasomotor pathways and mechanisms through pharmacological manipulation 
of signalling systems of interest. It also affords the opportunity to perform experiments where the 
endothelium is removed from the interior of the vessel lumen (see Chapter 2, Study 1, 2.4 Materials and 
Methods for description), and thus the capacity to distinguish between responses originating from the 
endothelium (endothelium-dependent) versus those mediated by the VSM (endothelium-independent).  
 In vascular myography experiments, isolated vessel segments are carefully mounted between two 
metal wires, the bottom of which is held stationary, and the top attached to a force transducer, allowing 
the experimenter to evaluate changes in isometric tension as the vascular ring dilates or contracts in 
response to the introduction of pharmacological stimuli during experimental protocols (Figure 1-7A & B). 
In order to observe vasodilatory responses, vessels must first be pre-contracted with a vasoconstrictory 
agent to generate a state of active tone from which the vessels can relax (the resting or baseline tension set 
by the experimenter at the beginning of the protocol is passive and theoretically does not contain any 
active vessel tone, and therefore vasodilatory agents to not produce an effect in vessels in this state). The 
ability to generate contraction is assessed in vessels from a quiescent state (non-precontracted, at 
baseline/optimal resting tension) that are then exposed to constrictor agonists. Endothelial dysfunction is 
observed by comparing the relative inability of arteries to relax to endothelium-dependent vasodilators 
(such as acetylcholine in pre-contracted arteries), or by the presence of enhanced contractions to 




dysfunction can also be identified by observing altered responses of VSM to endothelium-independent 
vasoactive agents (i.e. phenylephrine, potassium chloride, TP-receptor agonists, etc.). The isolated tissue 
bath apparatus used for evaluation of large conduit arteries and small resistance arteries of rats, and the 
general type of results obtained by typical wire myograph protocols are depicted in Figure 1-7. 
 
Figure 1-7 (adjacent page).  The vascular myography isolated vessel set-ups and protocols used for 
evaluation of arterial vasomotor responses in vitro.  A) The tissue bath set-up utilized for large conduit 
artery (aorta) experiments and a schematic diagram of an aortic ring mounted on the apparatus that is 
immersed in the tissue bath during experimental protocols  B) The dissection of 3
rd
 order mesenteric 
arteries, and small artery wire myograph apparatus used for experiments in Study 3. C) The derivation of 
data from raw tension tracings generated during a typical experimental protocol using i) vasodilatory and 
ii) vasoconstrictory agonists. The aortic ring schematic diagram in A) was obtained from 








1.10.2 Rationale for the choice of vessel types studied 
Conduit thoracic aortae were used for most of the experiments performed in this thesis. We chose 
to study these vessels for several reasons: 1) the aorta is excellent model of vasomotor dysfunction in 
many disease models, and its dysfunctional characteristics have been well documented in SHR 2) since 
one of our main hypotheses was regarding the potential influence of AMPK on vascular signalling 
involving NO, conduit arteries provide a good model for investigating NO-dependent effects as 
vasorelaxation in these vessels is mainly NO-mediated (as opposed to many resistance arteries where the 
contribution of NO to vasodilation is much less and other mechanisms play a larger role), 3) for practical 
purposes, aorta provide a larger volume of tissue on which to perform biochemical analyses than small 
arteries and 4) large conduit artery dysfunction has implications for vascular pathologies such as 
atherosclerosis and coronary artery disease in animals and humans 
[45,66,107]
. 
Resistance mesenteric arteries are used in Study 3 in order to expand our characterization of the 
role of AMPK to include arteries from another vascular bed, and to determine if responses to AMPK 
manipulation are conserved across different artery types (since a substantial amount of heterogeneity 
exists in vasomotor regulation of arteries across different vascular beds). Mesenteric arteries are readily 
accessible and are available in considerable quantity relative to other resistance vessels, thereby providing 
a convenient source of tissue that serves the purpose of our experiments and is viable for analysis using 
our biochemical techniques. Given a possible role for AMPK in blood pressure modulation, examining 
resistance arteries may also provide insight into potential mechanisms for AMPK-mediated regulation of 
vascular resistance, which could influence blood pressure.  
1.10.3 Animal models of vasomotor dysfunction 
Spontaneously Hypertensive Rats  
Spontaneously hypertensive rats (SHR) are an inbred genetic model of essential hypertension 
(defined as high blood pressure without obvious cause
[9,37]




selectively breeding for high blood pressure in Wistar Kyoto rats (WKY; the normotensive control 
strain)
[165,166]
. SHR begin to exhibit elevated blood pressure as early as 2 weeks of age
[87]
, which 
progresses to severe hypertension (i.e. mean arterial pressures reaching ~200 mmHg) by 12-14 weeks of 
age and persists for the duration of their lifespan
[58,114]
. Most importantly for the purposes of this thesis, 
arteries of SHR progressively develop impaired vasomotor function (a condition that parallels vasomotor 
dysfunction characteristic of human essential hypertension) that is consistently well-developed compared 
to WKY (that display normal vasomotor function) by 16 weeks of age 
[47,62,65,85,114,233]
.  
Aged Sprague-Dawley Rats 
 Aged male Sprague-Dawley rats (80-95 weeks) were used as a second model of vasomotor 
dysfunction in the thesis experiments of Study 4 (Chapter 5) in conjunction with young male Sprague-
Dawley controls (~ 10 weeks of age). Vasomotor dysfunction has been observed in aorta of aged male 
Sprague-Dawley rats ~80-90 weeks of age compared to young male Sprague-Dawley rats that display 
normal vasomotor function
[16,26,49,96,156]. Since vascular dysfunction escalates with the progression of 
age
[1,129]
, examining arteries of animals at this stage of maturation allows adequate time to maximize 
vasomotor dysfunction before the spontaneous mortality rate of the animal group becomes too high (the 
spontaneous mortality rate for rats of this age is ~ 20%, data provided by Harlan Laboratories, 
Indianapolis, IN).  
1.10.4 Pharmacological manipulation of AMPK activation 
AICAR (5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside) is the most commonly used 
pharmacological activator of AMPK. It is imported into the cell by adenosine transporters (and 
importantly, is not an adenosine receptor agonist)
[77]
, where it is phosphorylated by adenosine kinase
[184]
 
to form the AMP analogue ZMP
[36,99]
. ZMP binds to the AMP/ATP Bateman binding sites on AMPK to 
induce activation
[124]
. AICAR is a favourable method of studying of AMPK because it effectively 






. Compound C is currently the only available pharmacological inhibitor of AMPK, and acts 
competitively and reversibly by competing with AMP/ATP for the nucleotide binding sites on the gamma 
subunit
[266]
. Although Compound C can exert non-AMPK mediated effects in some circumstances (and 
therefore should not be used to study AMPK in isolation), its efficacy as a pharmacological AMPK 
inhibitor is acceptable if it is utilized in conjunction with other tools (i.e. AMPK activator AICAR), and 
results obtained are carefully examined along with other indications that the effects generated are AMPK-
mediated (i.e. identification of the co-existence of AMPK activation/inhibition, complete reversal of 
AICAR-mediated effects, appropriate control experiments performed with Compound C alone, etc.).  
  
That concludes the general introduction section of the thesis. The experimental chapters that 
follow provide a focussed overview, introduction, methods, results and discussion section for each of the 
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2.1 Review of Study 1 Objectives and Hypotheses 
 The specific objectives and hypotheses for this chapter have already been stated in the 
introduction section, but are reproduced identically here solely for the reader‟s convenience. 
Purpose: To characterize the vasomotor responses of isolated arteries from healthy and hypertensive rats 
to acute AMPK activation and to investigate mechanisms involved.  
Specific objectives and hypotheses: 
Objective 1: To characterize the state of AMPK activation in aorta from WKY and SHR rats. Hypothesis 
1: AMPK activation (as determined by phosphorylation of AMPK activation site threonine 172 and 
downstream target serine 79 of acetyl-CoA carboxylase) will be depressed in aorta of hypertensive versus 
normotensive rats. [Note: this data is actually included in the manuscript for Study 3, Chapter 4] 
Objective 2: To investigate whether relaxation to AICAR is comprised of both an endothelium-
dependent and an endothelium-independent component in WKY aortic rings. Hypothesis 2: Relaxation to 
AICAR will be only partly abolished in the absence of functional endothelium, demonstrating partial 
endothelium- and partially vascular smooth muscle dependence of relaxation to AICAR. 
Objective 3: To assess if endothelium-dependent and –independent relaxation responses to AICAR are 
intact or altered in aortic rings from SHR compared to those of WKY. Hypothesis 3: The magnitude of 
relaxation to AICAR may be depressed in aorta from hypertensive rats. This hypothesis is based on 1) 
pilot work showing that basal AMPK activation is depressed in aorta of SHR versus WKY and 2) that 
vasomotor dysfunction exists in arteries from these animals; therefore it is reasonable to expect that 
vasomotor signalling through these pathways would be compromised. 
Objective 4: To confirm uptake of AICAR into aortic rings of WKY and SHR by assessing its 
intracellular metabolite ZMP, and adenine nucleotide content (ATP, AMP and ADP) in control versus 




rings treated with AICAR but undetectable in those receiving no drug, and that ZMP content will be 
similar in aortic rings of WKY and SHR. AICAR treatment will not affect ATP and AMP content of 
WKY and SHR aortic rings. 
Objective 5: To evaluate dose-dependent AMPK activation in aortic rings of WKY and SHR over the 
increasing concentrations of AICAR used in the vasomotor function experiments. Hypothesis 5: AICAR 
will increase P(Thr172)-AMPK and P(Ser79)-ACC phosphorylation in a dose-dependent manner that 
mirrors the relaxation responses observed in the functional experiments. 
Objective 6: To pharmacologically dissect potential mechanisms responsible for AICAR-induced 
functional outcomes in WKY and SHR aortic rings. Hypothesis 6: The endothelium-dependent 
component of relaxation to AICAR will be NO-dependent in WKY and SHR aortic rings. 
Objective 7: To evaluate phosphorylation of eNOS at Ser1177 in aortic rings of WKY and SHR exposed 
to increasing doses of AICAR to determine if this may be a mechanism of enhanced NO-dependent 
relaxation. Hypothesis 7: AMPK will dose-dependently increase phosphorylation at eNOS serine 1177 
and therefore present a possible mechanism by which active AMPK generates NO-dependent relaxation. 
 
2.2 Overview of Study 1 
Activation of AMP-activated protein kinase (AMPK) induces vasorelaxation in arteries from 
healthy animals, but the mechanisms coordinating this affect are unclear and the integrity of this response 
has not been investigated in dysfunctional arteries of hypertensive animals. Here we investigate the 
mechanisms of relaxation to the AMPK activator 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside 
(AICAR) in isolated thoracic aorta rings from Spontaneously Hypertensive (SHR) and normotensive 




 M) relaxation in pre-
contracted WKY and SHR aortic rings with (E+) or without (E-) endothelium, relaxation was enhanced in 
E+ rings. Relaxation in SHR E+ rings was also enhanced at low [AICAR] (10
-6




WKY (57±8% vs 3±2% relaxation in SHR vs WKY E+), but was similar and near 100% in both groups at 
high [AICAR]. Pharmacological dissection showed that the mechanisms responsible for the endothelium-
dependent component of relaxation across the dose range of AICAR are exclusively NO-mediated in 
WKY rings, but partly NO- and partly cyclooxygenase-dependent in SHR vessels. Further investigation 
revealed that acetylcholine-stimulated COX-EDCF-mediated contractions were suppressed by AICAR, 
and this effect was reversed in the presence of the AMPK inhibitor compound C in quiescent E+ SHR 




)-ACC (indices of AMPK 
activation) were elevated is SHR vs WKY E+ rings at low AICAR (~2 fold). Together these findings 
suggest that AMPK-mediated inhibition of EDCF-dependent contraction and elevated AMPK activation 
may contribute to the enhanced sensitivity of SHR E+ rings to AICAR. These results demonstrate 
AMPK-mediated vasorelaxation is present and enhanced in arteries of SHR, and suggest that activation of 
AMPK may be a potential strategy to improve vasomotor dysfunction by suppressing enhanced 
endoperoxide-mediated contraction and enhancing NO-mediated relaxation.  
 
2.3 Introduction 
AMPK is emerging as a potential regulator of vascular function. Although recognized primarily 
as a modulator of cellular energy status and metabolism
[99,247]
, the identification of its existence in 









 mediators of vasomotor function suggest a potential 
role for AMPK in the regulation of vascular control. Of particular importance to the modulation of 
vasomotor tone, cell culture and in vitro biochemical experiments have shown that activated endothelial 









, and to increase nitric oxide (NO) availability
[29,30,44,145]
. While the 
potential for AMPK to generate endothelium-dependent, NO-mediated relaxation in vivo and in intact 




isolated vessels, or in vivo. In addition, endothelium-independent relaxation has been documented in 







, suggesting that vasorelaxation can be generated 
directly by activation of vascular smooth muscle AMPK. Biochemical experiments have shown that 
AMPK can directly regulate myosin light chain kinase (MLCK) by decreasing its sensitivity to 
intracellular calcium
[116]
 and thus presumably reduce vascular tone. Collectively, these observations 
suggest that AMPK may modulate vasomotor function through both endothelium-dependent and –
independent mechanisms.  
 Hypertension is associated with vasomotor dysfunction, which manifests in part as impaired 
endothelium-dependent vasorelaxation and also as altered vascular smooth muscle function 
[62,85,93,95,148,233]
. Impaired endothelium-dependent vasomotor function in hypertensive models has been 
attributed to both reduced NO-bioavailability and enhanced endothelium-dependent vasoconstriction 
[48,62,85,93,95,142,233]
. Endothelium-derived contracting factors (EDCFs) are products of cyclooxygenase 
(COX), and have been identified as prostaglandins that exert contraction through TP-receptor mediated 
signalling in the vascular smooth muscle
[48,62,233]
. Recent work suggests that activation of AMPK may be 
able to interact with the COX vasomotor signalling axis to suppress the EDCF-mediated vasoconstriction 
in dysfunctional vessels
[141]
. Since AMPK may also play a role in facilitating the generation of NO and 
vasodilation of vascular smooth muscle, it is conceivable that exogenous activation of AMPK may be 
able to improve vasomotor function by stimulating processes that are otherwise impaired in diseased 
arteries. Interestingly, depressed AMPK activation, or AMPK dysregulation, has been observed in arteries 
of rodent models where vascular dysfunction exists, including in streptozotocin-induced diabetes 
[243]
, 
Zucker diabetic fatty rats 
[10]
, aged rats 
[179]
 and Otsuka Long Evans Tokushima Fatty (OLETF) rats
[135]
. In 
pilot work, we determined that basal AMPK activation is also blunted in aorta of Spontaneously 
Hypertensive Rats (SHR; a genetic model of essential hypertension and vasomotor dysfunction) 




ability to activate AMPK is impaired in arteries of hypertensive animals, and whether pharmacological 
activation of AMPK in dysfunctional arteries is able to generate relaxation in a similar manner to that 
observed in healthy vessels. 
 The objectives of this study therefore are: to characterize the endothelial-dependency and –
independency of AMPK-mediated vasorelaxation and AMPK activation in aortic rings from 
normotensive (WKY) rats; to determine if these responses are altered in aortic rings from hypertensive 
(SHR) animals; and to elucidate potential mechanisms responsible for AMPK-mediated vasomotor 
outcomes. Our data: illustrate that AMPK-mediated relaxation in response to exogenous AMPK 
activation occurs through both endothelium-dependent and –independent mechanisms in arteries from 
normotensive animals; demonstrate for the first time that these responses also occur and are actually 
enhanced in arteries from hypertensive animals despite depressed basal AMPK activation; and suggest 
that the mechanisms responsible for endothelium-dependent relaxation are exclusively NO-mediated in 
WKY, but both NO- and COX-, EDCF-dependent in SHR aorta. Activation of AMPK suppresses the 
exaggerated EDCF-dependent contractions observed in SHR compared to WKY arteries, and this effect 
likely contributes to the enhanced endothelium-dependent, AICAR-mediated relaxation observed in SHR.   
 
2.4 Materials and Methods 
Animal care and procedures.  The University of Waterloo Animal Care Committee approved all animal-
related procedures in this study. Experiments were performed using a total of 50 male WKY and 50 male 
SHR obtained from Harlan (Indianapolis, IN). Animals were group-housed at a constant air temperature 
(20-21
o
C) and humidity (~50%) in a 12 h:12 h reverse light:dark cycle. Rats had free access to standard 
22/5 Rodent Diet (W) lab chow (Harlan) and tap water. Prior to all experiments, body mass was recorded 
and rats were anesthetised by sodium pentobarbital injection (50-65 mg/kg, i.p.; Vetoquinol N.-A. Inc., 
Lavaltrie, QC, Canada). In order to confirm blood pressure levels in SHR and WKY, a subset of 




(HR) measurements by inserting a Mikro-Tip Pressure Transducer catheter (Millar Instruments, Houston, 
TX) into the left common carotid artery
[47,86]
. Data were collected as previously described
[47,86]
. 
Vasomotor responses in isolated vessels. Animals were killed by rapidly removing the heart which was 
dissected and weighed. The thoracic aorta was excised and 2mm aortic rings were prepared for vascular 
myography as previously described
[74]
. In some experiments, the endothelium was removed by inserting a 
256 μm diameter titanium wire through the vessel lumen and rolling it on Whatman blotting paper 
(Whatman, Maidstone, England) soaked with 4°C Krebs-bicarbonate buffer. Consistent removal of the 
endothelium by this method was verified functionally by non-responsiveness to a maximal dose of the 
endothelium-dependent vasodilatory agent acetylcholine in phenylephrine pre-constricted aortic rings, 
and biochemically by substantial removal of endothelial-nitric oxide synthase (eNOS) protein content (i.e. 
< 10-15% residual eNOS compared with endothelium-intact aortic rings from the same animals) assessed 
by western blotting (Figure A2-1). Rings were mounted onto a vascular myography apparatus (Radnotti, 
Monrovia, CA) where they were immersed in 37°C Krebs-bicarbonate buffer continuously aerated with 
95% O2/5% CO2, and data collected as already described
[74]
. Gradual stretching to a pre-determined 
optimal resting tension of 7 g
[85]
 was achieved by increasing the tension by 0.5g increments from 1g every 
5 minutes, and rings were equilibrated at optimal resting tension for 30 minutes. Each vessel was then 
contracted by two consecutive exposures to 60mM potassium chloride (KCl, with washouts in between) 
to ensure contractile integrity of all aortic rings.  
Dose-dependent vasorelaxation to AICAR. Following washout of KCl and return to baseline 
tension, rings were allowed to equilibrate for 30 minutes and then pre-contracted with phenylephrine (PE; 
10
-6.5
 M). When a stable plateau in tension was achieved, each ring was exposed to increasing 





 M) to generate dose-dependent relaxation responses. In some experiments, some rings with 
and without endothelium were pre-incubated with the NOS inhibitor Nω-nitro-L-arginine methyl ester (L-
NAME; 10
-4
 M), the cyclooxygenase inhibitor indomethacin (INDO; 10
-5




INDO for 30 minutes prior to PE pre-constriction. The dose range for AICAR was based on prior 
experiments examining rodent aorta
[82]
 and on our own pilot work. The functional viability of aortic rings 
following exposure to this dose and duration of AICAR was also tested in pilot experiments by evaluating 
the ability of rings to generate tension to KCl and PE following the AICAR dose-response curve (DRC) 
protocol. Tension generated to KCL or PE post AICAR DRC was not significantly different from values 
obtained prior to the AICAR DRC in rings both with and without endothelium (KCL: E+ 83±7%, E- 
103±9% of KCl exposure pre-AICAR and PE: E+ 108±2%, E- 92±1% of PE pre-contracted tension pre-
AICAR in n =3 rats) when rings under-went extensive wash out (i.e. 6 consecutive exchanges of buffer 
bath) and a one hour recovery period post AICAR DRC (Figure A2-2). This is consistent with previous 
reports that it is possible to wash out AICAR
[36,60]
, and that AICAR does not produce non-specific toxic 
effects under these conditions. 
Functional index of NO bioavailability. In other experiments, rings were pre-incubated with no 
drug, L-NAME (10
-4
M), AICAR (2mM), or AICAR + L-NAME for 30 minutes (following KCl 
exposures) and then contracted with PE (10
-6.5
M). The difference in tension generated to PE was 
compared across groups to assess the interactive effects of L-NAME and AICAR on NO bioavailability. 
Endothelium-dependent contractions. Quiescent aortic rings (not pre-contracted) were pre-
incubated with L-NAME (10
-4
M, to block the NO-mediated component of the response to ACh) and with 
either no drug, AICAR (500µM, 30 minutes), the AMPK inhibitor Compound C (CC; 20µM, 45 
minutes), or AICAR + CC. The lowest dosages of AICAR and CC capable of generating maximal 
functional effects were chosen based on pilot experiments (data not shown). Rings were then exposed to 
increasing concentrations of acetylcholine to elicit endothelium-dependent, COX-EDCF-mediated 
contractions as previously described
[47,48]
.  
ZMP and adenine nucleotide content in aortic rings. Using other WKY and SHR animals, aortic rings 




described above, and subjected to the same set-up and equilibration procotol. Following incubation with 
or without AICAR (2mM) for 30 minutes, rings were quickly removed from the apparatus, snap frozen in 
liquid nitrogen and stored at -80
o
C. Samples were freeze-dried under vacuum, weighed, cut into small 
pieces and extracted for analysis of ZMP (the intracellular metabolite of AICAR responsible for AMPK 
activation
[36]
) and adenine nucleotide content by high performance liquid chromatography (HPLC) as 
previously described
[88,120]
. ZMP (Sigma) was included in the methodological calibration standards, and 
was clearly resolved from other peaks in standards and samples.  
Immunoblot analysis of protein content and phosphorylation levels. Aortic rings from a different set of 
WKY and SHR animals were prepared with and without endothelium and mounted on the vascular 
myography apparatus as described above. Rings were exposed to the protocol used above to obtain the 
AICAR dose-response functional measures (with all rings being assigned to the „no drug‟ condition) and 
were removed before and during the AICAR DRC to be snap frozen for Western blotting. Some rings 
were removed immediately prior to administration of the first AICAR dose (following PE precontraction) 
for baseline measures, and when stable responses were obtained at each consecutive AICAR dose. Some 
rings were also snap frozen as time controls (pre-contracted with PE and allowed to remain contracted for 
the duration of the AICAR DRC protocol, but not exposed to AICAR) to ensure that AMPK activation 
did not occur as a function of time during the collection period of the DRC. Rings were rapidly removed 
from the apparatus at appropriate points (care was taken not to damage the endothelium), snap frozen in 
liquid nitrogen, and stored at -80
o
C. The time from removal of the rings from the buffer to immersion in 
liquid nitrogen was < 5 seconds. One ring was removed for each control point and AICAR dose, and all 
rings (controls and AICAR doses) were obtained from a single rat for each E+ or E- experiment. Sample 
preparation and immunoblotting procedures were performed as described previously
[74]
. Briefly, 30µg of 
protein was loaded per well, and membranes were ponceau stained to confirm consistent protein loading 
across lanes. All blots were normalized to a thoracic aorta standard (aorta from young male Sprague-




Drugs, Chemicals and Antibodies. All drugs and chemicals were purchased from either Sigma-Aldrich 
(St. Louis, MO) or Bioshop Canada Inc. (Burlington, ON, Canada), with the exception of AICAR which 
was purchased from Toronto Research Chemicals (Toronto, ON, Canada). For immunoblotting 
experiments, primary antibodies specific for the α subunit of AMPK (recognizing both α1 and α2 subunit 
isoforms, 1:500 dilution) and P(Thr
172
)-AMPK (1:1000 dilution), acetyl-CoA carboxylase (1:250), 
P(Ser
79
)-ACC (1:500), and P(Ser
1177
)-eNOS (1:3000) were obtained from Cell Signaling Technology (via 
New England Biolabs, Pickering, ON, Canada). eNOS primary antibody (1:750) was obtained from BD 
Biosciences (Mississauga, ON, Canada) and horse-radish-peroxide conjugated secondary antibodies were 
from Santa Cruz Biotechnology (Santa Cruz, CA). 
Data Analyses. Values are reported as mean ± standard error, with n referring to the number of animals 
per group. For comparisons consisting of more than two treatment conditions or groups, one- or two-way 
ANOVAs with Tukey‟s or Bonferroni post-hoc analyses were conducted to evaluate within or between 
group comparisons. A two-tailed Student‟s t-test was used for comparisons involving only two groups. 
Differences were considered significant if P < 0.05. All statistical analyses were performed using SAS 
(SAS Institute, Cary, NC) or GraphPad Prism 4 analysis software (La Jolla, CA).   
   
2.5 Results 
Animal Characteristics. Animals were 20-24 weeks of age at the time of experiment (Table 2-1). 
Hypertension was confirmed in SHR by measuring mean arterial pressure in a sub-set of animals prior to 
removal of the aorta for in vitro experiments (Table 2-1). Left ventricular hypertrophy, apparent in the 
greater left ventricle/BM and heart weight/BM ratios, also confirms typical cardiovascular pathology in 






Endothelium-dependent and –independent vasomotor responses to AICAR.  
AICAR generates both endothelium-dependent and endothelium-independent relaxation in aortic 
rings from WKY rats. Figure 2-1A displays representative tracings of responses to AICAR for both WKY 
E+ (middle tracing) and WKY E- (bottom tracing) rings, and for a PE-contracted time control (WKY E+ 
ring, no AICAR; top tracing). Pre-contracted tension to 10
-6.5
M PE was not different between WKY rings 
with or without endothelium (E+: 2.39 ± 0.32g, E-: 2.31 ± 0.12g, P = NS). WKY rings with intact 
endothelium relaxed from PE pre-constriction in an AICAR dose-dependent manner to a maximum of 
99±7 % in response to 10
-2
M AICAR (Figure 2-1C). Removal of the endothelium blunted relaxation to 
AICAR at all concentration points, with relaxation reaching only 60±1% at 10
-2
M (P < 0.0001 vs. WKY 
E+; Figure 2-1D). Relaxation was not detectable in either E+ or E- WKY rings until 10
-3
M AICAR 
(Figure 2-1C and 1D).  
Endothelium-dependent and –independent relaxation to AICAR is enhanced in aortic rings from 
SHR compared to those from WKY. Representative tracings for SHR E+ (middle), E- (bottom) and time 
control (top) are shown in Figure 2-1B. Since SHR E+ rings unexpectedly relaxed ~ 50% of pre-
contracted tension at the lowest AICAR concentration (10
-6
M) used in our experimental protocol, we 
retrospectively performed a small number of experiments, in SHR E+ rings only, at lower concentrations 
of AICAR in order to demonstrate the full dose-response relationship in this group. A sample tracing over 
the expanded [AICAR] range (i.e. beginning 10
-9
M AICAR) has been included in Figure 2-1B (middle 
tracing) for SHR E+ rings. Relaxation to AICAR in SHR rings with endothelium intact was elevated 
above that observed in WKY aorta at 10
-6
M AICAR and remained higher at every concentration to 10
-2
M 
AICAR (Figure 2-1C). In rings with endothelium removed, SHR rings relaxed more than rings from 
WKY beginning at 10
-4
M AICAR and at each increasing concentration to 10
-2
M (Figure 2-1D). PE pre-
contraction was 1.88 ± 0.25g in SHR E+ rings and 1.84 ± 0.25g in SHR E- rings and these values were 




ZMP and adenine nucleotide content following incubation with AICAR. 
ZMP and adenine nucleotide content is not different in SHR versus WKY aortic rings following AICAR 
treatment. ZMP was not detectable in control rings from either WKY or SHR (Table 2-2).  Following 
exposure to AICAR, ZMP content was not different in WKY or SHR rings either in the presence or 
absence of the endothelium (Table 2-2). Similarly, ATP, AMP and the AMP to ATP ratio were not 
different in WKY or SHR rings with or without endothelium following AICAR treatment, and AICAR-
treated values for these parameters were not different from those of the non-treated controls (Table 2-2).    
AMPK protein content and activation status in SHR and WKY aortic rings before and during the 
AICAR dose-response protocol.  
Basal AMPK activation is blunted in SHR versus WKY aortic rings with endothelium prior to 
AICAR exposure. Phosphorylation of AMPK at Thr
172
, a mandatory modification required for enzyme 
activation
[99]
, and phosphorylation of acetyl-CoA carboxylase (ACC) at Ser
79
, a downstream target and 
well established marker of AMPK activity
[99]
, were evaluated as surrogate markers of AMPK activation. 
AMPK phosphorylation was expressed as the phosphorylated-to-total protein ratio to account for slightly 
higher levels of AMPK total protein expression in SHR versus WKY rings with endothelium (total 
AMPK: 1.31±0.04 vs 1.00±0.13 in SHR and WKY E+ rings respectively, P = 0.0317). Prior to AICAR 
exposure, the P(Thr
172
)-AMPK/AMPK ratio in SHR rings with endothelium was only ~39% of that 
observed in WKY rings (Figure 2-2A; 0.39±0.07 vs 1.00±0.11 respectively at baseline, P = 0.0008). 
P(Ser
79
)-ACC was similarily depressed in E+ rings from SHR vs WKY rings prior to AICAR exposure 
(Figure 2-3A; 0.33±0.10 vs 1.00±0.20 respectively at baseline, P = 0.0185), although total ACC protein 
content was not different in SHR vs WKY rings with endothelium (1.00±0.26 vs 0.93±0.16 respectively, 





(Figure 2-2B and 2-3B), nor total AMPK and ACC protein levels, were different in SHR versus WKY 




in SHR and WKY E- rings respectively, P = 0.8601). Thus, the depressed AMPK activation in SHR 
versus WKY aorta appears to be localized to the endothelium rather than the smooth muscle.   
 AMPK activation is enhanced in SHR versus WKY aortic rings with endothelium at low AICAR 
doses, but is similar in SHR and WKY aortic rings without endothelium. The levels of P(Thr
172
)-AMPK 
(Figure 2-2) and P(Ser
79
)-ACC (Figure 2-3) were increased significantly from baseline with increasing 
concentrations of AICAR in E+ and E- rings from WKY and SHR. Time controls, pre-contracted with 





)-ACC from baseline in SHR or WKY rings with (Figure 
2-2A and 2-3A) or without (Figure 2-2B and 2-3B) endothelium, demonstrating that no changes in 
AMPK activation occurred as a function of time over the duration of the protocol in the absence of 
AICAR. When data were expressed relative to WKY baseline values (Figure 2-2A/B), P(Thr
172
)-
AMPK/AMPK in SHR E+ was either not different, or was lower (at 10
-4
 P = 0.0041 and 10
-3
M P = 
0.0029) than in WKY E+ rings in response to AICAR (Figure 2-2A), and was not different at any 
concentration in SHR versus WKY E- rings (Figure 2-2B). Similarly, P(Ser
79
)-ACC was not significantly 
different at any AICAR concentrations in SHR versus WKY rings either with (Figure 2-3A) or without 
(Figure 2-3B) endothelium. However, when values were expressed as fold increase from their respective 
baseline values, the increase in P(Thr
172
)-AMPK/AMPK over baseline was significantly greater in SHR 
than in WKY E+ rings at 10
-6
M (P = 0.0430) and 10
-5
M (P = 0.0065) (Figure 2-2E), and P(Ser
79
)-ACC 
was increased in SHR over WKY at 10
-5
M (P = 0.0137) and 10
-4
M (P = 0.0250) in rings with 





)-ACC fold increases from baseline between SHR and WKY in E- rings at any AICAR dose 





Pharmacological dissection of mechanisms responsible for endothelium-dependent relaxation to 
AICAR.  
Endothelium-dependent relaxation to AICAR in WKY aortic rings is NO-mediated. Aortic rings 
were incubated with L-NAME, indomethacin (INDO), or L-NAME + INDO to determine the 
involvement of NO- and cyclooxygenase-dependent signalling in the vasodilatory responses to AICAR. 
Relaxation was blunted in WKY E+ aortic rings treated with either L-NAME or L-NAME + INDO 
compared the untreated controls (Figure 2-4A), to levels resembling those of E- rings (P = NS vs. E- 
CON; Figure 2-4C). Indomethacin alone, however, did not alter relaxation compared to the E+ control 
condition at any AICAR concentration (Figure 2-4A). In WKY E- rings, relaxation to AICAR was not 
affected by L-NAME, INDO or L-NAME + INDO (Figure 2-4C). Pre-contraction to PE was not affected 
by drug incubation and was not significantly different across groups (WKY E+ CON: 2.39±0.32g, E+ 
LN: 2.72±0.27g, E+ INDO: 2.13±0.24g, E+ LN INDO: 2.82±0.20g, E- CON: 2.31±0.12g, E- LN: 
2.42±0.28g, E- INDO: 2.62±0.36g, E- LN INDO: 2.55±0.10g).  
Endothelium-dependent relaxation to AICAR in SHR aortic rings is NO- and endoperoxide-







M), aortic rings with endothelium intact and pre-incubated with INDO relaxed only ~20-40% from pre-
contraction while no drug controls relaxed 57-71% (P < 0.0001 E+ INDO vs. CON at each of the three 
lowest concentrations; Figure 2-4B). E+ rings treated with L-NAME relaxed only ~15-25% (P < 0.0001 






M; Figure 2-4B). Relaxation was absent across the lowest three AICAR 







M; Figure 2-4B) and was not different from responses observed in SHR E- CON rings (P = 
NS vs. E- CON; Figure 2-4D). L-NAME and INDO groups were also each significantly different from the 
L-NAME + INDO group across the first three doses of AICAR (P < 0.0001 for both L-NAME and INDO 






M; Figure 2-4B). In contrast, pre-incubation with L-NAME, 




to E- CON (Figure 2-4D). In general, tension generated to PE was not affected by drug pre-incubation 
and was not different from the respective WKY treatment groups, except that SHR E+ LN pre-contracted 
tension was greater than SHR E+ CON (P=0.0321), and pre-contracted tension in SHR E+ INDO was 
lower than that of WKY E+ INDO (P=0.0043) and of SHR E+ CON (P = 0.0163). All other pre-
contracted tension values were not significantly different from each other (SHR E+ CON: 1.88±0.25g, E+ 
LN: 2.98±0.15g, E+ INDO: 0.95±0.16g, E+ LN INDO: 1.91±0.15g, E- CON: 1.84±0.25g, E- LN: 
1.77±0.14g, E- INDO: 2.17±0.20g, E- LN INDO: 2.05±0.23g). Vasorelaxation responses to the 
endothelium-independent vasodilator sodium nitroprusside in rings pre-contracted with phenylephrine 
were not altered between drug conditions where pre-contraction values were different (as determined by 
comparison of EC50 and maximal response in each group, data not shown), confirming that drug-
dependent variations in pre-contraction values per se did not significantly influence relaxation responses. 
Phosphorylation of eNOS at activation site Ser
1177
 was not increased in aortic rings over the 
AICAR dose-response curve. To determine if AMPK-mediated phosphorylation of eNOS activation site 
Ser
1177
 could account for the NO-dependent vasomotor responses to AICAR (a potential mechanism 
suggested by previous work of others), P(Ser
1177
)-eNOS was assessed in the homogenates of aortic rings 
collected over the functional AICAR dose-response curve. P(Ser
1177
)-eNOS was not significantly different 
between SHR and WKY aortic rings at baseline, and was not significantly affected by AICAR over the 
AICAR dose-response curve protocol (Figure 2-5A). Total eNOS protein content also did not change over 
the AICAR dose response curve in either SHR or WKY (data not shown), although total eNOS content 
was greater in SHR versus WKY (SHR 1.56 ± 0.07 vs. WKY 1.00 ± 0.05, P < 0.0001).  
NO bioactivity is increased with AICAR incubation in SHR and WKY aortic rings as determined 
by the influence of AICAR on phenylephrine contraction in the presence or absence of L-NAME. The 
additional tension generated to PE in the presence versus the absence of NOS inhibition (L-NAME) is an 
established functional indicator of NO bioavailability in in vitro pharmacological studies
[53,93]
. Greater NO 




one condition compared to that in another condition. Since the functional data in Figure 4 indicate a role 
for NO in AICAR-induced relaxation generated in WKY and SHR aortic rings despite a lack of increase 
in eNOS Ser
1177
 phosphorylation with AICAR treatment (Figure 2-5), we evaluated the influence of 
AICAR on PE contraction in the presence versus absence of L-NAME as an additional functional index 
of the effect of AICAR on NO bioavailability
[53,93]
 (Figure 2-6). As expected, pre-incubation of aortic 
rings with L-NAME alone resulted in greater PE-generated tension compared to the no L-NAME control 
group in both WKY and SHR, demonstrating the influence of NO on net PE contraction. Pre-incubation 
with AICAR significantly decreased the contraction generated to PE compared to the no drug condition in 
both SHR and WKY aortic rings. This effect was fully prevented in WKY and partially prevented in SHR 
rings that had been pre-treated with AICAR and L-NAME (Figure 2-6C and D). The resulting differential 
in PE generated tension comparing L-NAME to no L-NAME groups is thus much greater in rings treated 
with AICAR than in the respective control rings, demonstrating that AICAR enhances NO bioavailability 
in both WKY and SHR groups.    
Endothelium-dependent, EDCF-mediated contraction is blunted in the presence of AICAR but 
recovered with AMPK inhibitor Compound C in both SHR and WKY aortic rings. In addition to 
producing NO-dependent relaxation, acetylcholine (ACh) also generates COX-, EDCF-dependent 
contraction that is augmented in conduit arteries of SHR versus WKY and is considered to be a major 
contributor to the vascular dysfunction in this and other models of cardiovascular disease
[48,62,233]
. As 
expected based on previous work in SHR and WKY conduit arteries
[48,62,233]
, endothelium-dependent 
contractions generated to increasing concentrations of acetylcholine in quiescent vessel preparations were 
robust in aortic rings from SHR (Figure 2-7A) but were of a much lower magnitude in those from WKY 
(Figure 2-7B). Both removal of the endothelium, and pre-incubation of rings with the cyclooxygenase 
inhibitor indomethacin, abolished contractions in SHR and WKY aortic rings (Figure 2-7A and B), 
confirming the endothelium- and cyclooxygenase dependency of these responses respectively as has been 
previously reported
[48,233]




contraction to ACh in both SHR and WKY compared to the E+ CONs (Figure 2-7C and D). Compound C 
almost completely reversed the effect of AICAR in WKY (Figure 2-7D) and SHR rings (Figure 2-7C), 
although contractions were not completely restored in SHR at lower acetylcholine concentrations. 
Responses in rings pre-incubated with CC alone were not different from those treated with AICAR + CC 
in either SHR or WKY (data not shown) confirming the AMPK-specificity of the AICAR effect. 
Collectively these data imply that AMPK suppressed the COX-EDCF-mediated contractile response that 






Table 2-1. Animal Characteristics  
 WKY SHR P 
Age, wks 21.0±2.0 21.9±2.5 0.332 
Whole body mass (BM), g 308±19 334±12 0.004 
Tissue Masses    
Left Ventricle, mg 857±65 1111±56 <0.001 
Left Ventricle/BM (mg/g BM) 2.81±10 3.31±14 <0.001 
Right Ventricle, mg 200±12 220±11 0.007 
Right Ventricle/BM (mg/g BM) 0.659±0.034 0.657±0.025 0.657 
Heart, mg 1058±72 1331±61 <0.001 
Heart/BM, (mg/g) 3.47±0.10 3.97±0.14 <0.001 
Mean Blood Pressure, mmHg 77±6 172±10 0.003 
Heart Rate, beats/min 323±21 414±34 0.096 
 
Hemodynamic parameters were assessed in the left common carotid artery of anesthetized WKY and 
SHR using a Millar pressure probe (n = 3). n=12 for all other measures. Due to differences in body 
weight between strains, values were expressed both in absolute terms and relative to body weight. Data 





Figure 2-1. Vasorelaxation to AICAR is both endothelium-dependent and –independent and is 
enhanced in aorta from SHR. Representative tracings demonstrate the relaxation responses to 
increasing concentrations of AICAR in aortic rings from A) WKY and B) SHR rats with (E+; middle 
tracings) and without (E-; bottom tracings) endothelium following phenylephrine (10
-6.5
M) pre-
contraction. Time control tracings (top; rings pre-contracted with PE but not exposed to AICAR doses) 
demonstrate the ability of rings to maintain contraction over the duration of the AICAR dose-response 
protocol. Relaxation of WKY and SHR aortic rings C) with and D) without endothelium to increasing 
concentrations of AICAR. Responses are expressed as mean percent relaxation from phenylephrine pre-
contraction (PE 10
-6.5






Table 2-2. ZMP and Adenine Nucleotide Content of SHR and WKY aortic rings 
 E+  E- 
 WKY SHR  WKY SHR 
ZMP       
CON  ND ND  ND ND 
AICAR  4.0 ± 0.9 4.0 ± 0.3  3.4 ± 0.2 3.7 ± 0.3 
ATP       
CON  0.89 ± 0.15 1.32 ± 0.26  0.82 ± 0.12 0.78 ± 0.17 
AICAR  0.79 ± 0.13 1.12 ± 0.19  0.62 ± 0.13 0.69 ± 0.17 
AMP       
CON  0.67 ± 0.06 0.46 ± 0.10  0.53 ± 0.08 0.60 ± 0.15 
AICAR  0.72 ± 0.04 0.47 ± 0.09  0.72 ± 0.15 0.75 ± 0.17 
AMP/ATP       
CON  0.87 ± 0.15 0.56 ± 0.24  0.77 ± 0.18 1.02 ± 0.37 
AICAR  1.03 ± 0.19 0.55 ± 0.19  1.00 ± 0.27 0.99 ± 0.31 
 
All values are expressed as µmol/g dry weight except the AMP/ATP ratio which is unitless. Aortic 
rings were loaded on the myography apparatus, subjected the same start and equilibration protocol as used 
in collection of functional measures and then incubated with 2mM AICAR or no drug (CON) for 30 
minutes. Rings were snap frozen and then extracted for analysis by high performance liquid 
chromatography. No significant differences were present between groups following AICAR incubation or 
compared to control rings. n = 5-6 rings per group from different animals. Data represents means ± sem. 







Figure 2-2. Phosphorylation of AMPK activation site Thr
172
 during AICAR dose-response curves in 
SHR and WKY aortic rings. P(Thr
172
)-AMPK and total protein content of the AMPKα subunit were 
assessed by western blotting in homogenates of aortic rings that were removed during the AICAR dose-
response curve protocol. The ratio of phosphorylated to total AMPK protein is expressed in rings A) with 
(E+) and B) without (E-) endothelium immediately prior to AICAR exposure (baseline; B, PE pre-
contraction only), at each AICAR concentration during the dose-response curve (expressed in log M) and 
in time controls (TC; PE precontraction for the duration of the dose-response curve with no AICAR 
exposure). Representative blots are shown for p-AMPK and AMPK in SHR and WKY aortic rings C) 
with and D) without endothelium. The bottom two panels show the same data expressed as fold increase 
normalized to the respective WKY or SHR baseline in E) E+ and F) E- rings to account for initial 
baseline differences between WKY and SHR. Legend conventions are conserved across panels. Results 
represent data collected from 3 independent experiments where aortic rings from a single animal were 
used to generate all treatment conditions for each experiment. Blots were run in duplicate for each set of 





Figure 2-3. Phosphorylation of AMPK downstream target acetyl-CoA carboxylase during AICAR 
dose-response curves in SHR and WKY aortic rings. P(Ser
79
)-ACC and total ACC protein content 
were assessed by western blotting in aortic ring homogenates prepared from vessels frozen during the 
AICAR dose-response curve protocol. P(Ser
79
)-ACC is expressed in rings A) with (E+) and B) without 
(E-) endothelium either immediately prior to AICAR exposure (baseline; B, PE pre-contraction only), at 
each AICAR concentration during the dose-response curve (expressed using log M nomenclature) and in 
time controls (TC; PE precontraction for the duration of the dose-response curve with no AICAR 
exposure). Representative blots are shown for p-ACC and ACC in SHR and WKY aortic rings C) with 
and D) without endothelium. The bottom two panels show the same data expressed as fold increase 
normalized to the respective WKY or SHR baseline in E) E+ and F) E- rings to account for initial 
baseline differences between WKY and SHR. Results represent data collected from 3 independent 
experiments where aortic rings from a single animal were used to generate all treatment conditions for 
each experiment. Blots were run in duplicate for each set of samples. Legend conventions are conserved 





Figure 2-4. Mechanisms of AICAR-mediated endothelium-dependent relaxation in SHR and WKY 
aortic rings. Aortic rings from SHR and WKY rats were incubated with either NOS inhibitor L-NAME, 
cyclooxygenase inhibitor indomethacin (INDO), or L-NAME + INDO to determine the NO- and 
endoperoxide-dependency of relaxation responses to AICAR. Percent relaxation from phenylephrine pre-
constriction is displayed in WKY and SHR rings with (A and B) and without (C and D) endothelium. 
Legend conventions are conserved across E+ and E- panels. SHR and WKY E+ CON and E- CON data 
has been repeated in the figure above (from previous figures) for comparison. Each treatment was 
performed in aortic rings from each animal. n = 3-6 rings per group from different animals.  * P < 0.01, # 






Figure 2-5. Phosphorylation of eNOS at Ser
1177
 was not increased in response to AICAR in SHR or 
WKY aortic rings. P(Ser
1177
)-eNOS content was assessed by western blotting in aortic rings removed 
during the AICAR dose-response curve protocol. A) P(Ser
1177
)-eNOS is expressed in rings with 
endothelium either immediately prior to AICAR exposure (baseline; B, PE pre-contraction only), at each 
AICAR concentration during the dose-response curve (expressed using log M nomenclature) and in time 
controls (TC; PE precontraction for the duration of the dose-response curve with no AICAR exposure). 
Representative blots depict B) p-eNOS for all conditions in the figures above. Results represent data 
collected from 3 independent experiments where aortic rings from a single animal were used to generate 
all treatment conditions for each experiment. Blots were run in duplicate for each set of samples. Legend 
conventions are conserved across panels. Data represents means ± sem. No significant differences were 






Figure 2-6. AICAR pre-incubation blunts contraction to phenylephrine in an NO-dependent 
manner demonstrating an AICAR-mediated increase in NO-bioavailability. Aortic rings from A) 
WKY and B) SHR were pre-incubated with no drug (CON), AICAR (2mM), L-NAME (LN; 10
-4
M) or 
AICAR + L-NAME for 30 minutes and then contracted with phenylephrine (PE; 10
-6.5
M). Values are 
expressed as the mean difference in developed tension from the no drug control group (E+ CON). n = 5-
15 rings per group from different animals. # P < 0.05, † P < 0.001 versus E+ CON or versus an adjacent 






Figure 2-7. EDCF-mediated contractions are blunted in aortic rings from SHR and WKY rats pre-
incubated with AICAR. Endothelium-dependent contractions were observed by exposing rings to 
increasing concentrations of acetylcholine (ACh) in the presence of NOS inhibitor L-NAME and in the 
absence of pre-contraction (quiescent rings). The endothelium- and COX-dependency of these responses 
was verified in A) SHR and B) WKY aortic rings by removal of the endothelium (E-) and by pre-
incubation with the COX inhibitor indomethacin (INDO), respectively. In some experiments rings from 
C) SHR or D) WKY were pre-incubated with either no drug (CON), AICAR (500µM), or AICAR + 
AMPK inhibitor Compound C (CC; 20µM) to determine the influence  of AMPK on this response. Some 
rings were also pre-incubated with CC alone; these responses were not different from the AICAR + CC 
response in SHR or WKY and have therefore not been illustrated in the figure  for clarity. Values are 
expressed as mean percent of tension developed to 60mM potassium chloride (KCl). Each treatment was 
performed in aortic rings from each animal.  n = 3-10 rings per group from different animals. # P < 0.05, 






The main findings of our study are: that AICAR generates both endothelium-dependent and –
independent relaxation in arteries from normotensive rats, that these responses also occur and are actually 
enhanced in arteries from hypertensive animals despite depressed basal AMPK activation, and that the 
mechanisms responsible for endothelium-dependent relaxation are exclusively NO-mediated in WKY but 
NO- and COX-dependent in SHR aorta. Further investigation into the mechanisms responsible for the 
enhanced endothelium-dependent relaxation to AICAR in SHR, revealed that AMPK-mediated 
suppression of downstream COX-EDCF-dependent vasoconstrictory signalling pathways and enhanced 
AMPK activation at low AICAR doses likely account for a significant portion of the augmented 
sensitivity of SHR versus WKY E+ aortic rings. These results are novel and add significantly to our 
understanding of AMPK-mediated vasomotor function by being the first to investigate endothelium-
dependent and –independent functional responses to AICAR in arteries of hypertensive animals and by 
elucidating mechanisms responsible for the endothelium-dependent functional response to AICAR in a 
conduit artery from WKY and SHR.  
Endothelium-independent relaxation to AICAR and other AMPK activators (i.e. deoxy-glucose/ 
hypoxia and metformin) has been observed by others in isolated arteries from several animal models and 
vessel types, including murine aorta
[82]
, porcine carotid arteries
[181]
 and rat aorta
[139]
. During the 
preparation of this manuscript, observations were also published showing that endothelium-dependent 
dilation of isolated resistance arteries and increased flow in an isolated vessel bed in situ occur following 
exposure to AICAR
[15]
. While our findings partly confirm these observations made in other models, they 
also provide the first evidence for the co-existence of endothelium-dependent and independent relaxation 
to AICAR in isolated conduit arteries from SHR and WKY. Consistent with the dose-dependent 
functional relaxation to AICAR observed in SHR and WKY aortic rings during our experiments (Figure 
2-1), markers of AMPK activation (phosphorylation at both AMPK activation site Thr
172
 and AMPK 
downstream target Ser
79




AICAR dose-response curve protocol in SHR and WKY rings with and without endothelium during our 
experiments (although responses in E+ rings were several fold higher and began at lower doses than those 
of E- rings, Figures 2-2 and 2-3), supporting the involvement of AMPK in mediating the dose-dependent 
functional responses to AICAR.  
We were interested in investigating mechanisms responsible for the endothelium-dependent 
component of the relaxation generated by AICAR in SHR and WKY aortic rings. A number of cell 





, and that AMPK activation has been associated with increased NO 
release from endothelial cells
[29,31,44,145]
, establishing NO as a potential mediator of endothelium-
dependent effects of AMPK. However, AMPK activation does not result in eNOS phosphorylation under 
some conditions
[69,147]
, suggesting that AMPK activity and eNOS phosphorylation can be dissociated and 
that the influence of AMPK on NO-mediated vasomotor function may also involve other mechanisms in 
addition to the Ser
1177
 phosphorylation-mediated activation of eNOS. While some studies infer that NO-
dependent relaxation stimulated by AMPK-mediated activation of eNOS may be possible, there is limited 
evidence from previous studies that acute activation of AMPK is capable of generating functional 
vasodilatory outcomes by this mechanism in an intact blood vessel, or in the context of an in vivo vascular 
system
[13,15]
. Our data, along with the recently published work of Bradley et al
[15]
, are some of the first to 
our knowledge to demonstrate an association between endothelium, NO-dependent relaxation and the 
activation of AMPK in isolated intact vessels. Pre-incubation with L-NAME completely removed the 
endothelial component of AICAR-mediated relaxation in WKY and partially blocked the endothelium-
dependent component in SHR aortic rings (Figure 2-4), suggesting that AICAR-mediated endothelium-
dependent relaxation is completely NO-dependent in WKY and only partially NO-dependent in SHR. Our 
observations indicate no AICAR-dependent increases in phosphorylation of eNOS activation site Ser
1177
 
in SHR or WKY aortic rings (Figure 2-5), but further experiments verified that functional NO 




blunts contraction to phenylephrine in rings from WKY and SHR in an NO-dependent manner (Figure 2-
6). Therefore we conclude that AMPK must be facilitating the eNOS-mediated production of NO through 
mechanisms other than Ser
1177




, assisting in 
eNOS association with heat shock protein 90
[44,189]
, promoting the deacetylation of eNOS
[30]
 to assemble 
active eNOS complexes, etc.  Alternatively, AMPK may increase NO bioavailability independently of 
NO production per se via possible effects on NO destruction or the sensitivity of vascular smooth muscle 
to NO (i.e. the other determinants of NO bioavailability). For example, activation of AMPK has been 
associated with decreased oxidative stress in human aortic endothelial cells and mouse aorta
[137,241]
, and 
could thus potentially increase NO bioavailability by reducing the interaction of NO with reactive oxygen 
species. However, the mechanisms attributed to the AMPK-mediated reduction in oxidative stress in these 
studies involved AMPK-mediated modifications in protein transcription, translation, etc., processes which 
require a time frame of hours to days to produce effects, and therefore such mechanisms do not likely 
contribute to the acute functional responses observed here. Further studies will be required to determine if 
oxidative stress is involved in mediating acute effects of AMPK activiation on vasomotor function. 
Interestingly, a portion of the endothelium-dependent component of the relaxation generated by 
AICAR was COX-dependent in SHR but not WKY aortic rings, as the COX 1 and 2 inhibitor 
indomethacin partially blocked endothelium-dependent relaxation in SHR, but not in WKY vessels 
(Figure 2-4). Since a portion of the tension generated by PE is EDCF-mediated in SHR aorta from our 





), it appeared that AICAR was causing endothelium-dependent relaxation of pre-
contracted SHR aortic rings by inhibiting the enhanced COX-EDCF-mediated contraction that is present 
in SHR (an effect that would not be expected to occur in WKY since the contribution of EDCFs to PE-
mediated contraction in WKY rings is minimal
[2,86,142]
). In order to test this hypothesis, we assessed ACh-
induced contraction in quiescent rings in the presence of L-NAME according to an established protocol 




to be greatly enhanced in SHR vs WKY
[48,62,233]
. Indeed, our results herein confirm the endothelium- and 
COX-dependency of the ACh-induced contractions and that the magnitude of these contractions is greater 
in SHR versus WKY aorta. We found that these responses were robustly blunted with AICAR and that 
the effect of AICAR was largely prevented by pre-incubation of rings with the AMPK inhibitor 
compound C, confirming AMPK specificity of this observation (Figure 2-7). Therefore, these novel 
results demonstrate that AMPK is suppressing COX-EDCF-mediated contractions in SHR aortic rings, 
through inhibition of either COX-EDCF production/release, or TP-receptor signalling in the vascular 
smooth muscle. These results are consistent with related work in other models from other investigations 
that have reported that AICAR and metformin both blunt endothelium-dependent contraction in 
mesenteric arteries from OLETF rats (another model of enhanced endothelium-derived contraction) likely 
by suppressing the release of both prostacyclin and thromboxane A2 
[141]
. These findings also support the 
hypothesis that AICAR-mediated dilation of pre-contracted SHR aortic rings was achieved in part 
through suppression of COX-EDCF-mediated contraction.  
The relaxation responses to AICAR in SHR and WKY aortic rings were also partially 
endothelium-independent (Figure 2-1). Although we did not investigate intracellular signalling 
mechanisms within the vascular smooth muscle that could contribute to AICAR-mediated endothelium-
independent relaxation in the present study, previous in vitro biochemical experiments demonstrate that 
AMPK is able to phosphorylate and desensitize MLCK, and thus could presumably induce relaxation in 
the context of an intact vascular system 
[116]
. Endothelium-independent relaxation to AICAR may also 
occur due to effects of AMPK on HMG-CoA reductase 
[36,59,131,157]
, which could involve modulation of 
Rho-kinase and L-type channel extracellular calcium entry
[170]
, thus potentially exerting influence over 
vascular smooth muscle mechanisms of calcium-sensitization and calcium-mediated contraction. As 
indicated, however, we did not undertake to study these mechanisms in the current study, and additional 
cellular and physiological studies will be required to elucidate mechanisms of AMPK-mediated relaxation 




Both the endothelium-dependent and –independent components of the relaxation response to 
AICAR were enhanced in SHR aortic rings compared to those of WKY (Figure 2-1). Initially it was 
tempting to speculate that functional responses in SHR vessels would be less responsive to AICAR than 





)-ACC in SHR vs. WKY E+ rings, Figures 2-2A and 2-
3A). However, studies performed in tissues from diseased or aging models have shown that the ability to 
activate AMPK pharmacologically is not necessarily compromised when AMPK activation is depressed 
in the basal state
[176,182,261]
, and thus there does not appear to be dysfunction in the capacity to activate the 
AMPK protein per se under these conditions. In order to help explain the different functional sensitivities 
of SHR and WKY rings to AICAR, we assessed the intracellular stimulus for AMPK activation and the 
activation of AMPK over the AICAR dose-response curve protocol in SHR and WKY vessels. The 
stimulus for AMPK activation was not different between SHR and WKY rings, as all rings were similarly 
capable of uptake and conversion of AICAR to ZMP (Table 2-2). ZMP is the intracellular metabolite of 
AICAR, and acts as an AMP analogue to activate AMPK both allosterically and by rendering it a poorer 
substrate to upstream phosphatases
[186,208]





increases from baseline were ~ 2 fold greater in SHR versus WKY E+ rings at the lower concentrations of 




)-ACC were similar in SHR versus 
WKY E- rings over all AICAR doses (Figures 2-2F and 2-3F).  It is unknown whether expression and/or 
activity of upstream kinases (i.e. LKB1, CaMKK, TAK-1) and phosphatases (i.e. PP2C), that 
phosphorylate and dephosphorylate AMPK at Thr172, respectively
[68]
, are altered in SHR versus WKY 
vascular tissue.  Thus, it is difficult to speculate on how these might contribute to the SHR/WKY 
differences observed here. While slightly elevated AMPK activation may have contributed to greater 
relaxation in SHR E+ rings than those from WKY (although this does not appear to be the case for SHR 
and WKY E- rings), it is likely that enhanced sensitivity of downstream signalling targets, rather than 




versus WKY E+ and E- rings to AICAR. Indeed, as already discussed, dissection of the mechanisms 
responsible for the endothelium-dependent component of the relaxation response to AICAR provided 
insight into the interpretation of differences in tissue sensitivity by revealing that a COX-dependent 
component of the vasodilatory response to AICAR in SHR but not WKY (Figure 2-7), contributing to the 
responsiveness of SHR E+ rings at lower AICAR concentrations. Furthermore, conduit vessels from SHR 
exhibit higher levels of eNOS protein content expression than those from WKY (see results discussed 
above
[47,85]
), presenting a more abundant target for AMPK stimulation and NO generation and thus 
possibly contributing to greater sensitivity and enhanced NO-mediated relaxation observed in SHR aortic 
rings. In the vascular smooth muscle, signalling through mechanisms such as the Ca
2+
 sensitization that 
are responsible for regulating contraction is up-regulated in aorta from SHR versus WKY
[110,148]
. Any or 
all of these mechanisms may contribute to the SHR versus WKY differences observed in relaxation to 
AICAR, and further investigation will be necessary to elucidate the contribution of these and other 
mechanisms to vascular smooth muscle responses in SHR and WKY aortic rings. 
A limitation of the present study is that we cannot rule out the potential for non-specific activity 
of AICAR
[36,247]
, and caution should be exercised in interpreting results generated using only 
pharmacological tools. However, two features of the current study help mitigate against this limitation: 
first, the consistency between the functional responses to AICAR and the biochemical indices of AMPK 
activation under control and pharmacological dissection conditions (L-NAME, INDO) across a wide 
range of AICAR concentrations, and secondly, the reversibility of the AICAR-mediated effects 
demonstrated by that AMPK inhibitor Compound C. While there has been some concern regarding 
toxicity of AICAR in cell and tissue preparations at high doses, we determined in pilot work that the 
contractile viability of vessels was not compromised following the AICAR dose response curve, as 
tension generated in response to KCl and PE was not different from that obtained prior to AICAR 
exposure (see discussion of pilot work in methods). Thus relaxation to AICAR in our study was not due 




 In summary, AICAR-mediated relaxation is comprised of both endothelium-dependent and –
independent components in aortic rings from WKY and SHR rats. Endothelium-dependent relaxation is 
NO-mediated in WKY, but NO- and COX-mediated in SHR. Greater activation of AMPK in vessels with 
intact endothelium as well as the suppression of COX-, EDCF-mediated vasoconstriction that is enhanced 
in SHR versus WKY are likely the main contributors to the enhanced endothelium-dependent relaxation 
respectively of SHR versus WKY aortic rings to AICAR. These results suggest AMPK may be a useful 
target for improving vasorelaxation in arteries from hypertensive rats and demonstrate that these vessels 
maintain their ability to respond in spite of lower basal AMPK activation. Activation of AMPK in the 
vasculature may be a potential strategy for improving the vascular dysfunction that exists in 
cardiovascular disease states such as hypertension or other disease states exhibiting vasomotor 
dysfunction due to impaired NO-dependent relaxation and/or enhanced COX-mediated contraction.  
 
2.7 Addendum to Study 1: 
 The addendum contains data collected in conjunction with this study but not published as part of 
the American Journal of Physiology Heart and Circulatory Physiology manuscript. These items include: 
Figure A2-1: Functional and biochemical validation for removal of the endothelium from aortic rings by 
mechanical denudation (stated as data not shown in manuscript publication). 
Figure A2-2: Functional viability of aortic rings is not compromised following the AICAR dose response 
curve protocol (stated in the methods section of the manuscript publication). 
Figure A2-3: AMPK activation over time in rat aortic rings following treatment with AICAR. This data 
demonstrates the consistency between the time it takes an aortic ring to achieve full relaxation to a single 
dose of AICAR (i.e. ~ 30 minutes at high doses, Figure 2-1) and AMPK activation over time to a single 





Figure A2-1. Functional and biochemical validation for removal of the endothelium from aortic 
rings by mechanical denudation. Aortic rings isolated were prepared either with (E+) or without (E-) 
endothelium. A) Functional removal of the endothelium was verified by exposing pre-contracted rings to 
a maximal dose of the endothelium-dependent vasodilator aceylcholine (10
-4
M). Vascular smooth muscle 
vasodilatory and vasoconstrictory capacities were tested in the same rings by exposure to a maximal dose 
of endothelium-independent vasodilator sodium nitroprusside (A; 10
-4
M, following pre-contraction with 
PE) and B) vasoconstrictor potassium chloride (B, 60mM) respectively. C) Biochemical verification of 
removal of the endothelium was assessed by immunoblotting for total endothelial nitric oxide synthase 
(eNOS) protein content in E+ and E- rings. D) Representative blot pics are shown for eNOS content in E+ 
and E- rings. n = 4 for E+ vasomotor function data, n = 8-10 for E- vasomotor function data, n = 6 for 






Figure A2-2. Functional viability of aortic rings is not compromised following the AICAR dose 
response curve protocol. Tension generated to potassium chloride (KCl; 40mM) or phenylephrine (PE; 
10
-6.5
M) before and after execution of the AICAR dose-response curve protocol were compared and used 
as indices of functional viability following exposure to AICAR. Rings were contracted with either KCl or 
PE prior to exposure to AICAR (Pre AICAR DRC) to obtain initial values. Following the AICAR dose-
response curve procotol, rings under-went extensive wash out (i.e. 6 consecutive exchanges of buffer 
bath) and a one hour recovery period before being contracted by the second KCl or PE exposure (Post 
AICAR DRC). The numerical values displayed over the Post AICAR DRC data columns represent 
tension generated Post AICAR DRC as a mean percentage of the Pre AICAR DRC values. All data is 
expressed as means ± sem. n = 3 rings per group for PE experiments and n = 5 rings per group for KCl 
experiments. There were no significant differences between tension values Pre versus Post AICAR DRC 
for any groups. The observations above are consistent with previous reports that it is possible to wash out 
AICAR 
[36,60]






Figure A2-3. AMPK activation over time in rat aortic rings following treatment with AICAR. 
Aortic rings were loaded on the myography apparatus, subjected to a standard start and equilibration 
protocol and then incubated with 2mM AICAR. At the specified time points beginning at time 0 (addition 
of AICAR to the tissue bath), rings were quickly removed and snap frozen for western blots of A) 
P(Thr172)-AMPK and B) P(Ser79)-ACC. All time points were collected in rings from the same rat. Data 
represents results from three independent experiments. Values from densitometry analyses were 















AMP-activated protein kinase blunts acetylcholine-induced contractions by endothelium-dependent 











This chapter is presented in manuscript form. 
 




3.1 Review of Study 2 Objectives and Hypotheses 
 The specific objectives and hypotheses for this chapter have already been stated in the 
introduction section, but are reproduced identically here for the reader‟s convenience. 
Purpose: To evaluate the influence of AMPK activation status on endothelium-dependent contractions in 
dysfunctional arteries of hypertensive rats and to elucidate mechanisms responsible for this interaction. 
Specific objectives and hypotheses: 
Objective 1: To verify that endothelium-dependent contractions to ACh are enhanced in quiescent (non-
precontracted) aortic rings from SHR versus those of WKY, and that these contractions are COX-
dependent (as has been shown by others and previously in our own lab). Hypothesis 1: Contractions to 
ACh will be enhanced in aortic rings of SHR versus WKY, and will be abolished by inhibition of COX or 
removal of the endothelium. 
Objective 2: To determine the effect of the AMPK activator AICAR on endothelium-dependent 
contractions in SHR aortic rings. Hypotheses: Endothelium-dependent contractions to ACh will be 
blunted by AICAR pre-incubation in aortic rings of both WKY and SHR. 
Objective 3: To demonstrate reversibility the inhibitory effect of AICAR on endothelium-dependent 
contractions by co-incubating rings with the AMPK inhibitor Compound C. Hypothesis 3: Co-incubation 
of WKY and SHR aortic rings with Compound C will preserve the magnitude of endothelium-dependent 
contraction generated in these vessels to ACh (contractions to ACh will be no different from those in no 
drug control rings). 
Objective 4: To verify that AMPK is activated by AICAR but inhibited by AICAR-Compound C co-
incubation in aortic rings. Hypothesis 4: AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) will 
be elevated in rings treated with AICAR, but unaltered in rings treated with AICAR and CC compared to 




Objective 5: To evaluate the effect of the presence of AICAR on contraction to increasing doses of  TP-
receptor agonists U46619 and PGH2 to evaluate vascular smooth muscle responsiveness to TP-receptor 
stimulation. Hypothesis 5: Contraction to increasing concentrations of TP-receptor agonists U46619 and 
PGH2 will be blunted in aortic rings of WKY and SHR in the presence of AICAR 
Objective 6: To investigate the production/release of 6-keto-prostaglandin F1α (a stable metabolite of  
prostacyclin) by aortic rings of WKY and SHR stimulated with acetylcholine Hypothesis 6: 6-keto-
prostaglandin F1α levels will be blunted in buffer bathing aortic rings of WKY and SHR treated with 
AICAR, but unaltered in the presence of AICAR together with Compound C. 
Objective 7: To determine the effect of AICAR on dose-dependent relaxation/re-contraction of 
phenylephrine pre-contracted SHR aortic rings to increasing [ACh]. Since the vasomotor response of 
phenylephrine pre-contracted SHR aorta to increasing [ACh] is biphasic (relaxation at lower [ACh] is 
NO-dependent followed by COX-dependent recontraction at higher concentrations, this experiment will 
afford the opportunity to confirm the effect of AICAR on endothelium- and COX-dependent contraction, 
and also on NO-dependent relaxation. Hypothesis 7: The endothelium- and COX-dependent re-
contraction at higher concentrations will be abolished in SHR aortic rings pre-treated with AICAR, but 
NO-dependent relaxation will be enhanced with AICAR. 
 
3.2 Overview of Study 2 
Enhanced endothelium-dependent contractions contribute to vasomotor dysfunction in 
hypertension. Activation of vascular AMP-activated protein kinase (AMPK) blunts endothelium-
dependent contractions generated by acetylcholine (ACh) in isolated arteries. The purpose of this study 
was to dissect mechanisms responsible for this interaction in isolated aortic rings of Spontaneously 
Hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY). In vascular myography 




aortic rings of SHR and WKY pre-treated with the AMPK activator AICAR (500µM) compared to 
controls, but the contractions were fully preserved in rings treated with both AICAR and the AMPK 
competitive inhibitor Compound C (CC; 20µM). In contrast, contractions to vascular smooth muscle TP-
receptor agonists U46619 and prostaglandin H2 were not altered by AICAR in aortic rings of either SHR 
or WKY. ACh-stimulated production/release of 6-keto-PGF1α (the main product of prostacyclin) was 
blunted in WKY and SHR rings treated with AICAR, but not with AICAR + CC or with CC alone. In 
precontracted SHR rings, NO-dependent relaxation at low [ACh] was preserved while COX-dependent 
recontraction/blunted relaxation at high [ACh] was abolished with AICAR. These results suggest that 
active AMPK attenuates endothelium-, and COX-dependent contractions in WKY and SHR aorta by 
reducing endothelial prostanoid production, but not via alteration of VSM TP-receptor sensitivity or 
signalling. AMPK may be as a useful target to improve vasomotor function under conditions of enhanced 
endothelium-dependent contraction. 
 
3.3 Introduction  
The vascular endothelium is an important regulator of vessel tone through the production and 
release of both endothelium-derived relaxing and contracting factors, the balance of which is important 
for maintaining healthy vascular function. In arteries of hypertensive, diabetic and aged rats, endothelium-
dependent relaxation is reduced and endothelium-dependent contraction is enhanced 
[47,85,230,232]
, upsetting 
the homeostatic regulation of vessel tone and resulting in vasomotor dysfunction. Endothelium-dependent 
contractions are generated by endothelium-derived contracting factors (EDCFs) that are released from the 
endothelium in response to vasoactive stimuli such as acetylcholine (ACh), adenine nucleotides (ATP, 
ADP), endothelin-1, nicotine and calcium ionophore A23187 
[65,232]
. Although a variety of compounds can 
act as EDCFs depending on disease condition, artery bed, and agonist present 
[65,216,230,232]
, ample evidence 




primary contributors to endothelium-dependent contractions in conduit arteries of Spontaneously 
Hypertensive rats (SHR).  
The production of COX-derived EDCFs is initiated by elevatations in endothelial cytosolic 
calcium concentrations ([Ca
2+
]i) induced by agonists mentioned above. Recent findings
[250]
 suggest that 
agonist-mediated reductions in ER Ca
2+
 content result in activation of Ca
2+
-independent phospholipase A2 
β (iPLA2, presumably via the release of Ca
2+
 influx factor from the ER
[177]
, which displaces calmodulin 
from its inhibitory association with iPLA2)
[12,169,194]
. Activated iPLA2 then releases lysophospholipids 
from membrane lipids that interact with store-operated Ca
2+
 channels on the endothelial cell membrane to 
permit the entrance of extracellular Ca
2+
 into the cytoplasm 
[12,63,195,250]
. This influx of Ca
2+
 actives 
cytosolic phospholipase A2 α (cPLA2; a Ca
2+
-dependent isoform) to release arachondonic acid from lipid 
membranes 
[63,250]
. Arachadonic acid is converted by COX isoforms 1 and 2 (mainly by COX-1 in SHR 
aorta) to the endoperoxide prostaglandin H2 (PGH2)
[63]
, which is subsequently converted by a family of 
prostanoid synthases into prostanoid by-products such as thromboxane A2, prostaglandin E2, 
prostaglandin F2α, and, prostacyclin (PGI2)
[65,230,233]
. Prostanoids and endoperoxides initiate contraction by 
acting on underlying vascular smooth muscle (VSM) thromboxane prostanoid (TP)-receptors, that 
activate the calcium-sensitization signalling axis to inhibit myosin light chain phosphatase and effectively 
increase net phosphorylation of the myosin light chain 20 regulatory subunit of VSM myosin to promote 
contraction 
[25,48]
. Although under normal, healthy conditions PGI2 acts as a vasodilator via activation of 
VSM IP-receptors, it paradoxically stimulates TP-receptor mediated contraction in dysfunctional arteries 
of SHR, and is the prostanoid primarily responsible for enhanced endothelium- and COX-dependent 
contraction in aorta of SHR to ACh
[65,79,80]
. In SHR aorta, endothelium-dependent contractions are 
amplified by pathophysiological alterations such as enhanced [Ca
2+
]i  release to agonists, increased 
expression of COX-1 and PGI2 synthase, increased production and release of PGI2, elevated ROS levels, 




functionally antagonizes EDCF contraction) 
[64,65,217,230]
. Together these factors synergistically contribute 
to enhanced endothelium-dependent contraction and contribute to the vasomotor dysfunction. 
AMP-activated protein kinase (AMPK) is a novel regulator of vascular tone, and can interact with 
a number of vasoactive signalling pathways in both the endothelium 
[27,30,31,44,73,141]
 and VSM 
[73,82,116,181,242]
. Recently we and others have shown that acute activation of AMPK generates both 
endothelium-dependent 
[13,15,73]
 and independent relaxation
[73,82,181]
 in pre-contracted arteries, the former 
occurring partly by suppression of endothelium-derived contractions 
[73]
. Although we have previously 
demonstrated that AMPK suppresses endothelium-dependent contractions 
[73]
, mechanisms responsible 
for this observation have not been defined in arteries of hypertensive rats. Depressed basal AMPK 







 animals, presenting an intriguing question of whether or not enhancing AMPK 
activation may help remedy the vasomotor dysfunction in conditions where endothelium-dependent 
contractions are major contributors to vascular pathology. Thus, since the AMPK-EDCF interaction could 
have important implications for vasomotor function in hypertension, the specific mechanisms involved in 
this relationship warrant attention. 
In this investigation, we explore mechanisms involved in the interaction between AMPK and 
endothelium-dependent contractions by pharmacologically manipulating AMPK activation in isolated 
artery preparations in vitro. The primary objectives of this investigation are: 1) to evaluate the effects of 
AMPK activation on endothelium- and COX-dependent contractions in isolated aortic rings of 
normotensive and hypertensive rats, 2) to investigate the influence of AMPK on TP-receptor mediated 
contraction of the VSM, 3) to determine the influence of AMPK on the production/release PGI2, the main 
EDCF responsible for enhanced endothelium-dependent contraction in SHR aorta. We hypothesize that 
activation of AMPK will suppress endothelium-dependent contractions, lower production/release of PGI2, 




AMPK-mediated suppression of endothelium-, COX-dependent contractions (in arteries from a model of 
hypertension), and broaden the current understanding of the AMPK and COX-EDCF-TP receptor-
mediated signalling axis interaction and the general involvement of AMPK in vasomotor signalling 
processes. 
 
3.4 Materials and Methods  
Animal care and procedures. The University of Waterloo Animal Care Committee approved all animal-
related procedures in these experiments. A total of 50 male Wistar-Kyoto rats (WKY) and 50 male 
Spontaneously Hypertensive rats (SHR) (all 20-22 weeks of age) obtained from Harlan Laboratories 
(Indianapolis, IN) were used for this study. Animals were maintained on a 22/5 Rodent Diet (W) and tap 
water ad libitum, and group-housed at constant air temperature (20-21
o
C) and humidity (~50%) on a 12 
h:12 h reverse light-dark cycle. On the day of experiment, animals were weighed to obtain body mass, 
anesthetized by pentobarbital sodium injection (50-65 mg/kg ip; Vetoquinol N.-A., Lavaltrie, QC, 
Canada) and then euthanized by rapid removal of the heart. Hearts were dissected and weighed. Blood 
pressure was confirmed in a cohort of animals by inserting a Mikro-Tip Pressure Transducer catheter 




Vasomotor responses of isolated vessels. Isolated vessel experiments were performed as already 
described 
[73]
. Briefly, aortic rings 2mm in axial length were prepared, mounted on a myography apparatus 
and maintained in 37
o
C Krebs-bicarbonate buffer aerated with 95%O2/5%CO2. For some experiments, the 
endothelium was mechanically removed (E-) from rings prior to mounting by gently rolling a titanium 
wire over the vessel lumen (as previously described 
[73]
). After step-wise adjustment to a pre-determined 
optimal tension of 7g 
[85]
, rings were contracted with two consecutive doses of 60 mM potassium chloride 
(KCl, with washout back to baseline tension following each). To evaluate endothelium-dependent 
contractions, quiescent rings (not pre-contracted, at baseline tension) with intact endothelium (E+) were 






 (AICAR; 500µM, 30 min), the AMPK inhibitor Compound C 
[266]
 (CC; 20µM, 45 min), 
AICAR + CC, or the cyclooxygenase (COX) inhibitor indomethacin (INDO; inhibits both COX1 and 
COX2 isoforms; 10
-5
M, 30 min), and then exposed to increasing concentrations of muscarinic receptor 




M). VSM responses to increasing concentrations of TP-receptor 
agonist U46619 (10
-10
 M to 10
-6 
M) or prostaglandin H2 (PGH2; 10
-9
 M to 10
-6
 M) were evaluated in rings 
pre-incubated using the same drug conditions as above. All of these experiments were performed in the 
presence of nitric oxide synthase inhibitor Nω-nitro-L-arginine methyl ester (L-NAME; 10
-4
M) to 
optimize observation of the contractile responses (i.e. by removing the functional antagonistic 
vasodilatory influence of NO, net contraction is enhanced). All contractions are expressed as a percentage 
of the tension generated by 60mM KCl (2
nd
 exposure) in the same ring. Concentrations and timing for 
AICAR and CC pre-incubation were chosen based on our own pilot (data not shown) and previous work 
[73]
. In other experiments, rings were pre-incubated with no drug or with AICAR (2mM) for 30 minutes, 
then pre-contracted with the α-adrenergic receptor agonist phenyephrine (PE; 10
-6.5
M), followed by a 




M). These data are expressed 
as percent relaxation from PE pre-contracted tension.  
Immunoblot analyses. Immunoblotting was performed as previously described 
[73,74]
. Briefly, aortic rings 
were carefully removed from the myography apparatus at peak contraction after exposure to the last 
concentration of the ACh dose response protocol (10
-4
M, during the quiescent vessel functional 
experiments), snap frozen in liquid nitrogen, and stored at -80
o
C until time of analysis. Rings were 
homogenized in urea extraction buffer containing protease (Complete Protease Inhibitor, Roche, 
Mannheim, Germany) and phosphatase inhibitors (Halt Phosphatase Inhibitor, Thermo Scientific, 
Nepean, Canada). Samples were prepared at 1ug/ul and wells of polyacrylamide gels were loaded with 
30ug protein/lane. After detection, membranes were stained with ponceau red to confirm equal protein 




Prostanoid release from aortic rings. Aortic rings from a different set of animals were prepared for 
vascular myography as described above, pre-incubated with L-NAME (10
-4
M) and either no drug, 
AICAR (500µM, 30 min), CC (20µM, 45 min), or AICAR + CC, and then exposed to increasing 




M). Additionally, some rings from the no drug condition were not 
exposed to ACh in order to evaluate unstimulated, basal prostanoid release, and to act as time controls. At 
peak contraction following addition of the final ACh concentration (10
-4
M), the Krebs-bicarbonate buffer 
bathing the aortic rings (5mL) was collected, snap frozen in liquid nitrogen and stored at -80
o
C. 6-keto-
PGF1α, the primary metabolite of prostacyclin, was measured in thawed buffer samples using competitive 
EIA kits according to the manufacturer‟s instructions (Cayman Chemical Company, Ann Arbour, MI). 
 Drugs, Chemicals and Antibodies. All drugs and chemicals were purchased from either Sigma-Aldrich 
(St. Louis, MO) or Bioshop Canada (Burlington, ON, Canada) unless otherwise stated. AICAR was 
obtained from Toronto Research Chemicals (Toronto, ON, Canada) and Compound C from Calbiochem 
(EMD Biosciences, La Jolla, CA). Prostaglandin H2 and U46619 were purchased from Cayman Chemical 
Company (Ann Arbour, MI). Primary antibodies specific for P(Thr172)-AMPK (1:1000 dilution), acetyl-
CoA carboxylase (ACC; 1:250), P(Ser79)-ACC (1:500), and the α-subunit of AMPK (recognizing both 
α1 and α2 isoforms) were obtained from Cell Signaling Technology (via New England Biolabs, 
Pickering, ON, Canada), and horse-radish-peroxidase conjugated secondary antibodies from Santa Cruz 
Biotechnology (Santa Cruz, CA). 
Data Analyses. All data is reported as means ± s.e.m., with n referring to the number of animals per 
group. One- or two-way ANOVAs were used for comparisons consisting of more than two groups, with 
Tukey‟s or Bonferonni post hoc tests to evaluate within or between group comparisons. A two-tailed 
Student‟s t-test was utilized for comparisons involving only two groups. All statistical analyses were 
performed using either SAS (SAS Institute, Cary NC), or GraphPad Prism 4 analysis software (La Jolla, 




3.5 Results  
Animal Characteristics. SHR displayed traits associated with cardiovascular pathology including greater 
left ventricle mass, total heart mass, left ventricle-to-body mass ratio and heart-to-body mass ratio 
compared to WKY (Table 3-1). Mean body mass of SHR was also slightly greater than WKY of the same 
age (Table 3-1). Blood pressure measurements confirmed the presence of hypertension in SHR and 
normotension in WKY (mean arterial pressure WKY: 91 ± 4 mmHg vs SHR: 192 ± 4 mmHg, n=4, P < 
0.0001). 
Contractions to acetylcholine are blunted by AMPK activation in SHR and WKY aortic rings. As 
expected and previously observed in dysfunctional arteries of hypertensive animals 
[47,48,138]
, contraction to 
increasing [ACh] was enhanced in aortic rings of SHR versus WKY (P < 0.001 at all concentrations > 10
-
6.5
M), with SHR rings reaching peak contraction of 76±6% of the tension level generated by 60mM KCl 
(Figure 3-1B), and WKY only 19±3% of KCl-generated tension (Figure 3-1A). These contractions were 
completely abolished by either pre-incubation with indomethacin or removal of the endothelium in both 
WKY (Figure 3-1A)  and SHR rings (Figure 3-1B), confirming COX- and endothelium-dependency of 
these responses, as previously reported 
[47,48,138]
. Examination of the AMPK-mediated influence on this 
response revealed that pre-incubation of rings with AICAR blunted ACh-induced contractions in both 
WKY (peak contraction: 4±1%, P < 0.0001 vs E+ CON, Figure 3-1C) and SHR (peak contraction: 
31±9%, P < 0.0001 vs E+ CON, Figure 3-1D). Co-incubation of rings with AICAR and CC completely 
prevented the blunting of contractions induced by AICAR alone (contractions with AICAR + CC were 
not different from respective WKY and SHR E+ CON at any [ACh], Figures 3-1C and 3-D). Contractions 







M) compared to those in the respective E+ CON rings (Figure 3-1C and 3-1D).  
AMPK activation by AICAR and inhibition by Compound C in SHR and WKY aortic rings following 




activation/inhibition, phosphorylation at AMPK activation site threonine 172 (P(Thr172)-AMPK; a 
modification both necessary and sufficient for AMPK activation) 
[99,104]
, and phosphorylation of serine 79 
on acetyl-CoA carboxylase (P(Ser79)-ACC; a well known downstream target of AMPK) 
[99]
, were 
analyzed by immunoblotting in homogenates of aortic rings collected following the ACh dose-response 
functional experiments. AICAR is taken up by cells and converted to the AMP analogue ZMP, which 
activates AMPK in an AMP-like fashion by binding to the nucleotide binding sites of the λ subunit to 
make it a poorer substrate to upstream kinases, and thus facilitating increased phosphorylation of Thr172 
[36,208]
. Compound C is an ATP-competitive inhibitor of AMPK 
[266]
 by presumably interfering with the 
nucleotide binding sites. P(Thr172)-AMPK (Figure 3-2A & B) and P(Ser79)-ACC (Figure 3-2C & D) 
were elevated ~3-4 fold in aortic rings of both WKY and SHR rats in the presence of AICAR alone 
versus no drug controls (E+ CON). Co-incubation of AICAR and CC fully prevented elevation of 
P(Thr172)-AMPK (Figure 3-2B) and P(Ser79)-ACC (Figure 3-2D) in SHR aortic rings and partially 
prevented elevation of P(Thr172)-AMPK (Figure 3-2A) and P(Ser79)-ACC (Figure 3-2C) in aortic rings 
from WKY (values remained slightly elevated relative to E+ CON, but were significantly lower than 
AICAR alone). Phosphorylation at both sites was not different from E+CON in all other treatment 
conditions (CC alone, INDO, E-) following the ACh curve. Exposure of aortic rings to ACh alone did not 
generate detectable differences in P(Thr172)-AMPK compared with un-stimulated time controls (E+ TC, 
not exposed to ACh) in either WKY (E+ CON (ACh): 1.00 ± 0.15 vs E+ TC:1.37 ± 0.15, P = 0.1976) or 
SHR (E+ CON (ACh): 1.00 ± 0.14 vs E+ TC: 1.10 ± 0.03, P = 0.4318).  
Contractions to vascular smooth muscle TP-receptor agonists U46619 and prostaglandin H2 are 
unaffected by AICAR. To determine if blunting of ACh-mediated contractions with AMPK activation 
originated from changes in VSM sensitivity to vasoconstrictor prostanoids, we evaluated VSM 
responsiveness to increasing concentrations of TP-receptor agonist U46619 in SHR and WKY aortic 











. Pre-treatment with AICAR, AICAR + CC or CC alone did not alter contractions to 
U46619 compared to the no drug controls in WKY or SHR aortic rings (Figure 3-3A & B). Results 
generated using U46619 (a synthetic TP-receptor agonist) sometimes vary compared to those obtained 
using endoperoxides in WKY and SHR aorta (i.e. U46619 is a more potent activator of TP-receptors than 
endoperoxides, and may mask subtle differences in VSM responses under some circumstances) 
[78]
; 
therefore we also investigated responses using prostaglandin H2 (PGH2) as a second TP-receptor agonist. 
However, similar to the results obtained using U46619, pre-incubation with AICAR did not affect 
contractions to increasing [PGH2] in WKY (Figure 3-3C) and SHR (Figure 3-3D) vessels.  
Pre-incubation with AICAR suppresses ACh-induced production/release of 6-keto-prostaglandin F1α 
by aortic rings of WKY and SHR. We investigated whether 6-keto-PGF1α (the primary metabolite of 
PGI2) levels were altered in buffer obtained from aortic rings stimulated with ACh in the presence of 
AICAR. PGI2 is the main COX-derived EDCF released by the endothelium in response to stimulation 
with ACh in WKY and SHR aorta, and is the primary contributor to endothelium-dependent contractions 
in aorta of WKY and SHR to this agonist (PGI2 release by these vessels in response to ACh is 
overwhelmingly greater than other prostanoids
[79]
, originates primarily from the endothelium
[80]
, and 
paradoxically generates contraction rather than vasodilation in aorta of SHR and WKY
[79]
; the authors 
refer readers to Félétou et al. 2009 
[65]
 for an excellent review of the evidence supporting the primary role 
of PGI2 as an EDCF in SHR and WKY conduit arteries stimulated with ACh). These considerations allow 
us to assume that major changes in 6-keto-PGF1α using this assay can be reasonably attributed to 
alterations in PGI2 production/release and not to other prostanoid /endoperoxide mediators. As expected 
and previously observed 
[65,79]
, stimulated (E+ CON, exposed to ACh) and unstimulated (E+ TC, no ACh 
exposure) aortic rings of SHR produced/released greater levels 6-keto-PGF1α than those of WKY (ACh-
stimulated E+ CON WKY: 1862±144 vs SHR: 8754±1509 pg/mL, P < 0.001, unstimulated E+ TC WKY: 
520±70 vs SHR: 2831±830 pg/mL, P < 0.05, Figure 3-4A & B). Evaluation of the ability of AMPK to 




AICAR reduced 6-keto-PGF1α to levels nearing those of un-stimulated WKY and SHR E+ time controls 
respectively (E+ AICAR WKY: 799±68 pg/mL, Figure 4A, SHR: 3533±1061 pg/mL, Figure 3-4B). 6-
keto-PGF1α levels in buffer of rings co-incubated with AICAR + CC were not different from those pre-
incubated with CC alone in either WKY (Figure 3-4A) or SHR (Figure 3-4B), but were elevated by 
treatment with AICAR + CC in WKY, and CC and AICAR + CC in SHR above their respective E+ CON 
groups (Figure 3-4A & B).  
Endothelium- and COX-dependent re-contraction/blunted relaxation to acetylcholine is inhibited by 
AICAR in pre-contracted aortic rings of SHR. Exposure of pre-contracted arteries to increasing 
concentrations of ACh generates a biphasic response in dysfunctional vessels of SHR, where 
endothelium-, NO-dependent relaxation is observed at lower [ACh], and COX-dependent re-contraction 
(or blunted relaxation) occurs at higher [ACh] 
[47,86]
 (Figure 3-6B). Therefore exposure of pre-contracted 
SHR aortic rings to this protocol afforded the opportunity to confirm the effects of AICAR on 
endothelium- and COX-dependent contractions using a different protocol/experimental approach, and to 
also investigate potential effects of AICAR on NO-mediated vasodilatory effects to ACh. Re-
contraction/blunted relaxation is not observed in WKY aortic rings at higher [ACh] (an effect observed 
only in SHR arteries using this protocol due to the presence of enhanced endothelium-dependent 
contractions in these vessels), and therefore we did not perform these experiments in WKY aortic rings. 
As expected, relaxation to ACh was blocked by L-NAME, re-contraction/blunting of relaxation was 
reversed by indomethacin, and both responses were completely abolished by the combination of L-
NAME + INDO, confirming the NOS- and COX-dependency of the relaxation and contraction/blunted 
relaxation phases of the responses to ACh, respectively, in SHR aorta (Figure 3-6A). 
Recontraction/blunted relaxation to high concentrations of ACh was blocked by AICAR in SHR aorta 
(Figure 3-6B, in a manner similar to that observed in SHR aortic rings treated with indomethacin (Figure 




observed in the quiescent vessel experiments (Figure 3-1). NO-dependent relaxation to lower 





Table 3-1. Physical Characteristics of WKY and SHR  
 WKY SHR 
Whole body mass (BM), g 321 ± 4 354 ± 4‡ 
Tissue Masses   
Left Ventricle, mg 651 ± 13 848 ± 16‡ 
Left Ventricle/BM (mg/g BM) 2.02 ± 0.02 2.44 ± 0.03‡ 
Right Ventricle, mg 177 ± 5 195 ± 4† 
Right Ventricle/BM (mg/g BM) 0.55 ± 0.01 0.56 ± 0.01 
Heart, mg 828 ± 17 1043 ± 18‡ 
Heart/BM, (mg/g) 2.56 ± 0.02 3.01 ± 0.03‡ 
Kidney (mg) 1033 ± 22 1117 ± 17† 
Kidney/BM (mg/g) 3.20 ± 0.03 3.22 ± 0.03 
 
Due to differences in body weight between strains, values were expressed both in absolute terms and 







Figure 3-1. Activation of AMPK blunts endothelium-dependent contractions generated by 
acetylcholine in WKY and SHR aortic rings. Endothelium-dependent contractions were generated by 
exposing quiescent (non-precontracted) aortic rings to increasing concentrations of acetylcholine (ACh). 
The endothelium- and COX-dependency of these responses is demonstrated in WKY (A) and SHR (B) 
aortic rings by removal of the endothelium (E-) or pre-incubation with the COX-inhibitor indomethacin 
(INDO) respectively. In some experiments, rings from WKY (C) and SHR (D) were pre-incubated with 
either no drug (CON), AMPK activator AICAR (500µM), AMPK competitive inhibitor Compound C 
(CC; 20µM), or AICAR + CC to investigate the influence of AMPK on endothelium-, COX-dependent 
contractions. All experiments were performed in the presence of NOS-inhibitor L-NAME (10
-4
M). Values 
are expressed as mean percentage of tension developed by individual rings to 60mM potassium chloride 
(KCl). Each treatment was performed in aortic rings from a single animal. n = 8-12 rats per group. * P < 
0.05, † P < 0.01, ‡ P < 0.001 vs. E+ CON. In panels A and B, E+ INDO and E-CON are all P < 0.0001 vs. 
E+ CON for concentrations greater than 10
-6.5
M in SHR and 10
-6
M in WKY, but significance symbols 
have been excluded for clarity.  






Figure 3-2. AMPK activation by AICAR and inhibition by Compound C is confirmed in aortic 
rings of WKY and SHR following the functional acetylcholine dose response curve protocol. After 
attaining a stable functional response at the last dose of ACh in the functional protocol used to generate 
data in Figure 1, rings were carefully and rapidly removed from the apparatus, snap frozen in liquid 
nitrogen and stored at -80
o
C until they were processed for immunoblotting. The status of AMPK 
activation was assessed by immunoblotting for phosphorylation of AMPK activation site Thr172 (A) and 
AMPK downstream target Ser79 on acetyl-CoA carboxylase (ACC; B). Values are expressed as the mean 
± s.e.m. of the densitometry analyses (arbitrary units), and all values are normalized such as that the mean 
of the WKY E+ CON or SHR E+ CON is equal to 1.00. Representative blot images for WKY and SHR 
P(Thr172)-AMPK or P(Ser79)-ACC display 1 lane from each group. n = 6 animals for each group 
(samples run in duplicate). * P < 0.05, ‡ P < 0.001 vs WKY E+ CON or SHR E+ CON, # P < 0.05 vs 
WKY E+ AICAR. INDO; cyclooxygenase 1 and 2 inhibitor indomethacin, E-; aortic rings with 







Figure 3-3. Contraction to vascular smooth muscle TP-receptor agonists is unaltered by AMPK 
activation or inhibition. Endothelium-independent contractions were generated by exposing WKY and 
SHR aortic rings to increasing concentrations of TP-receptor agonists U46619 (A,B) or prostaglandin H2 
(C,D) in the presence of either no drug (CON), AMPK activator AICAR (500µM), AMPK competitive 
inhibitor Compound C (CC; 20µM), or AICAR + CC to investigate the influence of AMPK on VSM 
sensitivity to TP-receptor stimulation. All experiments were performed in the presence of NOS-inhibitor 
L-NAME (10
-4
M). Values are expressed as mean percentage of tension developed to 60mM potassium 
chloride (KCl) by individual rings. Each treatment was performed in aortic rings from a single animal. n = 







Figure 3-4. Pre-incubation with AICAR suppresses the production/release of 6-keto-PGF1α by 
aortic rings of SHR and WKY rats. 6-keto-prostaglandin F1α (6-keto-PGF1α) a stable metabolite of 
prostacyclin, was assessed in the Kreb‟s bicarbonate buffer bathing aortic rings over the duration of the 
functional ACh dose-response curve data generated in Figure 1. After attaining a stable functional 
response at the last dose of ACh, buffer was collected, snap frozen in liquid nitrogen and stored at -80
o
C 
until processed using an EIA kit. Buffer was also collected from a time control (TC) ring, that present for 
the duration of the experiment but not exposed to ACh, in order to assess basal, unstimulated prostacyclin 
production/release by the rings. Values are expressed as means ± s.e.m. in picograms per millilitre. n = 6-







Figure 3-5. Endothelium- and COX-dependent recontraction/blunted relaxation to acetylchloline is 
inhibited by AICAR in precontracted aortic rings of SHR. Relaxation to increasing concentrations of 
acetylcholine (ACh) was generated in SHR aortic rings pre-contracted with phenylephrine (PE). Panel A) 
demonstrates the NO-dependency of vasodilation to lower [ACh] and COX-dependency of re-
contraction/blunted relaxation at higher [ACh] by pre-incubating rings with endothelium (E+) for 30 
minutes with either no drug (CON), NOS-inhibitor L-NAME (10
-4
M), COX inhibitor indomethacin 
(INDO; 10
-5
M), INDO + L-NAME prior to precontraction with PE. In panel B), rings were pre-incubated 
with either no drug (CON) or AICAR (2mM) to evaluate the effect of AMPK activation on the vasomotor 
responses of to ACh. Values are expressed as mean percent relaxation of tension developed to PE.  n = 4-
12 rings per group from different animals. * P < 0.05, † P < 0.01, ‡ P < 0.001 vs. E+ CON, # P < 0.05 vs 







In this study, we investigate the interaction of AMPK with endothelium-, COX-dependent 
contraction in isolated aortic rings of normotensive and hypertensive rats. The major findings are: 1) 
AMPK activator AICAR blunts ACh-induced contractions in SHR and WKY aorta, an effect that is 
prevented in the presence of AMPK inhibitor Compound C, 2) contractions initiated by direct stimulation 
of VSM TP-receptors are unaffected by pharmacological manipulation of AMPK activity, and 3) AICAR 
blunts ACh-stimulated production/release of 6-keto-PGF1α (the major metabolite of PGI2 that is primarily 
responsible for endothelium-dependent contractions in SHR and WKY aorta to ACh). This is the first 
description of the mechanisms involved in AMPK-mediated inhibition of endothelium-dependent 
contractions in arteries of hypertensive animals.  
We begin by showing that ACh-induced endothelium-dependent contractions are blunted in the 
presence of AMPK activation with AICAR (Figure 3-1). These results are consistent with our previous 
results
[73]
 and with those of Matsumoto et al. who have shown that pharmacological activation of AMPK 
with AICAR and metformin (an anti-diabetic drug that also activates AMPK 
[266]
) inhibits endothelium-
dependent contractions to ACh in mesenteric arteries of diabetic rats 
[141]
. Together our observations and 
those of Matsumoto and colleagues are the first reports to our knowledge of an interaction of AMPK with 
endothelium-dependent contractions, and ours are the first reported in arteries from a model of 
hypertension.  
Collectively, the observations of this study indicate that the blunted endothelium-dependent 
contractions to ACh originate from AMPK-mediated effects on the endothelium rather than the VSM of 
WKY and SHR aorta. Sensitivity of VSM to TP-receptor agonists U46619 and PGH2 was unaltered by 
the presence of AICAR in WKY or SHR aorta (Figure 3-3), and thus blunted ACh-induced contractions 
by AMPK activation cannot be explained by altered responsiveness of the VSM to EDCFs. These results 




AMPK can alter vascular responsiveness to contractile agonists. However, since some agonists (i.e. KCl 
and PE) are more reliant on increases in intracellular Ca
2+
 where as others operate more predominantly 
via increased Ca
2+
 sensitization (i.e. TP-receptor agonists)
[197,198]
, it is conceivable that the effects of 
AICAR could vary depending on the constrictor agonist applied if the effects of AMPK were mediated 
through either one or the other of these pathways. Contraction to other stimuli such as membrane 




, and correspondingly, we have also observed that AMPK activation with AICAR blunts endothelium-
independent contraction of rat aorta to these two agonists (Figure A3-1 and data not shown). However, 





 mice, along with depressed contraction to these agonists in mouse 
aorta with AICAR pre-incubation 
[242]
. Pre-incubation of rings with a higher dose of AICAR may have 
elicited effects on VSM responsiveness in our experiments with TP-receptor agonists, as the observations 
discussed above were generated from arteries pre-incubated with 2mM AICAR (rather than 500µM used 
to generate our data) 
[242]
. Nonetheless, altered VSM TP-receptor sensitivity at AICAR concentrations 
used here do not explain AMPK-mediated blunting of contraction to ACh in this study. Further work will 
be required to resolve discrepancies in the currently available data.  
ACh-induced 6-keto-PGF1α production/release by WKY and SHR aortic rings is also reduced in 
the presence of AICAR (Figure 3-4). Gluais et al. (2006) have shown that ACh-induced 6-keto-PGF1α 
release originates almost exclusively from endothelial sources
[80]
, and thus we can assume that major 
alterations in 6-keto-PGF1α production/release observed here originate from direct effects on the 
endothelium. This is the first report of AMPK-dependent suppression of PGI2 production/release from 
arteries of hypertensive rats, and is consistent with the ability of AICAR and metformin to inhibit the 
production/release of prostanoids in diabetic rat mesenteric arteries 
[141]
. Although we only investigated 
the effect of AICAR on PGI2 (6-keto-PGF1α) production/release, Matsumoto et al. demonstrated that 




thromboxane B2 (stable metabolite of thromboxane A2), other prostanoids derived from PGH2 by their 
respective synthases
[141]
. Considering these data collectively, it seems more reasonable that 
AICAR/AMPK likely acts upstream of the prostanoid synthases to inhibit the production of their common 
substrate (PGH2), and that the blunted PGI2 levels observed in our study in the presence of AICAR 
probably did not result from a direct effect of prostacyclin synthase specifically. 
Examining vasomotor responses of precontracted aortic rings to ACh afforded the opportunity to 
confirm the inhibitory effects of AICAR on endothelium- and COX-dependent contractions and also to 
evaluate the effect of AMPK activation on the NO-dependent component of relaxation to ACh. Although 
AICAR pre-incubation abolished COX-dependent re-contraction/blunted relaxation to high [ACh] (in 
accordance with observations on the endothelium-dependent contractions quiescent vessel experiments in 
SHR vessels), the NO-dependent vasorelaxation portion of the response to lower [ACh] was unaffected 
by AMPK activation in SHR aorta (Figure 3-5B). NO-dependent relaxation was also maintained in 
similar experiments using AMPK activators in diabetic rat mesenteric arteries 
[141]
, and ACh-mediated 
relaxation is also unaltered in arteries from AMPK α1-/- or AMPKα2 -/- mice 
[68,86]
. Since the production 
of NO and COX-derived prostanoids both require elevated [Ca
2+
]i, it is unlikely that AMPK is acting 
upstream of Ca
2+
 release by the intracellular ER stores in these experiments (if this were the case, both 
COX-dependent contraction and NO-dependent relaxation would be expected to be inhibited by AMPK 
activation); thus it is more probable that AMPK acts downstream of SR Ca
2+
 release on a signalling 
process specific to COX-dependent contraction.  
Perspectives 
These experiments are the first to investigate mechanisms of AMPK-mediated suppression of 
endothelium-derived contractions in arteries of hypertensive animals, and some of the first data to suggest 
a link between AMPK and the COX-EDCF signalling axis. Our data demonstrate that activation of 




These results highlight the potentially important therapeutic utility of AMPK, as the ability to suppress 
COX-dependent contractions, but not NO-dependent relaxation, would be favourable for treating 
endothelial dysfunction where endothelium-dependent contraction is enhanced. In future experiments it 
will be important to investigate whether chronic improvements in AMPK activation can reduce 
endothelium-dependent contractions and improve vascular function by an AMPK-dependent mechanism 
in vivo. The link between AMPK activation and reduced endothelium-dependent contraction detailed here 
provides support for targeting AMPK as a therapeutic strategy for interventions aiming to improve 
vasomotor function in essential hypertension and in other conditions of vascular dysfunction where 






3.7 Addendum to Study 2: 
 The addendum includes data collected in conjunction with this study that is not part of the 
manuscript.  







Figure A3-1. Contraction to potassium chloride is blunted in aortic rings of WKY and SHR pre-
treated with AICAR. Aortic rings of A) WKY and B)  SHR without functional endothelium were pre-
incubated with no drug (CON), AMPK activator AICAR (2mM), NOS inhibitor L-NAME (10
-4
M), or 
AICAR + L-NAME for 30 minutes, and then exposed to 60 mM potassium chloride (KCl). Values are 
expressed as tension developed to KCl in grams.  n = 10-18 rings per group from different animals. † P < 
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4.1 Review of Study 3 Objectives and Hypotheses 
 The specific objectives and hypotheses for this chapter have already been stated in the 
introduction section, but are reproduced identically here for the reader‟s convenience. 
Purpose: To determine the effects of AMPK activation by an acute injection of AICAR on in vivo 
hemodynamic responses of normotensive and hypertensive rats, and to evaluate whether parallel 
relaxation responses occurs in isolated, pre-contracted resistance arteries of normotensive and 
hypertensive rats exposed to AICAR acutely in vitro. 
Specific objectives and hypotheses: 
Objective 1: To investigate the effect of acute AICAR injection on blood pressure responses of SHR and 
WKT in vivo, and to determine the NO-dependency of these effects via carotid arterial catheter pressure 
transducers. Hypothesis 1: Acute injections of AICAR will lower blood pressure in WKY and SHR, and 
that this effect will be partly NO-dependent. 
Objective 2: To investigate the effect of acute AICAR injection on heart rate response of SHR and WKY 
in vivo by carotid arterial catheter. Hypothesis 2: AICAR will have minimal to no influence on heart rate 
of WKY or SHR.  
Objective 3: To verify the efficacy of the AICAR treatment during the in vivo experiments by assessing 
AMPK activation in vascular tissue from these animals by immunoblotting. Hypothesis 3: Acute 
injections of AICAR will elevate P(Thr172)-AMPK levels in aortas of WKY and SHR rats. 
Objective 4: To characterize basal levels of AMPK activation and expression in mesenteric artery 
sections from SHR and WKY by immunoblotting. Hypothesis 4: AMPK activation (P(Thr172)-AMPK) 




Objective 5: To evaluate the vasomotor response of pre-contracted isolated mesenteric resistance artery 
segments to acute AICAR exposure, to determine the endothelium- and NO-dependency of this response, 
and to compare the responses generated in SHR versus WKY vessels using vascular myography. 
Hypothesis 5: Relaxation to AICAR will occur in mesenteric arteries of both WKY and SHR and will be 
partly endothelium-, NO-dependent. 
Objective 6: To verify AMPK activation in mesenteric artery segments from SHR and WKY incubated 
with AICAR by immunoblotting. Hypothesis 6: AMPK activation (P(Thr172)-AMPK) will be elevated 
in mesenteric arteries of WKY and SHR following incubation with AICAR. 
Objective 7: To compare baseline levels of P(Ser1177)-eNOS and total eNOS protein content in aortas 
and mesenteric arteries of WKY and SHR rats. Hypothesis 7: P(Ser1177)-eNOS will be depressed in 
aorta and mesenteric arteries of SHR versus those of WKY, and total eNOS protein content will be 
elevated in these vessel types in SHR versus WKY. 
Objective 8: To evaluate the effect of AICAR injections in vivo and AICAR incubation in vitro on 
P(Ser1177)-eNOS (and total eNOS protein content) by immunoblotting in aortas and mesenteric arteries 
respectively of WKY and SHR. Hypothesis 8: Acute exposure to AICAR will increase P(Ser1177)-
eNOS in both types of experiments (aorta and mesenteric arteries) but total eNOS protein content will not 
be altered by AICAR.  
 
4.2 Overview of Study 3 
Activated AMPK may alter blood pressure by directly influencing vascular tone. The purpose of 
this study is to examine if these effects occur acutely in a model of hypertension. Using distinct groups of 
Wistar-Kyoto (WKY) and Spontaneously Hypertensive Rats (SHR) we compare 1) baseline aortic and 
mesenteric artery AMPK activation (by immunoblotting), 2) hemodynamic (blood pressure and heart rate 




aminoimidazole-4-carboxyamide-1-β-D-ribofuranoside (AICAR) in vivo, and 3) vasomotor responses of 
isolated mesenteric vessels to AICAR exposure in vitro using myography. Mean arterial pressure (MAP) 
decreased from 196±3 to 122±15 mmHg (P < 0.001) during the 30 minutes following AICAR injection in 
SHR (an effect partially prevented by NOS inhibitor L-NAME), but in WKY MAP was unaffected by 
AICAR. Basal AMPK activation (phosphorylation of AMPK activation site threonine 172) was reduced 
~50% in aorta of SHR versus WKY (0.49±0.1 vs 1.0±0.1 arbitrary units, P < 0.001), and was improved 
~1.6 fold in SHR but not WKY aorta 30 minutes following AICAR injection. In isolated vessel 
experiments, dose-dependent vasorelaxation to AICAR was similar in mesenteric arteries of SHR and 
WKY, although responses were more reliant on NO in SHR than in WKY.  The ability of AICAR to 
improve vascular AMPK activation, and to generate parallel reductions in blood pressure and relaxation 
of SHR resistance vasculature, highlights the potential importance of AMPK in the regulation of blood 
pressure and vascular tone.  
 
4.3 Introduction 
A potential role for AMP-activated protein kinase (AMPK) in blood pressure (BP) regulation is 
suggested from incidental observations that 5-aminoimidazole-4-carboxamide-1--D-ribofuranoside 
(AICAR), a compound that results in the activation of AMPK
[124]
, has hypotensive effects when 




. AMPK has also been identified a regulator 
of vascular tone by experiments showing that activation of AMPK generates vasorelaxation in conduit 




 and porcine 
[181]
 models and in rat 
[15]
 and human 
[13]
 resistance 
vasculature. The potential hemodynamic effects of AMPK-activation, coupled with acute AMPK-
mediated vasodilation in isolated vessels, make it is reasonable to suggest that AMPK activation may 
exert BP lowering effects by directing vasorelaxation responses in resistance arteries. The hemodynamic 
effects of acute AICAR/AMPK activation have not been studied in models of essential hypertension, in 
which systemic artery endothelium-dependent dilation is impaired
[62,236]




available data investigating vasomotor responses to AMPK activation in resistance arteries of a 
hypertension model.  
 AMPK increases nitric oxide (NO) bioavailability in isolated protein experiments 
[27]
 in cultured 
bovine 
[44]
 and human 
[145]
 endothelial cells, and in mouse aorta in vivo
[44]
 via mechanisms that could 
include phosphorylation of eNOS at activation sites serine 1177
[145] [27,44] or serine 633[31], or by 
facilitation of active eNOS complexes
[30,44]
. We and others have provided evidence to suggest that 
vasorelaxation of conduit arteries evoked by activation of vascular AMPK with AICAR is partially 
endothelium-, NO-dependent 
[13,15,73]
 and partly endothelium-independent via direct vasorelaxation of 
vascular smooth muscle
[73,82,181]
. Therefore it is plausible that activation of AMPK in resistance 
vasculature is also partly NO-dependent and that this response could translate into an NO-dependent BP 
response to acute AMPK activation in vivo. 
The main purposes of this study were: 1) to determine the BP responses to acute in vivo injections 
of the AMPK activator AICAR in WKY and SHR, and the NOS-dependency and -independency of these 
responses and 2) to investigate the influence of AICAR-induced AMPK activation on vasorelaxation of 
isolated resistance vasculature in vitro using mesenteric arteries of normotensive Wistar Kyoto Rats 
(WKY) and Spontaneously Hypertensive Rats (SHR). We hypothesized that acute administration of 
AICAR in vivo will lower BP in hypertensive and normotensive animals in a NOS-dependent manner, 
and that parallel AICAR-dependent vasorelaxation of isolated resistance vessels will support a potential 
role for AMPK-mediated control of vascular resistance in the acute regulation of BP in hypertensive 
animals.  
 
4.4 Methods  
Animal care procedures.  The University of Waterloo Animal Care Committee approved all animal-




SHR all aged 20-24 weeks and obtained from Harlan (Indianapolis, IN). Animals were group-housed at a 
constant air temperature (20-21
o
C) and humidity (~50%) in a 12 h:12 h reverse light:dark cycle. Rats had 
free access to standard 22/5 Rodent Diet (W) lab chow (Harlan) and tap water. Prior to all experiments, 
body mass was recorded and rats were anesthetised with pentobarbital sodium injection (50-65 mg/kg, 
i.p.; Vetoquinol N.-A. Inc., Lavaltrie, QC, Canada).   
Hemodynamic responses following acute injections of AICAR in vivo. Anesthetized animals were 
instrumented for mean arterial pressure (MAP) and heart rate (HR) measurements by inserting a 
heparinized saline-filled PE-50 cannula into the left common carotid artery, and data were collected as 
previously described
[74]
. Baseline MAP was analyzed during the final 5 minutes of an initial 15 minute 
equilibration period. AMPK activator AICAR and NOS inhibitor Nω-Nitro-L-arginine monoethyl ester (L-
NAME; L-arginine analog and competitive NOS inhibitor) were then administered acutely according to 
the protocol outlined in Figure 4-2A to evaluate AMPK- and NOS-dependent hemodynamic responses. L-
NAME (30 mg/kg body weight in 200μl of 37
o
C saline) or saline only (200μl) was administered via the 
carotid artery catheter (slowly over 1 minute), and AICAR (0.5mg AICAR/g body weight in 2mL 37
o
C 
saline) or saline alone (2 ml) was injected intraperitoneally according to doses previously reported
[19]
.  
Vasomotor responses of isolated WKY and SHR thoracic aorta and mesenteric artery rings to acute 
AICAR exposure. Animals were anesthetized as outlined above and killed by rapid removal of the heart. 
For thoracic aorta experiments, aortic rings 2mm in axial length were prepared for the collection of 
vasomotor data using vascular myography as previously described 
[74]
. Following a standard set-up 
protocol, rings were pre-contracted with phenylephrine (PE, α-adrenergic receptor agonist, 10
-6.5
M) then 
exposed to a single dose of 2mM AICAR to observe vasodilation (concentration selected based on 
previous experiments in WKY and SHR aorta
[73]
). For the mesenteric artery experiments, the superior 
mesenteric artery from SHR and WKY rats was exposed and the mesentery was excised from ~2cm distal 
to the pylorus to the beginning of the large intestine. Tissue was immediately placed in 4°C, aerated 




1.17 MgSO4◦7H2O, 1.18 KH2PO4, 2.50 CaCl2◦2H2O, 25.00 NaHCO3, 0.03 EDTA, 5.50 glucose). The 3
rd
 
order arteries were cleaned of connective tissue and the venous branches were carefully removed under a 
dissecting microscope (Zeiss; VWR, Mississauga, ON). A single section of 3
rd
 order mesenteric resistance 
artery was divided into two segments which were placed into aerated PSS at room temperature (22°C). 
The vessel segments were then placed in baths filled with 10mL of 37°C aerated PSS and mounted onto a 
calibrated wire myograph (DMT, Denmark) as outlined previously
[61,151,159]
. Artery segments were washed 
and incubated for 30min in 37°C PSS prior to normalization according to previous protocols
[151]
. Ninety 
percent of the normalized diameter was used as the experimental diameter based on previous studies
[61]
, as 
well as our own pilot work. The experimental diameter was set for each vessel for the remainder of the 
protocol. Mean normalized mesenteric resistance artery diameters were not significantly different 
between groups (256±10 µm in SHR and 310±12 µm in WKY). All vessels were incubated for another 30 
minute equilibration period following the standard start protocol
[159]
, and were then incubated for 30 
minutes with propranolol (3μmol/L) to block β-adrenergic receptor-mediated signaling, which remained 
present during all subsequent experiments. In addition to propranolol, rings were incubated with either no 
drug or L-NAME (10
-4
M) to determine the NOS-dependency of the responses. All vessels were then pre-
constricted using norepinephrine (NEPI; 10
-5
 M), and after achieving a stable plateau, exposed to 






M). These concentrations of AICAR were chosen 
based on pilot work and previous experiments in WKY and SHR arteries 
[73]
.  Responses were expressed 
as percentage relaxation from pre-contracted tension in each ring. The functional viability of the 
endothelium in our preparations was tested by pre-constricting arterial segments with NEPI (10
-5
 M) 
followed by exposure to a maximal dose of acetylcholine (10
-4
 M).  
Immunoblotting analyses. Tissue for immunoblotting was derived from three distinct sets of animals: 
first, thoracic aorta and 3
rd
 order mesenteric arteries were harvested from untreated SHR and WKY. 
Secondly, thoracic aortas were retained from WKY and SHR of all treatment groups (after animals were 




vivo experiments (Figure 4-2A). Thirdly, for mesenteric artery experiments, 3
rd
 order mesenteric artery 
segments were isolated as for small vessel myography experiments, placed in aerated phosphate buffered 
saline (PSS), and warmed slowly to 37
o
C over 30 minutes and left to equilibrate for 1 hour. Vessels were 
then exposed to either AICAR (2mM, in PSS) or no AICAR (PSS only) for 30 minutes. In all 
experiments, arteries were quickly excised, dissected free of connective tissue in 4
o
C Krebs-bicarbonate 
buffer, snap frozen, and stored -80
o
C until processed for immunoblotting. Aortas and mesenteric artery 
segments were homogenized and samples prepared as previously described 
[74]
. Polyacrylamide gels were 
loaded with 30µg total protein per lane. All membranes were stained with ponceau to confirm equal 
protein loading across lanes.  
Drugs, Chemicals and Antibodies. All drugs and chemicals were purchased from either Sigma-Aldrich 
(St. Louis, MO) or Bioshop Canada Inc. (Burlington, ON, Canada) except AICAR which was purchased 
from Toronto Research Chemicals (Toronto, ON, Canada). For immunoblotting experiments, primary 
antibodies specific for the α subunit of AMPK (recognizing both α1 and α2 subunit isoforms, 1:500 
dilution), P(Thr172)-AMPK (1:500) and P(Ser1177)-eNOS (1:3000) were obtained from Cell Signaling 
Technology (via New England Biolabs, Pickering, ON, Canada), and eNOS (1:750) was from BD 
Biosciences. Horse-radish-peroxide conjugated secondary antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). 
Data Analyses Values are reported as mean ± standard error, with n referring to the number of animals 
per group. For comparisons consisting of more than two treatment conditions or groups, one- or two-way 
ANOVAs with Tukey‟s or Bonferroni post-hoc analyses were conducted to evaluate within or between 
group comparisons. A two-tailed Student‟s t-test was used for comparisons where only two groups were 
present. Differences were considered significant if P < 0.05. All statistical analyses were performed using 





4.5 Results  
Baseline AMPK activation in SHR and WKY arteries 
Phosphorylation of AMPK at activation site threonine 172 (a modification necessary and 
sufficient for AMPK activation 
[99]
) was used as marker of AMPK activation in our experiments. 
Although relative total AMPK-α protein levels were not different between aorta of WKY and SHR, 
P(Thr172)-AMPK and the P(Thr172)-AMPK/AMPK-α ratio were reduced by ~50% in SHR aorta 
compared to WKY, demonstrating reduced basal AMPK activation in aorta of SHR vs WKY (Figure 4-
1A). In mesenteric arteries, total AMPK-α protein was ~ 2 fold greater in SHR whereas P(Thr172)-
AMPK was similar in SHR vs. WKY, resulting in  a reduced P(Thr172)-AMPK/AMPK-α ratio (~50%) in 
SHR vs. WKY (Figure 4-1B). 
In vivo hemodynamic responses to acute AICAR injections in WKY and SHR 
MAP. Baseline MAP was 91±2 mmHg and 196±3 mmHg in WKY and SHR, respectively (P < 
0.0001). Saline injections did not alter MAP from baseline in WKY or SHR over the 30 minutes of data 
collection (Figure 4-2C and D respectively). Injections of AICAR generated a progressive decrease in 
MAP to ~ 75 mmHg below saline values by 30 minutes post-injection in SHR (Figure 4-2D), but AICAR 
did not alter MAP relative to the saline group in WKY (Figure 4-2C). MAP reductions to AICAR in SHR 
were partially NO-dependent, as pre-injections with L-NAME partly prevented the effects of AICAR on 
MAP in SHR, with SHR MAP only decreasing ~40 mmHg over the 30 minutes following AICAR 
injection in the L-NAME + AICAR group (Figure 4-2D). Pre-injections of L-NAME alone did not alter 
MAP from the saline control in SHR (Figure 4-2D), but generated a ~ 35 mmHg elevation in MAP above 
saline values in WKY that was maintained for the duration of the experiment and was not altered by the 
addition of AICAR (Figure 4-2C).  
Heart Rate. In SHR, HR was similar in all groups at time 0, did not change over the 30 minutes 
following injections of saline alone, but was depressed only modestly and transiently by a maximum of ~ 




minutes, P < 0.0001) (Figure 4-2B). Pre-injections of L-NAME did not alter HR compared with saline 
only, nor did HR of SHR treated with L-NAME and AICAR differ from those treated with only AICAR 
at any time point (Figure 4-2B). Mean HRs in WKY groups were ~ 235-275 bpm immediately prior to 
saline or AICAR injection (Time 0) and remained constant in all treatment groups through the duration of 
data collection (Figure 4-2B).   
AMPK activation in SHR and WKY aorta after AICAR treatment in vivo 
 AICAR is taken up by tissues and phosphorylation into its active form ZMP (an AMP analogue), 
that increases both AMPK activity allosterically and covalently by making it a more favourable substrate 
for upstream kinases and a poorer substrate for upstream phosphatases, (effectively increasing the net 
level of phosphorylation at activation site threonine 172). In SHR aortas harvested 30 minutes following 
AICAR injections, P(Thr172)-AMPK was increased ~1.6 fold compared to those of SHR injected with 
saline alone (Figure 4-3B), but was not increased in aortas of WKY 30 minutes after AICAR treatment 
relative to the saline controls (Figure 4-3A). As a control experiment, the efficacy of AICAR injections 
was confirmed in the WKY animals by examining liver tissue P(Thr172)-AMPK in WKY. Liver 
P(Thr172)-AMPK was 2.6 ± 0.45 fold greater in AICAR injected WKY compared to those injected with 
saline (1. 00 ± 0.05 arbitrary units, P < 0.05, Figure A4-3). L-NAME did not affect P(Thr172)-AMPK in 
aortas of WKY (Figure 4-3A) or SHR (Figure 4-3B) treated with saline or AICAR. Not surprisingly, 
AMPK-α total protein levels were not affected by any treatment condition in WKY or SHR (Figure 4-3A 
& B).  
Functional responses of isolated conduit and resistance arteries to acute AICAR exposure in vitro. 
Thoracic Aorta. We have previously demonstrated enhanced, dose-dependent relaxation in pre-






. As a 
control experiment, we chose to replicate experiments in aorta of WKY and SHR here using a single dose 
of AICAR, in order to confirm the previous conduit aorta work and add value to the overall interpretation 




exposure to a single submaximal dose of 2mM AICAR generated greater relaxation in aortic rings of SHR 
than of WKY (75±15% and 27±8% of pre-contracted tension respectively, P = 0.0133). Pre-contracted 
tension to phenylephrine was not different in WKY and SHR aortic rings (WKY: 1.8 ± 0.4g, SHR: 1.4 ± 
0.3g, P = 0.4160).   
Mesenteric arteries. AICAR generated dose-dependent relaxation that reached near 100% 
relaxation from pre-contracted tension at high [AICAR] (10
-2
M) in isolated mesenteric artery segments of 
both WKY and SHR. In contrast to the responses observed in aorta, relaxation to AICAR did not differ 
between SHR and WKY mesenteric arteries at any AICAR concentration (Figure 4-4A). Relaxation of 
mesenteric arteries to AICAR was more NO-dependent in SHR than in WKY, as L-NAME significantly 
blunted relaxation in SHR rings at all AICAR concentrations, but blunted relaxation in WKY rings only 
at 10
-6
M AICAR (Figure 4-4A). Pre-contraction to NEPI (10
-5
M) was not different across treatment 
groups or between SHR and WKY arteries (WKY: CON 15.5±1.0mN, L-NAME 15.4±1.0mN, SHR: 
CON 15.6±0.9mN, L-NAME 17.1±1.6mN). 
To more rigorously evaluate the contribution of NO-dependent and NO-independent mechanisms 
to the relaxation generated by AICAR in WKY and SHR mesenteric arteries, the proportion of the 
relaxation response accounted for by NO-dependent mechanisms were also expressed as at each 
concentration of AICAR for both WKY and SHR vessels (Figure 4-4B). Relaxation to AICAR was 
entirely NO-mediated at 10
-6
M AICAR in both WKY and SHR (100% of the relaxation response was 
removed by L-NAME in arteries of both groups at this concentration, Figure 4-4B). This proportion was 
significantly decreased in both WKY and SHR as [AICAR] increased, until NO-dependent mechanisms 
accounted for only ~2% and 29% of the relaxation generated by WKY and SHR rings respectively at 10
-
2
M AICAR (thus at higher [AICAR] responses were predominantly NO-independent, Figure 4-4B). 
Although there were no differences between WKY and SHR at each [AICAR], there was a main effect of 
rat type over the range of AICAR doses (P = 0.0133) in favour of greater overall reliance on NO-




AMPK activation in SHR and WKY mesenteric arteries after AICAR incubation in vitro 
The observation that P(Thr172)-AMPK was elevated ~2-2.5 fold in both WKY (Figure 5A) and 
SHR (Figure 4-5B) mesenteric artery segments following 30 minutes of AICAR (2mM) incubation 
relative to the no drug controls verifies that AICAR activates AMPK in mesenteric arteries of both SHR 
and WKY. The fold-increase in P(Thr172)-AMPK relative to their respective no drug control groups was 
significantly greater in SHR than WKY arteries (fold increase from respective CON: WKY 1.99 ± 0.04 
vs. SHR 2.73 ± 0.10 arbitrary units, P < 0.01). AMPK-α total protein content was unaltered with AICAR 
in either WKY (Figure 4-5A) or SHR (Figure 4-5B). 
Phosphorylation of eNOS Ser1177 in SHR and WKY aorta and mesenteric arteries after AICAR 
exposure 
Phosphorylation of eNOS at activation site Ser1177 and eNOS total protein content were 
unaltered in mesenteric artery segments of WKY and SHR following 30 minutes of AICAR incubation in 
vitro (Figure 4-6). P(Ser1177)-eNOS was also unaffected in aortas that were removed 30 minutes 
following injections of AICAR or saline during the in vivo experiments from WKY (saline: 1.00±0.10 





Figure 4-1. Baseline levels of AMPK total protein expression and phosphorylation in aorta and 
mesenteric arteries of untreated SHR versus WKY. Total AMPK-α protein content and 
phosphorylation of AMPK at activation site threonine 172 and were analyzed by immunoblotting in 
WKY and SHR (A) aortic and (B) mesenteric artery homogenates. The ratio of phosphorylated to total 
AMPK protein content was also calculated for both vessel types. Data are normalized such that the mean 
of WKY is 1.00. Representative blot images display 3 lanes from each group. n = 6 (samples run in 





Figure 4-2. Hemodynamic responses of SHR and WKY rats to acute injections of AICAR. A) The 
protocol and treatment groups used to generate in vivo hemodynamic responses to acute AICAR 
injections. Following instrumentation with a carotid catheter and a period of equilibration, animals were 
given an intra-arterial pre-injection of L-NAME (30 mg/kg body weight) or a saline control, followed 20 
minutes later by intra-peritoneal injections of either saline or AICAR (0.5 mg/g body weight) to generate 
four treatment groups: saline only (○), L-NAME pre-injection (□), AICAR only (●), or L-NAME pre-
injection + AICAR (■). B) Heart rate responses and mean arterial pressure for C) WKY and D) SHR 
were assessed over 30 minutes following the injections of AICAR or saline for each treatment. Legend 
conventions are conserved across panels. n = 5-7 rats per group. * P < 0.05, † P < 0.01, ‡ P < 0.001 vs. 







Figure 4-3. AMPK activation in WKY and SHR aorta following acute drug injection in vivo. 
Phosphorylation at AMPK activation site threonine 172 and total AMPK-α protein content were analyzed 
by immunoblotting in aortic homogenates of WKY (A) and SHR (B) rats treated with injections of either 
saline, AICAR, L-NAME or AICAR + L-NAME during the in vivo experiments (see Figure 1 for 
derivation of treatment groups). Data are normalized such that the mean of saline control is 1.00. Legend 
conventions are conserved across panels. Representative blot images for AMPK and P(Thr172)-AMPK 






Figure 4-4. Vasorelaxation of isolated WKY and SHR mesenteric artery segments to acute AICAR 
exposure in vitro. A) Mesenteric artery segments of WKY and SHR were pre-incubated with either no 
drug (CON) or the NOS inhibitor L-NAME (all in the presence of β-adrenergic receptor blocker 
propranolol, 3µM) for 30 minutes to illustrate the NOS-dependency of the response to AICAR. Vessels 
were then pre-contracted with norephinephrine (NEPI, 10
-5
M) prior to exposure to increasing AICAR 
concentrations, and responses are expressed as mean percent relaxation of NEPI pre-contracted tension. 
B) The portion of the relaxation response generated by NO-dependent mechanisms at each concentration 
of AICAR in WKY and SHR mesenteric arteries calculated from the data in panel A. n = 6-8 rings per 
group, obtained from different animals. † P < 0.01, ‡ P < 0.001 vs. respective WKY or SHR CON in 
panel A. # P < 0.05, a P < 0.001 versus 10
-6
M [AICAR] in WKY and SHR respectively. There was a main 
effect for rat type (P = 0.0153), but no significant differences between WKY and SHR responses at any 






Figure 4-5. AMPK activation in isolated WKY and SHR mesenteric artery segments following 
acute incubation with AICAR in vitro. Phosphorylation at AMPK activation site threonine 172 and total 
AMPK protein content were analyzed by immunoblotting in mesenteric artery homogenates from WKY 
(A) and SHR (B) rats. Mesenteric artery segments of WKY and SHR  were incubated with either no drug 
(PSS alone) or AICAR (2mM AICAR in PSS) in vitro for 30 minutes. Data are normalized such that the 
mean of the control group (CON) is 1.00. Representative blot images display 2 lanes from each group. n = 







Figure 4-6. Phosphorylation of eNOS at activation site Ser1177 does not change in WKY and SHR 
mesenteric artery segments following acute incubation with AICAR in vitro. Phosphorylation at 
eNOS activation site serine 1177 and total eNOS protein content were analyzed by immunoblotting in 
mesenteric artery homogenates from WKY (A) and SHR (B) rats. Mesenteric artery segments of WKY 
and SHR were incubated with either no drug (PSS alone) or AICAR (2mM AICAR in PSS) in vitro for 30 
minutes. Data are normalized such that the mean of the control group (CON) is 1.00. Representative blot 
images display 2 lanes from each group. n = 6 (samples run in duplicate). There were no significant 





We investigated the ability of the AMPK-activator AICAR to acutely alter BP and to cause 
vasorelaxation in isolated mesenteric arteries of normotensive and hypertensive rats. These data are the 
first to demonstrate dysregulated basal AMPK activation in conduit and resistance arteries of 
hypertensive versus normotensive rats, to observe the influence of acute AMPK activation on 
hemodynamic parameters in a model of severe hypertension, and to evaluate parallel vasorelaxation 
effects in resistance vasculature of hypertensive and normotensive models.  
AMPK activation is dysregulated in basal, unstimulated conduit aorta and resistance mesenteric 
arteries of hypertensive animals, as indicated by reduced P(Thr172)-AMPK/AMPK ratios in these tissues 
(Figure 4-1A and B respectively). The origin of these differences is unclear (i.e. whether reduced AMPK 
activation is influenced by genetic factors, high blood pressure or other metabolic abnormalities in SHR), 
and it was not the intent of this study to provide insight in this regard. These results do not represent an 
impaired ability to activate AMPK per se, (i.e. AMPK was activated by AICAR in SHR conduit and 
resistance arteries, and may even be more sensitive to stimulation than those of WKY as demonstrated in 
aorta and mesenteric arteries here, and previously in SHR versus WKY aorta 
[73]
), but instead suggest 
dysfunctional regulation of AMPK by upstream kinases and/or phosphatases. The expression and activity 
of AMPK upstream kinases (i.e. LKB1, CaMKKβ, TAK-1) and phosphatases (PP2A, PP2C) have not 
been evaluated in arteries of these animals or other cardiovascular disease models where vascular AMPK 
dysregulation persists; whether or not abnormal functioning of upstream regulatory systems contribute 
these observations is an intriguing question that warrants further investigation. 
In accordance with previous indications that AMPK may modulate BP 
[14,19,71]
, we report the novel 
finding that single injections of AICAR generate an acute, profound ~70mmHg reduction in BP of SHR 
(Figure 4-2D). Although we did not observe a significant reduction in BP in our normotensive animals 
following acute AICAR injections, there was a trend towards a BP lowering effect of AICAR over the 30 




WKY). Others have reported modest BP decreases in normotensive rats and humans following acute 
injections of AICAR (i.e. 4-20mmHg)
[14,71]
, although the ability of these studies to delineate significant 
BP reductions in normotension may be due to use of higher doses of AICAR
[71]
, different experimental 
protocols
[14,71]
, or human versus animal models 
[14]
. Although in vivo hemodynamic responses can be 
affected by the anesthetic regime in place during experimental protocols, heart rates of the anesthetized 
animals in our study are comparable to those of conscious animals 
[4,122]
 and thus our rats were not likely 
sedated to the extent required to compromise the integrity and validity of the hemodynamic 
measurements.  
Since we have previously observed relaxation of conduit WKY and SHR arteries in response to 
acute AICAR exposure
[73]
, in the current study we wanted to investigate whether similar effects could be 
generated in resistance arteries, and if to parallel these results, a single injection of AICAR also acutely 
depresses BP in these animals in vivo (an effect that could originate from altered vascular resistance). 
Here we demonstrate for the first time that AMPK activation causes vasorelaxation of WKY and SHR 
mesenteric arteries (Figure 4-4), observations that support the potential activity of AICAR on vascular 
resistance and depressed BP in our in vivo experiments. Several other observations from this study and 
from previous reports also support this hypothesis. First of all, despite the dramatic effects of AICAR on 
MAP in SHR, HR was relatively well maintained (only dropping transiently by ~10% over the 30 minutes 
post injection) and did not mirror the pattern of continual MAP drop observed with AICAR in SHR 
(Figure 4-2). Others have observed that acute AICAR administration in un-anesthetized human subjects 
even evokes a paradoxical increase in HR with AICAR
[14]
. The absence of concurrent decreases in heart 
rate and BP suggest that reduced vascular resistance, rather than alterations in central control, contributes 
to the BP decrease with AICAR in SHR. Secondly, we have also demonstrated that AMPK activation 
causes vasorelaxation of SHR aorta and that this response is enhanced in conduit arteries of SHR 
compared to those from WKY (here as described in results section and previously
[73]
), an effect that could 




consequently, in BP of SHR. Although relaxation to AICAR did not differ between SHR and WKY 
mesenteric arteries (where we may have expected to observe enhanced relaxation in SHR versus WKY 
based on the MAP responses), and collectively, resistance arteries hold the greatest capacity to influence 
BP, this is not to say that other conduit or resistance vascular beds do not more closely mirror responses 
observed in aorta of SHR versus WKY (given the heterogeneity that exists within the vascular tree) or 
that responsiveness of more conduit-like vasculature could not have produced some hemodynamic effect. 
Lastly and notably, our marker of AMPK activation was only increased in arteries of SHR but not WKY 
following in vivo injections of AICAR (Figure 4-3); thus if vascular resistance is a contributor to the BP 
effects, it is possible that the AICAR dose used here was not sufficient to exert an influence on the 
vasculature of WKY, as a previous report has also demonstrated that vascular AMPK can be more 
sensitive to activation by AICAR in blood vessels of SHR compared to those of WKY 
[73]
. While our data 
provide support for the involvement of resistance vessel vasorelaxation effects of AICAR on the BP 
responses, in vivo conditions (innveration, endogenous vasoactive factors, mechanical effects, 
hemodynamics etc.) may generate differential effects to AICAR in comparison with those of the isolated 
vessel experiments, or alternatively, any decreases in vascular resistance in WKY may have been masked 
by compensatory BP regulatory mechanisms that are impaired in SHR. Thus, these observations suggest 
that altered vascular resistance (rather than mechanisms involving central BP control) is likely a main 
effecter of the acute AICAR-mediated hemodynamic responses observed in SHR. 
Cell culture, biochemical, and in vitro functional experiments have associated AMPK activation 
with increased endothelial NO-bioavailability
[27,30,31,44,145]
. Consistent with these observations and 
implications of NO in the regulation of BP 
[119]
, pre-administration of NOS inhibitor L-NAME partially 
prevented the AICAR-induced MAP reduction in SHR (Figure 4-2D). We have previously demonstrated 
that vasorelaxation generated by acute AMPK-activation is partly NO-dependent in aortas of SHR 
[73]
 and 
here that relaxation of isolated SHR mesenteric artery segments to AICAR is also partly NO-mediated 




of the blood pressure responses. Although we did not endeavor to exhaustively elucidate mechanisms 
responsible for the NO-dependent effects of AICAR here, we did assess P(Ser1177)-eNOS in thoracic 
aorta of animals injected with AICAR in vivo (stated in the results section, Figure A4-2) and in 
mesenteric arteries incubated with AICAR in vitro (Figure 4-6), but found no differences in P(Ser1177)-
eNOS between control and AICAR-treated tissue (consistent with previous experiments where we 
demonstrate that phosphorylation at eNOS serine 1177 does not account for increased NO-dependent 
relaxation to AICAR in WKY and SHR aorta 
[73]
). Mechanisms suggested in other work that could 
account for enhanced NO-bioavailability or bioactivity with AMPK activation include phosphorylation of 
eNOS activation site Ser633
[31]
, formation of active eNOS complexes 
[30,44]
, increased sensitivity of 
downstream signaling mechanisms or other yet unidentified mechanisms. Importantly, a large portion of 
the BP (Figure 4-2) and vasodilatory responses of mesenteric arteries in SHR (Figure 4-4A), and most of 
WKY mesenteric artery vasodilation (Figure 4-4A), was not mediated by NO. These NO-independent 
effects are most likely accounted for by endothelium-independent, direct vasodilation of the vascular 
smooth muscle by AICAR/AMPK activation, as a number of former investigations have established the 
ability of acutely activated AMPK to relax vascular smooth muscle directly 
[73,82,181]
. In SHR, these effects 
could also be due in part to suppression of endothelium-dependent vasocontraction, as we have recently 
elucidated
[73]
. Further analyses of the functional responses of WKY and SHR mesenteric arteries to 
AICAR revealed that at low [AICAR] (i.e. 10
-6
M), relaxation was fully accounted for by NO-mediated 
mechanisms in both WKY and SHR rings, but that the contribution to relaxation was largely NO-
independent at high [AICAR] (although SHR mesenteric arteries maintained greater reliance on the NO-
dependent component over the range of AICAR doses than WKY, Figure 4-4B). The findings highlight 
the importance of considering the strength of the stimulus when examining the relative contribution of 
NO-mediated or other mechanisms to the vasodilatory response. 
In light of the profound hypotensive affect of acute AMPK activation observed in hypertensive 




sustained BP depression in SHR or under other conditions of severe hypertension. Chronic administration 
of AICAR lowers BP in Zucker diabetic fatty rats (that are moderately hypertensive)
[19]
, and other drugs 
associated with AMPK activation (such as metformin and thiazolidiones)
[75]
 also have modest 
hypotensive
[8,171,234]
  and vasomotor 
[234]
 effects when administered chronically to animals that exhibit 
hypertension. Elevated BP has also been reported recently in AMPK α2-/- mice 
[242]
, providing further 
evidence for a potential role of AMPK in BP regulation. Although it is not clear whether dysfunctional 
AMPK signalling contributes directly to hypertension or vasomotor dysfunction in SHR, an intriguing 
finding from a recent report by Dolinksy et al. 
[52]
showed that short-term caloric restriction prevents 
development of hypertension in SHR rats, a result that was accompanied by increased AMPK 
phosphorylation in mesenteric arteries of these animals, highlighting the potential importance of the link 
between AMPK activation/dysregulation, vascular function and the regulation of BP in hypertension. 
Further experiments will be necessary to delineate whether or not chronic increases in AMPK activation 
induce persistent depressions in blood pressure of SHR and whether these alterations are sustained by 
vasodilatory effects. Regardless of potential chronic benefit, the acute hemodynamic and vasomotor 
effects observed here are intriguing and may have interesting implications for physiological regulation of 
blood pressure and vascular tone by acute AMPK activation in conditions of regular vascular control and 
in hypertension. 
Perspectives  
This study represents the first parallel investigation into the influence of acute AMPK activation 
on isolated vessel function and BP in hypertension. We have extended previous work by establishing an 
anti-hypertensive effect of acute AICAR in vivo that is partially NOS-dependent, and by delineating a 
vasorelaxation effect of acute AICAR exposure on resistance arteries in a hypertensive rat model. Our 
findings support a role for AMPK in the mediation of vasomotor responses in vessels of hypertensive 




regulation in hypertension. Continued investigation regarding the implications of chronic AMPK 






4.7 Addendum to Study 3: 
The addendum contains data collected in conjunction with this study but not included as part of 
the manuscript submitted for publication.  These items include: 
Figure A4-1: As stated in the initial specific objectives for this study, we also measured P(Ser1177)-
eNOS and eNOS total protein content by immunoblotting in aortic rings from WKY and SHR removed 
untreated animals (to assess baseline differences). Since phosphorylation of eNOS at serine 1177 was 
unaltered by AICAR treatment, we did not include basal eNOS and P(Ser1177)-eNOS data in the 
manuscript. 
Figure A4-2: Phosphorylation of eNOS at activation site Ser1177 does not change in WKY and SHR 
aorta following acute drug injection in vivo. Some of this data is stated numerically in the results section 
of the manuscript. 
Figure A4-3: AMPK activation is increased in liver of WKY animals injected with AICAR in vivo 






Figure A4-1. Baseline levels of eNOS total protein expression and phosphorylation in aorta and 
mesenteric arteries of untreated SHR versus WKY. Total eNOS-α protein content and phosphorylation 
of eNOS at activation site serine 1177 and were analyzed by immunoblotting in WKY and SHR (A) 
aortic and (B) mesenteric artery homogenates. The ratio of phosphorylated to total eNOS protein content 
was also calculated for both vessel types. Data are normalized such that the mean of WKY is 1.00. 
Representative blot images display 3 lanes from each group. n = 6 (samples run in duplicate). † P < 0.01, 







Figure A4-2. Phosphorylation of eNOS at activation site Ser1177 does not change in WKY and SHR 
aorta following acute drug injection in vivo. Phosphorylation of eNOS activation site serine 1177 and 
eNOS total protein content were analyzed by immunoblotting in aortic homogenates from WKY (A) and 
SHR (B) rats treated with injections of either saline (CON), AICAR, L-NAME or AICAR + L-NAME 
(see Figure 1 for derivation of treatment groups). Aortas were removed from animals immediately 
following 30 minutes of hemodynamic data collection, quickly dissected free of connective tissue and 
immediately frozen in liquid nitrogen. Data are normalized such that the mean of saline control is 1.00. 
Representative blot images for eNOS and P(Ser1177)-eNOS display 2 lanes from each group. n = 6 






Figure A4-3. AMPK activation is increased in liver of WKY animals injected with AICAR in vivo. 
Phosphorylation at AMPK activation site threonine 172 was analyzed by immunoblotting in liver 
homogenates of WKY injected with saline or AICAR during the in vivo hemodynamic experiments. Liver 
samples were snap frozen and stored for immunoblotting analyses immediately following collection of 
hemodynamic data at 30 minutes post-injection of saline or AICAR (see Figure 4-2 for protocol). Data 
are normalized such that the mean of saline control is 1.00. Representative blot images display 2 lanes 














 Vasomotor responses generated by acute exposure to AMP-activated protein kinase activators in 









This chapter is presented in manuscript form. 
 





5.1 Review of Study 4 Objectives and Hypotheses 
 The specific objectives and hypotheses for this chapter have already been stated in the 
introduction section, but are reproduced identically here for the reader‟s convenience. 
Purpose: To characterize the vasomotor responses of isolated arteries from young and aged rats to 
pharmacological AMPK activators and to investigate the mechanisms involved. 
Specific objectives and hypotheses: 
Objective 1: To assess basal AMPK activation in aorta of aged versus young male Sprague-Dawley rats. 
Hypothesis 1: Basal AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) will be depressed in 
arteries of aged versus those of young rats. 
Objective 2: To determine if vasorelaxation to AICAR is intact in isolated aortic rings from aged rats 
compared to those of young rats. Hypothesis 2: AMPK-mediated relaxation will be impaired in arteries 
of aged versus young rats.  
Objective 3: To evaluate the endothelium-dependency and/or –independency of vasodilatory responses to 
AICAR in aortic rings young and aged rats.  Hypothesis 3: AICAR will generate relaxation in aortic 
rings of young and aged rats that is partly endothelium-dependent and partly endothelium-independent. 
Objective 4: To pharmacologically dissect the mechanisms responsible for AMPK-mediated vasodilation 
in aortic rings of young and aged rats (i.e. NO- and COX-dependency). Hypothesis 4: The endothelium-
dependent component of relaxation to AICAR will be primarily NO-dependent in aortic rings of young 
rats but will be NO- and COX-mediated in aortic rings of aged rats. Since NO-bioavailability and NO-
dependent functional responses are typically reduced in arteries of aged rats, we expect NO-dependent 
relaxation to AICAR may be reduced in aged versus young aorta. Responsiveness to vasoactive agents is 
often impaired in arteries of aged rats, so endothelium-independent relaxation to AICAR may also be 




Objective 5: To biochemically confirm AMPK activation by AICAR in aortic rings of young and aged 
rats. Hypothesis 5: AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) will be elevated by 
treatment with AICAR to a similar extent in rings of young and aged animals. 
Objective 6: To investigate whether or not vasorelaxation of young and aged pre-contracted aortic rings 
also occurs in response to other known AMPK activators, metformin and resveratrol, and to compare 
these responses in vessels of young versus aged animals. Hypothesis 6: Metformin and resveratrol will 
each generate relaxation in aortic rings of young and aged rats and relaxation to both of these agonists 
will be impaired in aortic rings of aged versus young animals. 
Objective 7: To biochemically confirm AMPK activation by metformin and resveratrol in aortic rings. 
Hypothesis 7: AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) will be elevated by treatment of 
rings with either metformin or resveratrol. 
Objective 8: To evaluate total eNOS protein content in aortic rings of young and aged rats, and the effect 
of AICAR on P(Ser1177)-eNOS of these vessels in vitro. Hypothesis 8: Total eNOS content will be 
depressed in aortic rings of aged versus young rats, and P(Ser1177)-eNOS will be enhanced in aorta rings 
of young and aged rats treated with AICAR. 
 
5.2 Overview of Study 4  
 Acute activation of AMP-activated protein kinase (AMPK) is associated with relaxation of pre-
contracted, isolated arteries via both endothelium-dependent, nitric oxide (NO)-mediated and endothelium 
independent direct effects on vascular smooth muscle (VSM). AMPK activation is dysregulated in 
arteries of aged versus young animals, and therefore vasorelaxation to acute AMPK activation may be 
altered with aging, but this hypothesis is untested. Here we investigate mechanisms of AMPK-mediated 
vasorelaxation and its associated mechanisms in isolated aortic rings of young and aged Sprague-Dawley 




animals relax dose-dependently in response to increasing concentrations of the AMPK activator 5-
aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) to levels approaching 100% relaxation 
from pre-contracted tension. Relaxation to AICAR was partly blunted by removal of the endothelium (E-
), revealing endothelium-dependent and -independent components of the response. Pre-incubation of rings 
with the NO synthase inhibitor L-NAME abolished the endothelium-dependent component of relaxation 
to AICAR in both young and aged vessels, showing that this portion of the response is NO-mediated. We 
also assessed the ability of the anti-diabetic drug metformin and the polyphenol resveratrol (other 
compounds known to activate AMPK) to relax isolated E- arteries. Relaxation, and the corresponding 
AMPK activation (phosphorylation of AMPK activation site threonine 172 and downstream target serine 
79 on acetyl-CoA carboxylase assessed by immunoblotting) to metformin, were modest compared to the 
AMPK activation induced by AICAR in aged aorta, and relaxation to metformin was enhanced in aorta of 
aged versus young rats. Although resveratrol generated robust, dose-dependent relaxation of pre-
contracted aortic rings of aged rats (that was enhanced compared to relaxation of young aorta to 
resveratrol), AMPK activation was not increased by resveratrol in these vessels. Therefore, these data 
demonstrate that AMPK-mediated vasorelaxation is intact and enhanced in arteries of aged animals, and 
that this response is mediated by both an endothelium-, NO-dependent component, and by endothelium-
independent relaxation of the vascular smooth muscle. Although metformin induces a mild vasodilatory 
effect associated with mild AMPK activation, relaxation of aged arteries to resveratrol is orchestrated by 
mechanisms distinct from AMPK activation.  
 
5.3 Introduction 
AMP-activated protein kinase (AMPK) is a ubiquitously expressed serine-threonine protein 
kinase, and is well known for its role as a regulator and integrator of cell and whole body energy 
metabolism 
[21,97,205]
. More recently, AMP-activated protein kinase (AMPK) has also been identified as a 




showing that acute activation of AMPK produces vasorelaxation of pre-contracted, isolated arteries from 
healthy animals 
[13,15,73,82,181]
, and that increased blood flow has been reported in vessel beds injected with 
AMPK activators in situ 
[13,15]
. In healthy conditions, the vasodilatory response to acute AMPK activation 
seems to originate from direct relaxation of vascular smooth muscle (VSM) 
[73,82,181]
 and/or by 
endothelium-mediated signalling that is nitric oxide (NO)-dependent 
[13,15,73]
, depending on the vessel bed 
or model studied. In dysfunctional conduit arteries that are characterized by the presence of enhanced 
endothelium-dependent contractions mediated by the cyclooxygenase (COX) signalling axis (i.e. aorta of 
spontaneously hypertensive rats 
[48,73,233]
), acute AMPK activation may also induce net relaxation by 
inhibiting this endothelium- and COX-dependent contractile response 
[73]
.  
AMPK is activated covalently via phosphorylation of threonine 172 on its catalytic alpha subunit 
by upstream kinases, and allosterically by the binding of AMP to the Bateman domains on the gamma 
subunit 
[70,99,104,205]
. Bound AMP also facilitates phosphorylation at threonine 172 by rendering AMPK an 
unfavourable substrate for upstream phosphatases 
[70,186,208]
, shifting the balance in kinase/phosphatase 
activity at this site in favour of augmented phosphorylation. AMPK can be activated pharmacologically 
using AICAR, a compound that is taken up by cells via adenosine transporters and phosphorylated 
intracellularly by adenosine kinase to form the AMP analogue ZMP 
[36,124]
.  
The antidiabetic drug metformin and the red-wine polyphenol resveratrol also activate AMPK. 
Metformin activates AMPK in cultured endothelial 
[44,102,117,268]
 and vascular smooth muscle 
[160,238]
 cells, 
in aorta of mice treated with metformin in vivo 
[44,268]





 and adipocytes 
[90]









, skeletal muscle 
[223]
, epididymal fat 
[223]
 and neurons 
[41]
. 
These compounds have notable clinical and health implications, as metformin is the most commonly 
prescribed drug for the treatment of type II diabetes 
[67]
, and resveratrol and moderate red-wine 








 and resveratrol 
[28,83,154,258]
 both generate relaxation when administered directly to 
isolated pre-contracted arteries; however, an association between the AMPK-activating activity of these 
compounds and their vasodilatory capacity has not been established.   





. Moreover, vasomotor function is impaired progressively with age 
[1,129]
, and is characterized by reduced NO-dependent relaxation 
[42,199,200,228,253]
, enhanced endothelium- 
and cyclooxygenase-dependent contractions 
[1,42,128,129,230]
, and general alterations in vascular reactivity 
(i.e. vasomotor responsiveness can be enhanced or reduced depending on the agonist applied or vascular 
bed studied) 
[5,46,140,149]
. Most investigations of AMPK-mediated vasomotor effects have been generated 
using functional arteries of young, healthy animals, but the vasodilatory capacity of AMPK has not been 
assessed in arteries of aged rats in which vasomotor dysfunction and AMPK dysregulation are known to 
occur. Therefore, the purpose of this study was to investigate the capacity of AMPK to generate 
vasorelaxation in arteries of young and aged rats, and to evaluate mechanisms underlying this response. 
Our main objectives were: 1) to determine the viability of the AMPK-mediated relaxation response in 
arteries of aged rats; 2) to assess the endothelium-dependency of the relaxation response to acute AMPK 
activation in pre-contracted aortic rings of young and aged rats; and 3) to elucidate mechanisms 
responsible for AMPK-mediated vasorelaxation using a pharmacological approach. We also tested 
whether metformin and resveratrol generate similar vasorelaxation effects to those of AICAR, and 
whether these effects are associated with AMPK activation in aorta of these animals. We hypothesize that 
AMPK-mediated relaxation to AICAR will occur through both endothelium-dependent and –independent 
mechanisms, that the endothelium-dependent component will be NO-mediated in aorta of young rats but 
NO- and COX-dependent in aged rat aorta, and that relaxation to AICAR will be impaired in arteries of 
aged animals compared to those of young controls. We also hypothesize that acute exposure of pre-
contracted aortic rings to AMPK-activators metformin and resveratrol will generate vasorelaxation that is 




5.4 Materials and Methods 
Animal care and procedures.  All animal-related procedures were approved by the University of 
Waterloo Animal Care Committee. A total of 30 young male and 30 aged male Sprague Dawley rats 
obtained from Harlan (Indianapolis, IN) were used for experiments in this study. Animals were group-
housed at a constant air temperature (20-21
o
C) and humidity (~50%) in a 12 h:12 h reverse light:dark 
cycle. Rats had free access to standard 22/5 Rodent Diet (W) lab chow (Harlan) and tap water. Prior to all 
experiments, body mass was recorded, animals were anesthetised by sodium pentobarbital injection (50-
65 mg/kg, i.p.; Vetoquinol N.-A. Inc., Lavaltrie, QC, Canada) and then euthanized by rapid removal of 
the heart. Hearts and kidneys from some young and aged animals were dissected and weighed to compare 
tissue masses. 
Vasomotor responses in isolated vessels. Thoracic aortas were excised and 2mm aortic rings were 
prepared for vascular myography as previously described 
[74]
. In some experiments, the endothelium was 
removed mechanically as outlined in other experiments 
[73]
. Removal of the endothelium was confirmed 
by immunoblotting for endothelial nitric oxide synthase in homogenates of aortic rings removed 
following the functional myography protocol (Supplemental Figure A5-4; we have previously 
demonstrated that vasorelaxation to endothelium-dependent agonists is absent in E- aortic rings with 
comparable eNOS content 
[73]
). Rings were mounted onto a vascular myography apparatus (Radnotti, 
Monrovia, CA), immersed in 37°C Krebs-bicarbonate buffer continuously aerated with 95% O2/5% CO2, 
and data collected as previously described 
[74]
. Gradual stretching to a pre-determined optimal resting 
tension of 5 g (the resting tension predetermined to elicit maximal active tension responses to KCl in 
aortic rings of young and aged male Sprague Dawley rats, obtained during pilot experiments and previous 
studies
[74]
) was achieved by increasing the tension by 0.5g increments from 1g every 5 minutes, and rings 
were equilibrated at resting tension for 30 minutes. Two consecutive exposures to 60mM potassium 




Dose-dependent vasorelaxation to AICAR. Following washout of KCl and return to baseline 
tension, rings with (E+) and without (E-) endothelium were allowed to equilibrate for 30 minutes and then 
pre-contracted with KCl (40mM) or phenylephrine (PE; 10
-6.5
 M). When a stable plateau in tension was 





M) to generate dose-dependent relaxation responses. In some experiments, rings were pre-incubated with 
the NOS inhibitor Nω-nitro-L-arginine methyl ester (L-NAME; 10
-4
 M), the cyclooxygenase inhibitor 
indomethacin (INDO; 10
-5
 M; inhibits both cyclooxygenase 1 and 2), or both L-NAME and INDO for 30 
minutes prior to pre-contraction in order to pharmacologically dissect mechanisms responsible for 
AICAR-mediated relaxation responses. The dose range for AICAR was based on prior experiments 
examining rodent aorta 
[73,82]
.  
Dose-dependent vasorelaxation to metformin and resveratrol. After undergoing the same set-up 
protocol used prior to the AICAR dose-response curve experiments, E- aortic rings from young and aged 
rats were pre-contracted with PE (10
-6.5









M) to generate dose-response curves. These dosage 
ranges were adapted from previous work in the literature 
[139]
 and from our own pilot work.  
Immunoblot analysis of protein content and phosphorylation levels. Tissue for immunblotting was 
obtained from three independent experiments: 1) Aortic rings from young and aged animals were 
prepared and mounted on the vascular myography apparatus at optimal tension as described above. After 
30 minutes of equilibration, rings were removed, snap frozen in liquid nitrogen, and stored at -80
o
C for 
comparison of basal protein content and phosphorylation levels in young and aged vessels. 2) When a 
stable response was obtained at the final [AICAR] (10
-2
M) in rings used for the functional protocol (pre-
incubated with no drug), rings were quickly and carefully removed from the myography apparatus, snap 
frozen and stored at -80
o
C for immunoblotting. To generate control rings for comparison against those 
treated with AICAR, rings were pre-contracted with KCL only (not exposed to AICAR) and allowed to 




frozen for immunoblotting to compare total protein and phosphorylation of rings treated with AICAR 
versus no AICAR. 3) To assess AMPK activation induced by metformin and resveratrol, E- rings of aged 
rats were collected upon completion of metformin or resveratrol functional dose-response curves for 
immunoblotting as described above for the AICAR experiments. Some E- rings were also collected 
following AICAR dose-response curves or no drug (pre-contraction with PE only, control) for 
comparison. Rings for all treatment groups (controls, AICAR, metformin and resveratrol) were obtained 
from a single rat for each experiment. Sample preparation and immunoblotting procedures were 
performed as described previously 
[74]
. Briefly, 30µg of protein was loaded per well in polyacrylamide 
gels, and membranes were ponceau stained to confirm consistent protein loading across lanes.  
Drugs, Chemicals and Antibodies. All drugs and chemicals were purchased from either Sigma-Aldrich 
(St. Louis, MO) or Bioshop Canada Inc. (Burlington, ON, Canada), with the exception of AICAR which 
was purchased from Toronto Research Chemicals (Toronto, ON, Canada). For immunoblotting 
experiments, primary antibodies specific for the α subunit of AMPK (recognizing both α1 and α2 subunit 
isoforms, 1:500 dilution) and P(Thr
172
)-AMPK (1:1000 dilution), acetyl-CoA carboxylase (1:250), 
P(Ser
79
)-ACC (1:500) and P(Ser1177)-eNOS (1:3000) were obtained from Cell Signalling Technology 
(via New England Biolabs, Pickering, ON, Canada). eNOS (1:750) was from BD Biosciences 
(Mississauga, ON, Canada). Horse-radish-peroxide conjugated secondary antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). 
Data Analyses. Values are reported as mean ± s.e.m., with n referring to the number of animals per group. 
For comparisons consisting of more than two treatment conditions or groups, one- or two-way ANOVAs 
with Tukey‟s or Bonferroni post-hoc analyses were conducted to evaluate within or between group 
comparisons. A two-tailed Student‟s t-test was used for comparisons involving only two groups. 
Differences were considered significant if P < 0.05. All statistical analyses were performed using SAS 





Animal Characteristics. The physical characteristics of the animals used in this study are reported in 
Table 5-1. Young and aged rats were ~ 11 and ~ 89 weeks of age respectively at the time of experiment 
(Table 5-1). The spontaneous mortality rate of male Sprague-Dawley rats used for the older cohort in this 
study is ~ 20% (Harlan). There were no differences in the heart or ventricle to body mass ratios between 
young versus aged animals, signifying the absence of confounding gross cardiovascular pathology. Two 
aged animals with abnormal heart masses (likely due to heart failure or pulmonary pathology) were 
excluded from the study. 
Basal AMPK activation in aorta of young and aged Sprague-Dawley rats. 
Basal AMPK activation is blunted in aortic rings of aged versus young rats. Phosphorylation of 
AMPK at threonine 172, a modification required for enzyme activation 
[99,103]
, and phosphorylation of 
acetyl-CoA carboxylase (ACC) at serine 79, a well-established downstream target of AMPK activity 
[99,152]
, were evaluated as surrogate markers of AMPK activation. AMPK-α and ACC total protein content 
did not differ in aorta of the two groups (Figure 5-1). In contrast, both P(Thr172)-AMPK and P(Ser79)-
ACC were ~ 60% lower in untreated aortic rings of aged versus young rats (Figure 5-1), demonstrating 
depressed baseline AMPK activation in vessels of the older animals.  
Functional responses of pre-contracted aortic rings from young and aged rats to AICAR.  
AICAR generates both endothelium-dependent and endothelium-independent relaxation in aortic 
rings from young and aged rats. Aortic rings of young rats with intact endothelium relaxed from KCl pre-
contracted tension in a dose-dependent manner in response to increasing [AICAR], with relaxation 
reaching a maximum of 95±3% of pre-contracted tension at 10
-2
M AICAR (Figure 5-2A). Removal of the 
endothelium in young rings (to expose the response of vascular smooth muscle alone), blunted relaxation 
to AICAR at all concentrations, and maximal relaxation was only 76±4% of pre-contracted tension at 10
-
2
M (Figure 5-2A). In aortic rings of aged rats, relaxation to AICAR reached ~90 % at 10
-2




rings, and this response was attenuated in the absence of endothelium, with relaxation responses of E- 








M AICAR compared to E+ vessels (Figure 5-2B). 





M P < 0.05 at 10
-3
M versus young) and without endothelium (P < 0.001 at 10
-
2.5
M, and P < 0.01at 10
-2
M versus young, Figures 5-2A and B). Maintenance of stable tension generation 
by time control rings (time control rings pre-contracted with 40mM KCl but not exposed to AICAR) is 
demonstrated for young (Figure 5-2A) and aged (Figure 5-2B) E+ and E- rings. Pre-contracted tension to 
40mM KCl was not significantly different between rings of young versus aged rats either with or without 
endothelium, but E- rings of aged animals developed greater tension than those of aged E+ CON (Table 
5-2). Similar functional responses to those generated by AICAR in KCl pre-contracted rings were 
observed across all groups when rings were pre-contracted with α-adrenergic agonist PE (10
-6.5
M) and 
then exposed to AICAR concentrations (Figure A5-1 and Table A5-1). 
To more rigorously evaluate the contribution of the endothelium and VSM to the relaxation 
generated by AICAR, we determined the percentage of the total relaxation response accounted for by the 






M [AICAR] (Figure 5-2C). In 
rings of young rats, 49 ± 8% of the total relaxation to AICAR at 10
-4
M was endothelium-dependent, a 
proportion that was decreased to 22 ± 4% at 10
-2
M AICAR (P < 0.01 versus 10
-4
M AICAR; Figure 5-2C). 
In aged rat aorta, endothelium-dependent relaxation comprised 67 ± 2% of the total relaxation response at 
10
-4




M respectively (both P < 0.001 versus 10
-4
M 
AICAR; Figure 5-2C). The endothelial contribution in aged rings was significantly greater than in those 
of young at 10
-4
M AICAR, but was significantly less than in young rings at 10
-2
M AICAR (Figure 5-2C). 
We also calculated the percentage of the total relaxation response dependent on the endothelium at the 
concentrations of AICAR that elicited 50% (logEC50) and 100% of the maximal relaxation response in E+ 
rings of young and aged rings (Figure 5-2D). At the logEC50 of E+ CON rings (young: -3.18 ± 0.08 and 




curves), the component of relaxation accounted for by the endothelium was greater in aged versus young 
rings (Figure 5-2D). At maximal relaxation from pre-contracted tension in E+ CON rings (maximal 
relaxation for E+ rings, young: 98 ±3 % and aged 96 ± 6%, P = 0.8044), 23 ± 4% of the relaxation to 
AICAR was endothelium dependent in aorta from young rats, but in rings from aged rats only 4 ± 4% was 
attributed to the endothelium (almost entirely endothelium-independent, Figure 5-2D). 
Pharmacological dissection of mechanisms mediating vasomotor responses to AICAR.  
Endothelium-dependent relaxation to AICAR is NO-mediated in aortic rings of both young and 
aged rats. Aortic rings were pre-incubated with L-NAME, indomethacin (INDO), or L-NAME + INDO 
to determine the involvement of NO- and cyclooxygenase-dependent signalling in the vasodilatory 
responses to AICAR. Following drug pre-incubation and pre-contraction with KCL, relaxation to AICAR 
was blunted in E+ aortic rings of young and old rats treated with either L-NAME or L-NAME + INDO 
compared the no drug controls (Figure 5-3A and B), to levels not different from those of E- rings (Figure 
5-3C and D). Indomethacin alone did not alter relaxation compared to the E+ control condition at any 
AICAR concentration in rings or young or aged rats (Figure 5-3A and B). In E- rings, relaxation to 
AICAR was not affected by L-NAME, INDO or L-NAME + INDO (Figure 5-3C and D). Pre-contraction 
to KCl was not significantly affected by any drug condition relative to the no drug controls in rings of 
either young or aged rats (Table 5-2). Similar results were obtained in experiments where rings were pre-
contracted with PE rather that KCl (Figure A5-2, Table A5-1). 
Confirmation of AMPK activation in aortic rings of young and aged rats following treatment with 
AICAR.  
 AMPK activation by AICAR was confirmed in aortic rings of young and aged rats. Both 
P(Thr172)-AMPK (Figure 5-4A & B) and P(Ser79)-ACC (Figure 5-4C &D) were significantly elevated 
following exposure to the AICAR dose-response curve protocol in E+ and E- rings from young and aged 




activation in these vessels. The fold-increases in P(Thr172)-AMPK (Figure 5-4E) and P(Ser79)-ACC 
(Figure 5-4F) were not different in aortic rings of aged and young rats with or without endothelium (no 
main effects or individual group differences), demonstrating that the relative degree of AMPK activation 
by AICAR was similar between groups. When P(Thr172)-AMPK and P(Ser79)-ACC were normalized to 
baseline values (from Figure 5-1), and main effects were significant for age (P-AMPK: P = 0.0022, P-
ACC: P = 0.0054) and drug treatment (P-AMPK: P = 0.0054, P-ACC: P = 0.0229) (Figure 5-4G and H).  
Functional responses of pre-contracted aortic rings from young and aged rats to metformin and 
resveratrol.  
Since the majority of the vasodilatory response to AICAR was endothelium-independent 
(involving the vascular smooth muscle only), and we were interested in testing the general vasodilatory 
capacity of metformin and resveratrol, we performed these experiments in E- rings only (experiments 
were also performed using AICAR for comparison). AICAR generated relaxation of young and aged E- 
rings that reached a maximum of 62±2% and 109±4% of pre-contracted tension to phenylephrine 
respectively at 10
-2
M AICAR (Figure 5-5A). The time control rings pre-contracted with PE but not 
exposed to AICAR demonstrate the ability of these rings to maintain tension to this agonist over the 
experimental protocol (Figure 5-5A). In contrast to the robust relaxation response observed in E- rings of 
young and aged animals to increasing [AICAR], maximal relaxation to metformin was only 17±1% of 
pre-contracted tension in E- rings of young animals (that did not begin until 10
-2.5
M metformin) and 
46±5% in E- vessels of aged rats (Figure 5-5B). Resveratrol generated substantial relaxation in both 
young and aged E- rings, with maximal relaxation reaching ~ 100% by 10
-4
M [resveratrol] in both groups 
(Figure 5-5C). As with AICAR (Figure 5-5A), relaxation was enhanced to both metformin (Figure 5-5B) 
and resveratrol (Figure 5-5C) in rings from aged versus those of young animals.  
AMPK activation in aortic rings of aged rats to metformin and resveratrol. 




AMPK activation following exposure to these agents. In E- rings of aged rats rings removed immediately 
following the functional dose-response curve protocols, exposure to metformin generated ~ 2-fold 
increase in P(Thr172)-AMPK (Figure 5-6A) and a concomitant increase in P(Ser79)-ACC (Figure 5-6B). 
Resveratrol failed to generate detectable elevations in either P(Thr172)-AMPK (Figure 5-6A) or 
P(Ser79)-ACC (Figure 5-6B) compared to no drug time controls. By contrast, AICAR robustly increased 







Table 5-1. Physical characteristics of young and aged male Sprague-Dawley rats.  
 
Young Aged P 
Age, wks 10.7 ± 0.3 88.8 ± 0.7 < 0.0001 
Whole body mass (BM), g 328 ± 6 552 ± 12 < 0.0001 
Tissue Masses 
   
Left Ventricle, mg 889 ± 14 1368 ± 73 < 0.0001 
Left Ventricle/BM (mg/g BM) 2.97 ± 0.06 2.67 ± 0.26 0.3358 
Heart, mg 1110 ± 14 1628 ± 82 < 0.0001 
Heart/BM, (mg/g) 3.71 ± 0.07 3.16 ± 0.29 0.1266 
Kidney (mg) 1029 ± 54 2129 ± 99 0.0007 
Kidney/BM (mg/g) 3.94 ± 0.08 4.05 ± 0.16 0.7740 
 
Hearts and kidneys were dissected immediately following their removal from anesthetized animals to 
obtain tissue masses (n = 6-9). n=29 for all other measures. Due to differences in body weight with age, 







Figure 5-1. Basal AMPK activation is depressed in aorta of aged versus young male Sprague-
Dawley rats. Thoracic aortas were removed from anesthetized animals, and aortic rings were prepared 
and mounted on a vascular myography apparatus. After undergoing a standard myography start-up 
protocol, rings were left to equilibrate for 30 minutes before being carefully removed from the apparatus, 
snap frozen and stored for immunoblotting. A) Phosphorylation of AMPK activation site Thr
172
 and 
AMPK-α total protein content and B) phosphorylation of AMPK downstream target Ser
79 
on acetyl-CoA 
carboxylase (ACC) and ACC total protein content were assessed as surrogate markers of AMPK 
activation. Data is expressed as mean ± sem. Values from densitometry analyses were normalized such 
that the mean of the young group values are equal to 1 normalized unit.  All samples were run in duplicate 







Figure 5-2. Vasorelaxation to AICAR is both endothelium-dependent and –independent in aorta of 
young and aged rats. Relaxation responses of aortic rings from (A) young and (B) aged rats with (E+) or 
without (E-) endothelium following pre-contraction with potassium chloride (KCl) to increasing 
concentrations of AICAR. Some rings were contracted with KCl but not exposed to AICAR (time 
controls; TC) to demonstrate the ability of rings to maintain stable tension for the duration of the 
experiments. Responses are expressed as mean percent relaxation from KCl pre-contracted tension. C) 







M in aorta of young and aged rats. D) The proportion of the 
relaxation response accounted for by the endothelium-dependent component of relaxation at the log EC50 
and maximal relaxation of E+ rings. n = 4-6 rings per group from different animals.  * P < 0.05, † P < 
0.01, ‡ P < 0.001 versus E+ in A) and B), * P < 0.05, † P < 0.01, ‡ P < 0.001 versus [AICAR] 10
-4
M and 
young in C) and D). E+ TC and E- TC are different (P < 0.001) from E+ CON in both young and old 






Figure 5-3. Mechanisms of AICAR-mediated relaxation in aortic rings from young and aged rats. 
Aortic rings from (A,C) young and (B,D) aged rats were incubated with either NOS inhibitor L-NAME, 
cyclooxygenase inhibitor indomethacin (INDO), or L-NAME + INDO to determine the NO- and 
endoperoxide-dependency of relaxation responses to AICAR. Percent relaxation from pre-contracted 
tension to potassium chloride (KCl) is displayed in rings from young and aged rats (A, B) with (E+) and 
(C,D) without (E-) endothelium. Young and Aged E+ and E- data from Figure 2 has been repeated here 
for comparison (no drug pre-incubation, CON groups above). Each treatment was performed in aortic 
rings from every animal. n = 4-11 rings per group from different animals.  * P < 0.05, † P < 0.01 and ‡ P 





Table 5-2. Pre-contracted tension of young and aged aortic rings to 40mM KCl 
 
Young (g) Aged (g) 
     E+ CON 1.8 ± 0.2 1.7 ± 0.2 
     E+ L-NAME 2.6 ± 0.2 2.7 ± 0.2 
     E+ INDO 1.7 ± 0.3 1.6 ± 0.3 
     E+ L-NAME INDO 2.5 ± 0.2 2.0 ± 0.2 
     E- CON 2.4 ± 0.2 3.3 ± 0.2‡ 
     E- L-NAME 2.5 ± 0.2 3.0 ± 0.1† 
     E- INDO 2.4 ± 0.2 3.4 ± 0.3† 
     E- L-NAME INDO 2.4 ± 0.1 3.0 ± 0.2† 
 
Data represents means ± s.e.m. n= 4 -11 rings per group. † P < 0.01, ‡ P < 0.001 versus E+ CON. There 










Figure 5-4. AMPK activation in aortic rings of young and aged rats following the AICAR dose-
response curve protocol. Aortic rings with (E+) and without (E-) endothelium were removed from the 
myography apparatus immediately following completion of the AICAR dose-response curve, snap frozen 
and stored at -80
o
C for immunoblotting analyses. Rings pre-contracted but not treated with AICAR (time 
controls, CON) were also obtained for control comparisons. Phosphorylation of AMPK activation site 
threonine 172 (A, B) and phosphorylation of AMPK downstream target serine 79
 
on acetyl-CoA 
carboxylase (C, D) were assessed on membranes prepared using aortic ring homogenates of young and 
aged rats. Data is expressed as mean ± sem. Values from densitometry analyses were normalized such 
that the mean of the E+ CON group values are equal to 1 normalized unit. Panels E and F compare the 
fold increase in P(Thr172)-AMPK and P(Ser79)-ACC respectively over the E+ CON groups in E+ and E- 
aortic rings of young and aged animals treated with AICAR. There were no main effects or individual 
group differences in the fold increase of either P(Thr172)-AMPK or P(Ser79)-ACC. In Panels G and H, 
data were normalized to baseline P(Thr172)-AMPK and P(Ser79)-ACC (values from Figure 5-1), and 
main effects were significant for age (P-AMPK: P = 0.0022, P-ACC: P = 0.0054) and drug (P-AMPK: P 
= 0.0054, P-ACC: P = 0.0229). n = 6-8, for young and old rats in both E+ and E- groups (all samples run 






Figure 5-5. Dose-dependent vasorelaxation to AICAR, metformin or resveratrol in aortic rings of 
young and aged rats. Aortic rings without endothelium (E-) from young and aged rats were pre-
contracted with phenylephrine (PE; 10
-6.5
M) and then exposed to increasing concentrations of AICAR 
(A), metformin (B) or resveratrol (C). Time controls (rings pre-contracted with PE but not exposed to 
vasodilatory agonists) are shown in A) to illustrate the ability of rings to maintain stable pre-contraction. 
All treatments elicited significant relaxation from baseline (P < 0.0001) by maximal concentrations of 
AICAR, metformin and resveratrol in aortic rings of both young and aged rats, but significance symbols 
have been excluded for clarity. Responses are expressed as mean percent relaxation from PE pre-
contracted tension. n = 6-14 rings per group from different animals.  * P < 0.05, † P < 0.01, ‡ P < 0.001 






Figure 5-6. AMPK activation in aortic rings of aged rats following AICAR, metformin and 
resveratrol dose-response curve protocols. Aortic rings without endothelium (E-) were removed from 
the myography apparatus immediately following completion of the dose-response curve protocols using 
AICAR, metformin (MET) or resveratrol (RSV), snap frozen and stored at -80
o
C for immunoblotting 
analyses. Some rings pre-contracted but not treated with AICAR, metformin or resveratrol (time controls, 
CON) were obtained for control comparison. A) Phosphorylation of AMPK activation site Thr172 and B) 
phosphorylation of AMPK downstream target Ser79 on acetyl-CoA carboxylase (ACC) were assessed in 
homogenates of aortic rings from young and aged rats. Data is expressed as mean ± sem. Values from 
densitometry analyses were normalized such that the mean of the E+ CON group values are equal to 1 







The main findings of this study are that: 1) AMPK-mediated relaxation to AICAR is intact and 
enhanced in aorta of young and aged rats, 2) that this response is partly endothelium-dependent and partly 
endothelium-independent, and 3) and that endothelium-dependent relaxation to AICAR is NO-dependent 
in aortic rings of both young and aged animals. Relaxation of pre-contracted aortic rings to metformin 
was not as robust as that generated to AICAR in aortic rings of aged rats, corresponding to weaker 
activation of AMPK in these vessels by metformin. Although relaxation of pre-contracted arteries was 
produced by resveratrol, this compound did not activate AMPK in aortic rings from our aged animals. 
This is the first examination of AMPK-mediated relaxation in aged arteries. 
AMPK activation becomes dysregulated with age 
[150,176,178,179,246,269]
. Herein we demonstrate that 
basal AMPK activation (P(Thr172)-AMPK and P(Ser79)-ACC) is lower in aorta of the aged animals 
compared to their younger counterparts (Figure 5-1). Others have also observed depressed AMPK activity 
in aorta 
[179]
 and gastrocnemius muscle 
[176]
 of aged rats, although this trend is not universal, and different 




 and rat plantaris 
muscle 
[219]
 or not changed in rat soleus 
[219]
 with age. Evaluations of the capacity to activate AMPK in 




, or unaltered 
[176,218]
  with age depending on the tissue and stimulus applied (i.e. AICAR, exercise). 
Although there was a trend towards a lower fold-increase in AMPK activation in rings of aged animals 
treated with AICAR versus those of young (P(Thr172)-AMPK and P(Ser79)-ACC), this effect did not 
reach statistical significance in our study (Figure 5-4E and F). There is no clear explanation to reconcile 
the discrepancies in currently available data, although factors such as tissue, stimulus and species 
differences or the stage of progression through the aging process likely account for some of the variation. 
More research will be necessary to reconcile the disparity in these findings and to provide insight 




Relaxation of aortic rings from both young and aged rats to AICAR is mediated partly by the 
endothelium and in part by direct effects on the vascular smooth muscle (Figure 5-2A and B). These 
results are consistent with our previous observations in healthy and hypertensive rat aorta
[73]
, and with 
observations by others that have demonstrated endothelium- 
[13,15]
 and vascular smooth muscle-dependent 
[82,181]
 relaxation to AMPK-activating stimuli. Further analyses of the relaxation responses to AICAR 
(Figure 5-2C & D) demonstrate that the relative contribution of the endothelium to the vasodilatory 
response to AMPK activation is dependent on the strength of the stimulus (i.e. relaxation at lower 
[AICAR] or submaximal relaxation is more endothelium-dependent than at higher [AICAR] or maximal 
relaxation in aorta of young and aged rats), and highlight the necessity for interpreting the endothelial and 
vascular smooth muscle contributions to functional responses in the context of the potency of the stimulus 
applied. The enhanced relaxation response to AICAR exhibited in aortic rings of aged versus young rats 
(both with and without endothelium) may be unmasking a compensatory adaptation of aged arteries in 
attempt to maintain responsiveness in the presence of other dysfunctional vasomotor pathways, or 
alternatively, could represent the outcome of a dysregulated vasomotor signalling process(es). The 
functional ramifications of this observation in a physiological context are unclear and will require further 
study to determine whether the enhanced vasodilation of aged arteries to AMPK stimulation is a 
beneficial adaptation or a manifestation of dysfunction in aging arteries.  
Examination of the mechanisms responsible for the endothelium-dependent component of the 
vasodilation to AICAR revealed that this response is NO-dependent in aortic rings of both young and 
aged rats, as it was abolished in both young and aged E+ vessels treated with L-NAME (Figure 5-3). A 
number of other studies have shown that the endothelium-dependent relaxation to AMPK activation is 
NO-mediated 
[13,15,73]
, and this is consistent with in vitro cell culture and biochemical experiments that 
have suggested a number of different mechanisms through which AMPK may activate endothelial nitric 
oxide synthase and improve NO bioavailability 
[27,29,30,44,145]
. Activated AMPK could increase NO 
production/bioavailability by phosphorylating eNOS at activation sites serine 1179 
[27,29,44,145]





, improving the associating of eNOS with HSP90 
[44,189]
, promoting deacetylation of eNOS by SIRT1
[30]
 
or through other yet unidentified mechanisms. Direct relaxation of the vascular smooth muscle by 
AICAR/AMPK may result from decreased sensitivity of MLCK to intracellular calcium (by 
phosporylation at serine 815) 
[116]
, and/or inhibition of the RhoA-Rho kinase pathway 
[242]
, both of which 
would presumably decrease vessel tone. The contribution of these mechanisms was not evaluated here, 
and more work is needed to verify which or if any of these possible mechanisms account for the 
endothelium,-NO-mediated and vascular smooth muscle-dependent functional responses observed in vitro 
in isolated vessels, or in vivo. The contribution of the endothelium, NO, and vascular smooth muscle to 
the vasorelaxation generated by AICAR is independent of the pre-constrictory agent used, as similar 
results were obtained when vessels were contracted with either KCl (vascular smooth muscle depolarizing 
agent; Figure 5-3) or phenylephrine (α-adrenergic receptor agonist; Supplemental Figures D1 and D2). 
We also evaluated the effect of the COX inhibitor indomethacin on AICAR-induced relaxation, as 
enhanced endothelium- and COX-dependent contractions have been observed in conduit arteries of aged 
animals 
[1,128,129]
, and in previous work we have shown that AICAR induces relaxation in part by 
suppression of the enhanced endothelium-dependent contractions in aorta of SHR 
[73]
. Inhibition of COX 
did not alter relaxation to AICAR in aorta of young or aged animals pre-contracted with KCl (Figure 5-3) 
or phenylephrine (Supplemental Figure D2). However, endothelium- and COX-dependent contractions 
were not particularly robust in aorta of this cohort of aged rats (Supplemental Figure D3) which may 
explain the lack of COX-mediated response in aged rat aorta in this study.  
Metformin and resveratrol both activate AMPK in a number of tissue types 
[24,44,160,223,258,263], and 
stimulate relaxation of isolated arteries in different studies 
[10,28,134,154]
. Herein metformin generated 
modest relaxation that was associated with a small but significant increase in markers of AMPK 
activation, and both of these responses were lower in magnitude compared to those generated by AICAR. 
Modest activation of AMPK with metformin in comparison with that induced by AICAR was not 
unexpected, as others have observed similar results in rodent aorta 
[145,258]




robust vasodilatory responses, no indication of AMPK activation could be found in aortic rings from 
these experiments, and therefore alternative mechanisms must account for the vasodilation to this agonist 
in aorta of aged rats. While activation of AMPK by resveratrol has been previously reported in 
endothelial cells and other tissues, the magnitude of this effect in endothelial cells is only ~2-fold 
[140]
, and 
resveratrol-mediated AMPK activation has not been observed in vascular smooth muscle in any prior 
studies to our knowledge. In examining the functional responses to these agonists, enhanced relaxation 
was also observed to metformin or resveratrol in aged versus young vessels (similarly to responses 
generated by AICAR, Figure 5-2 and Figure 5-5). However, since the robust relaxation to resveratrol 
occurred in the absence of AMPK activation, it seems as though greater sensitivity of a common 
downstream signalling target likely accounts for the enhanced vasodilatory propensity of aged arteries 
rather than a relationship to AMPK activation in particular. Aged arteries often display reduced 
vasoreactivity in response to agonist stimulation (vasodilatory and vasoconstrictory) 
[46,140,149]
, although 
age-related changes in vascular reactivity are heterogeneous and responses to some agonists are unaltered 
[5,162]
 or enhanced  
[5,265]
 depending on the vascular bed studied. Further investigation will be required to 
decipher whether similar findings using AMPK activators are observed in other vascular beds of aged 
animals. 
The findings of this study could have several important implications for the physiological 
function of arteries in vivo and for the vasomotor dysfunction that occurs in aging arteries. Although we 
activate AMPK pharmacologically in vitro here, vascular AMPK can be activated acutely and/or 
















, hydrogen peroxide 
[52,118], and by interventions such as exercise [20,181,264] and caloric 
restriction 
[243]
. In situ activation of AMPK by these mechanisms may translate into acute AMPK-
mediated vasodilatory events, or support a more tonic vasodilatory phenotype. Since aging arteries 






, and with enhanced endothelium-dependent contractions, it is possible that the capacity 
to promote vasodilation via improving the activation status of AMPK acutely or chronically in vivo, may 
help offset/alleviate some of the characteristics associated with vasomotor dysfunction that manifest in 
arteries with age. Enhanced AMPK activation has been associated with improved vasomotor function in 
models where vascular dysfunction exists including in arteries of Otuska Long-Evans Tokushima fatty 
rats (a model of type II diabetes) 
[141,245]
 and in mouse aortas exposed to hyperglycemia 
[13]
. Therefore, 
AMPK may have potential as a therapeutic target for improving vascular function, and may be one of the 
mechanisms by which interventions such as exercise and caloric restriction that could improve the health 
of aging arteries. 
In summary, acute AMPK activation generates robust endothelium-dependent and endothelium-
independent relaxation in aorta of both young and aged rats, the endothelial component of which is NO-
mediated. Further study will be required to specify the intracellular signalling mechanisms that account 
for the endothelial and vascular smooth muscle relaxation to acute activation of AMPK, whether or not 
acute activation of AMPK is a mechanism of immediate relaxation in vivo, and if chronic AMPK 











5.7 Addendum to Study 4:  
 The addendum includes data collected in conjunction with this study but not included as part of 
the manuscript. These items include: 
Figure A5-1: Vasorelaxation to AICAR is both endothelium-dependent and –independent in aortic rings 
from young and aged rats pre-contracted with phenylephrine. These results demonstrate that 
vasorelaxation responses generated in the presence of phenylephrine pre-contraction are similar to those 
generated with potassium chloride pre-contraction. 
Figure A5-2: Mechanisms of AICAR-mediated relaxation in aortic rings from young and aged rats pre-
contracted with phenylephrine. These results demonstrate that vasorelaxation responses generated in the 
presence of phenylephrine pre-contraction are similar to those generated with potassium chloride pre-
contraction. 
Table A5-1: Pre-contracted tension of young and aged aortic rings to phenylephine. 
Figure A5-3: Endothelium-dependent contraction to acetylcholine in aorta of the aged male Sprague-
Dawley rats. These data demonstrate minimal endothelium-dependent contractions to acetylcholine in 
aorta of aged rats used in this study 
Figure A5-4: eNOS total protein content and phosphorylation of eNOS activation site serine 1177 
following exposure to AICAR in aortic rings of young and aged rats collected immediately following the 
AICAR dose-response vascular myography protocols. These data confirm removal of the endothelium in 
E- aortic rings used for the functional myography protocols. They also demonstrate (in a representative 





Figure A5-1. Vasorelaxation to AICAR is both endothelium-dependent and –independent in aortic 
rings from young and aged rats pre-contracted with phenylephrine. Relaxation responses of aortic 
rings from (A) young and (B) aged rats with (E+) or without (E-) endothelium following pre-contraction 
with phenylephrine (PE) to increasing concentrations of AICAR. Responses are expressed as mean 
percent relaxation from PE pre-contracted tension. n = 6-11 rings per group from different animals. * P < 






Figure A5-2. Mechanisms of AICAR-mediated relaxation in aortic rings from young and aged rats 
pre-contracted with phenylephrine. Aortic rings from (A,C) young and (B,D) aged rats were incubated 
with either NOS inhibitor L-NAME, cyclooxygenase inhibitor indomethacin (INDO), or L-NAME + 
INDO to determine the NO- and endoperoxide-dependency of relaxation responses to AICAR. Percent 
relaxation from pre-contracted tension to phenylephrine (PE) is displayed in rings from young and aged 
rats (A, B) with (E+) and (C,D) without (E-) endothelium. Young and Aged E+ and E- data from Figure 
D-1 has been repeated here for comparison (no drug pre-incubation, CON groups above). Each treatment 
was performed in aortic rings from every animal. n = 4-11 rings per group from different animals.  † P < 





Table A5-1. Pre-contracted tension of young and aged aortic rings to 10
-6.5
M phenylephrine  
 
Young (g) Aged (g) 
     E+ CON 1.8 ± 0.2 1.4 ± 0.1 
     E+ L-NAME 2.4 ± 0.1 2.4 ± 0.1 
     E+ INDO 2.1 ± 0.2 1.0 ± 0.2# 
     E+ L-NAME INDO 2.5 ± 0.1 1.8 ± 0.2 
     E- CON 2.0 ± 0.2 3.0 ± 0.2‡# 
     E- L-NAME 1.8 ± 0.1 2.8 ± 0.2†# 
     E- INDO 1.8 ± 0.2 2.8 ± 0.1‡¶ 
     E- L-NAME INDO 2.0 ± 0.3 2.9 ± 0.4† 
 
Data represents means ± s.e.m. n= 4 -11 rings per group. † P < 0.01, ‡ P < 0.001 versus E+ CON, # P < 






Figure A5-3. Endothelium-dependent contraction to acetylcholine in aorta of the aged male 
Sprague-Dawley rats used in this study. Endothelium-dependent contractions were elicited by exposing 
rings to increasing concentrations of acetylcholine (ACh) in the presence of NOS inhibitor L-NAME and 
in the absence of pre-contraction (quiescent rings). Values are expressed as mean percent of tension 






Figure A5-4. Total eNOS protein content in aortic rings of young and aged rats, and 
phosphorylation of eNOS activation site serine 1177 following exposure to AICAR. Aortic rings with 
(E+) and without (E-) endothelium were removed from the myography apparatus immediately following 
completion of the dose-response curve protocols, snap frozen and stored at -80
o
C for immunoblotting 
analyses. In panel A), eNOS total protein content was assessed in rings pre-contracted but not treated with 
AICAR (time controls, CON) to confirm denudation of E- rings. Panel B) displays a representative blot of 
the phosphorylation of eNOS at serine 1177 in homogenates of aortic rings that were removed from the 
myography apparatus immediately following completion of the AICAR dose-response curve (E+A and E-
A) or in time controls not exposed to AICAR (E+C and E-C). Data is expressed as mean ± s.e.m. Values 
from densitometry analyses were normalized such that the mean of the Young E+ CON group values are 
equal to 1 normalized unit. n = 4-6 (all samples run in duplicate). There was a significant main effect for 
the presence/absence of endothelium (P < 0.0001) in panel A, but significance symbols have been 
excluded for clarity. * P < 0.05 vs Young E+ CON. E+C; time control with endothelium, E+A; AICAR 








6.1 Summary of the main thesis findings and conclusions 
The main purpose of this thesis was to investigate the role of AMPK in the vasoregulation of 
functional arteries from health animals and dysfunctional arteries from hypertensive and aged rats. We 
addressed this objective by executing four studies, each with their own set of specific objectives designed 
to assess the effects of AMPK activation on vasomotor function, and in some cases, to investigate the 
mechanisms mediating these responses.  
The findings of this thesis represent a significant contribution to the information that is currently 
available regarding the role of AMPK in regulating vascular function. Our work extends the findings of 
isolated biochemical and cell culture experiments detailing the relationship between AMPK and NO into 
the context of an intact, functional vessel system to demonstrate that these findings have functional 
consequences for vascular tone. While the experiments we performed in healthy arteries alone are novel 
and contribute substantially to the current body of knowledge (AMPK-mediated relaxation has not been 
assessed at all in arteries of WKY and Sprague Dawley rats), we have added an additional layer of 
originality to the work by exploring AMPK-mediated vasomotor regulation in arteries of hypertensive 
and aged animals (until our experiments, there were no data published relating to AMPK and acute 
vasomotor function in dysfunctional arteries, and to date our data remain the only observations of AMPK-
mediated regulation of vascular tone in arteries from models of aging and essential hypertension). A 
summary of the key findings and conclusions from each study are presented in the section below, 
followed by overall conclusions and comparisons based on the thesis data collectively. Since the main 
findings have already been discussed in the experimental chapters, the intent of the following section is 
not to comprehensively cover all comparisons or re-discuss points that have already been dealt with 




and some findings that consistently contradicted our initial hypothesis and warrant the further comments 
provided below. 
Key Findings and Conclusions of Study 1 (Chapter 2): 
 Vasorelaxation occurs following acute activation of AMPK in isolated, precontracted aortic rings 
of both normotensive WKY and spontaneously hypertensive rats (SHR). 
 This relaxation response is comprised of both endothelium-dependent and -independent 
components in aorta of WKY and SHR, demonstrating that activation of AMPK in either the 
endothelium or vascular smooth muscle can influence relaxation. 
 In WKY aorta, the endothelium-dependent component of the relaxation response to AMPK 
activation is solely NO-mediated. In SHR aorta, relaxation to AMPK activation is both NO- and 
COX-dependent. We interpret relaxation responses of this nature to mean that AMPK activation 
generates relaxation by enhancing NO-bioactivity and inhibiting COX-dependent endothelium-
derived contractile activity. 
 Enhanced NO bioavailability was not due to phosphorylation of eNOS at Ser1177 by AMPK 
 Relaxation responses to AICAR are enhanced in aortic rings of SHR versus WKY. This was 
contrary to our original hypothesis that any vasomotor effects induced by AMPK would be 
depressed in arteries of SHR. 
Key Findings and Conclusions of Study 2 (Chapter 3): 
 Increased AMPK activation by AICAR pre-incubation suppresses endothelium-dependent 
contractions generated by acetylcholine in aorta of both WKY and SHR. 
 AMPK activation does not alter sensitivity of the vascular smooth muscle to TP-receptor 
stimulation in WKY or SHR aorta, suggesting that suppressed endothelium-dependent 
contractions to acetylcholine in these vessels do not originate from effects on the vascular smooth 




 AMPK activation suppresses the production/release of PGI2, the main vasoconstrictor prostanoid 
released by the endothelium in response to stimulation of endothelium-dependent contraction by 
acetylcholine, in aorta of both WKY and SHR. 
Key Findings and Conclusions of Study 3 (Chapter 4): 
 Basal AMPK activation is depressed in aorta of SHR versus WKY rats, suggesting dysregulation 
of AMPK signalling in conduit arteries of the hypertensive animals. Since AMPK can still be 
robustly activated by AICAR in SHR arteries, this depression in basal AMPK activity does not 
result from an inability to activate AMPK.  
 An acute injection of AMPK activator AICAR generates an acute, profound decrease in blood 
pressure of SHR that is partly NO-dependent, but does not affect blood pressure of WKY. For a 
number of reasons outlined in the discussion of Chapter 3, we put forward the hypothesis that this 
depression is due partly to altered vascular resistance.  
 Acute exposure to the AMPK activator AICAR generates dose-dependent relaxation of similar 
magnitude in WKY and SHR isolated mesenteric arteries, however these responses are more 
reliant on NO in SHR than in WKY. 
Key Findings and Conclusions of Study 4 (Chapter 5): 
 Acute activation of AMPK generates relaxation of pre-contracted aorta from both young and aged 
rats, although relaxation is enhanced in aged versus young vessels.  
 Vasorelaxation is partly endothelium-dependent and partially endothelium-independent in both 
young and aged rat aorta. 
 The endothelium-dependent component of relaxation to acute AMPK activation is solely NO-
mediated in aorta of both young and aged rat aorta.  
 Other known activators of AMPK, metformin and resveratrol, also generated relaxation of aged 




degree of AMPK activation achieved by this drug), and although relaxation to resveratrol was 
robust, AMPK activation to this compound was not detected in aorta of aged rats. Therefore 
metformin induces modest relaxation of aged rat aorta that could be AMPK dependent, while the 
vasodilatory effects of resveratrol are not associated with AMPK activation. 
 Relaxation responses to metformin and resveratrol are enhanced in pre-contracted aortic rings of 
aged versus young rats.  
 
General conclusions, comparisons and interpretation of the collective findings of the thesis   
Consistent with observations in other models of vascular dysfunction 
[10,135,179,243]
 and with our 
initial hypotheses, basal AMPK activation was dysregulated in arteries of SHR and aged rats compared to 
their respective controls. Depressed P-(Thr172)-AMPK to AMPK total protein ratios (relative to controls) 
were achieved differently in conduit aorta of SHR and aged rats compared to resistance mesenteric 
arteries of SHR (P(Thr172)-AMPK was depressed but AMPK total protein unaltered in SHR and aged 
Sprague-Dawley aorta, however AMPK total protein was elevated with no change in P(Thr172)-AMPK 
in SHR mesenteric arteries); further experiments will be required to determine if/how this heterogeneity 
extends to other vessel types, and to confirm the existence of AMPK dysregulation in other artery beds 
and models of hypertension and aging. The ability to pharmacologically activate AMPK was not different 
or slightly enhanced in aorta of SHR versus WKY, but tended to be impaired in aorta of aged rats 
compared with aorta of the young controls. More work will be needed to clarify whether these trends 
persist across vascular beds in hypertension and aging, and if similar responses occur to other AMPK-
activating stimuli (i.e. endogenous AMPK activators, or those that activate AMPK by different 
mechanisms).   
As expected, AMPK-mediated vasodilation was evoked in pre-contracted arteries of all models 
(healthy and hypertensive, young and aged rats) and artery types (conduit aorta and resistance mesenteric 




acute AMPK activation (partly endothelium-dependent relaxation mediated by NO and partly 
endothelium-independent relaxation by direct activation of the VSM) were conserved across models and 
vessel beds; the only exception to this convention was the additional contribution of a COX-dependent 
component in aorta of SHR (discussed further below). Interestingly, relaxation associated with AMPK 
activation (in arteries with and without functional endothelium) was consistently enhanced in conduit 
artery models of vasomotor dysfunction where AMPK is dysregulated (hypertension and aging). This 
finding was contrary to our initial hypothesis (that AMPK-mediated relaxation would be impaired in 
dysfunctional arteries of aged and hypertensive rats), and may represent a compensatory upregulation in 
sensitivity of AMPK-mediated vasorelaxation in the conduit artery vasculature to try to offset other 
enhanced vasoconstrictory influences that exist in dysfunctional vessels. In contrast to the conduit aorta of 
SHR and aged rats versus their respective controls (WKY and young rats), relaxation of precontracted 
mesenteric artery resistance vessels of SHR was not enhanced compared to those of WKY, once again 
highlighting the heterogeneity that exists in responses between artery types investigated in this thesis.  
The initial front-running hypothesis for the potential role of AMPK in endothelium-, NO-
dependent relaxation was based on cell culture experiments in which activation of AMPK was associated 
with increased phophorylation at eNOS activation site serine 1177 and concominant increases in NO-
production/bioavailability (this was the first reported interaction of AMPK with eNOS and the 
mechanism initially put forward). Although our data demonstrate that AMPK activation by AICAR does 
generate relaxation that is NO mediated, contrary to our initial hypothesis, phosphorylation of eNOS 
serine 1177 does not appear to be the mechanism involved. We are not alone in our inability to observe 
eNOS serine 1177 phosphorylation in conjunction with AMPK activation, as others have also found the 
two responses to be dissociated 
[69,146,147,203]
. Nonetheless, our immediate observations all agree with one 
another, and the disparate nature of observations across the literature may highlight differences that exist 
between isolated protein, cell culture, in vitro, and in vivo experimental conditions or arteries from 




bioavailability via mechanisms other than Ser1177 phosphorylation of eNOS. These findings expose the 
necessity for identification of new mechanisms, and validation of other currently existing potential 
candidates (already discussed in the individual experimental chapters), that may be responsible for the 
interaction of AMPK with NO-mediated signalling pathways. 
Our observations regarding the ability of AMPK to influence endothelium-dependent contractions 
in aorta of SHR is a particularly novel element of this thesis; only one other study to date has investigated 
the potential interaction between AMPK and this vascular signalling axis 
[141]
. Our work is also novel 
being the first to investigate the nature of the AMPK-EDCF interaction in aorta from a model of 
hypertension where over-active endothelium-dependent contractions are of major importance to vascular 
pathology and significant contributors to vasomotor dysfunction. We also present mechanisms (i.e. 
inhibition of endothelium- and COX-dependent contractions by AMPK activation involves suppression of 
COX-derived prostanoids in the endothelium rather than by direct effects on the VSM) that will help 
provide direction for further dissection of the specific processes in the COX-EDCF signalling axis 
influenced by AMPK. The ability of AMPK to also influence contractions in aorta of normotensive WKY 
is intriguing, and it would also be interesting to explore the potential role for AMPK as a regulator of 
endothelium- and COX-derived prostanoids in healthy arteries. In contrast to the findings in SHR aorta, 
there was no COX-dependent component to the relaxation generated by acute AMPK activation in 
precontracted aorta of aged animals. Although we may have expected to observe COX-mediated 
relaxation in aged aorta as we did in that of SHR since enhanced COX-dependent contractions have also 
been reported in arteries of aged male Sprague-Dawley rats compared to their younger counterparts 
[49]
, 
this effect was absent in aorta of the aged animals. In retrospect, these results are reasonable, as these 
contractions are still much weaker in magnitude in aged Sprague-Dawley rat aorta compared with those 
observed in SHR (endothelium- and COX-dependent contractions are ~ 75% of tension generated by 
exposure to 60mM KCl in aortic rings of SHR, Figure 3-1, while in aged arteries these contractions were 




contraction observed in aorta of WKY (~ 20% of tension generated by KCl, Figure 3-1) where the COX-
dependent component of relaxation to AICAR was also absent. Therefore, it is likely that the magnitude 
of the endothelium- and COX-dependent contractions in aorta of aged animals was not substantial enough 
to allow for an observable COX-mediated contribution of AICAR-induced relaxation. 
 
6.2 Potential physiological relevance, clinical implications and future directions 
The findings of this thesis have implications for both physiological processes, and the 
pathophysiology and treatment of vascular dysfunction. Our work provides insight that supports a 
potential role for AMPK in acute regulation of vascular tone in situ, a vasoprotective role for AMPK in 
maintaining appropriate vasomotor responsiveness in healthy vessels, and a potential therapeutic 
application for AMPK activation in alleviating the vasomotor dysfunction present in aging and 
cardiovascular disease states. Over the duration of data collection and thesis preparation, other studies 
have been published that, along with our findings, provide additional evidence that support the ability of 
AMPK to function in these capacities. Examples of potential physiological and clinical implications for 
AMPK-mediated regulation of vasomotor function, and supporting findings from recently published 
literature are provided below. Important future research questions prompted by our data, and in 
combination with the work of others, are also highlighted. 
1) Basal AMPK activation may be vasoprotective 
Studies in this thesis demonstrate that basal AMPK activation is depressed in arteries of both 
SHR and aged rats relative to those of WKY and young animals, respectively. Since reduced AMPK 
activation co-exists with vasomotor dysfunction in arteries of hypertensive and aged animals, it is 
conceivable that some level of basal AMPK activity assists in maintaining healthy vasomotor function 
and protecting against vascular insult in arteries of healthy animals, or helps attenuate the development of 






 and accentuated agonist-induced VSM contraction (these animals also have elevated 
blood pressure)
[242]
, and the presence of AMPK α1 partially preserves endothelial function in mice 
chronically treated with angiotensin II (i.e. endothelial dysfunction is more pronounced in AMPK α1 -/- 
mice chronically treated with angiotensin II than their wild-type counterparts)
[188]
. These observations that 
may suggest that AMPK plays a vasoprotective function under healthy conditions and protects against 
vasomotor impairments induced by cardiovascular perturbation/stress. It is difficult to determine if 
vasomotor results obtained using these particular whole body knockout models of these AMPK subunit 
isoforms are valid, since these models also exhibit other major metabolic and physiological abnormalities 
that could contribute to altered vasomotor phenotypes independently of the absence of these AMPK 
catalytic subunit isoforms in the vasculature (i.e. elevated circulating trigylcerides, glucose intolerance, 
etc. 
[3,72,126,239]
). It is also unclear to what extent compensatory upregulation of the remaining AMPK α 
subunit isoforms compensate for the absence of the other, and therefore potentially attenuate 
effects/compensate for the function of the absent isoform. Therefore, while these results do appear to 
support a protective role for AMPK in maintaining physiological vasomotor function, continued 
examination will be necessary to confirm and clarify the current findings. If AMPK does play a role in 
regulating physiological responses to stimuli under healthy conditions, it is possible that the depression of 
AMPK activation in the arteries of hypertensive and aged rats confers or contributes to the dysfunctional 
phenotype characteristic of these animals. 
2) A potential role for AMPK in acute physiological regulation of vascular tone in healthy arteries 
in situ 
The acute nature of AMPK-mediated vasodilation of isolated vessels in this thesis, demonstrates a 
key property of AMPK that may be relevant to regulation of vascular tone and blood flow to vasoactive 
stimuli under physiological conditions. As outlined in the introductory thesis rationale (section 1.7 
Specific rationale for thesis topic), AMPK can be activated by a number physiologically relevant 




acutely by shear stress [30,31,69,265], a stimulus that contributes to coordinating vasomotor responses during 
exercise. Several recent findings demonstrate the potential involvement of vascular AMPK in shear stress 
and exercise-mediated vascular effects in vivo 
[20,264,265]
, and that AMPK, in addition to other contributing 
kinases PKA, PI3K and Akt,  may represent a contributing and/or redundant mechanism for eNOS 
phosphorylation and activation in arteries during dynamic exercise 
[20,264]
. Thus, it may be that activation 
of endothelial AMPK by increased shear stress during exercise is a contributing mechanism to the 
vasodilation and increased blood flow to exercising skeletal muscle, and this will undoubtedly be an 
interesting question to address in future research. AMPK may also participate in mediating vasomotor 
responses initiated by factors released by exercising skeletal muscle (i.e. ROS, NO etc.) that aid in 
satisfying exercising muscle blood flow requirements, and in doing so, assist in coupling blood flow with 
metabolic demand, although this has not been investigated. Further experiments will also be necessary to 
determine if AMPK is involved in mediating acute vasomotor responses generated by other major 
vascular signalling systems that are important for physiological vasomotor responses like EDHFs (an area 
that is completely unexplored at present), and to uncover yet unidentified factors that may influence 
AMPK-mediated alterations in vascular tone. Thus, the basic acute vasodilatory response and associated 
mechanisms of AMPK activation demonstrated here may have implications for vasoactivity of a number 
of agonist and stimuli under physiological circumstances, and establish an important vasoactive property 
of AMPK.  
3) Activation of AMPK may improve vasomotor function in dysfunctional arteries of disease models 
The mechanisms associated with vasoactivity of AMPK in our acute manipulations are consistent 
with a vasoprotective role for AMPK. Our results indicate that activation of AMPK stimulates NO-
dependent relaxation, attenuates COX-dependent contractions, and relaxes VSM; all of these effects 
counter pathological phenotypes that contribute to dysfunction in arteries of hypertension, aging, but also 
in other conditions like diabetes. Thus, although our observations were generated under acute conditions, 




fashion to improve vasomotor function of dysfunctional arteries in a more chronic manner. This 
hypothesis is supported by a number of studies that have recently examined the vasomotor benefits of 







), and the ability of these treatments to alleviate endothelial 
dysfunction. These studies have not investigated the ability of AMPK to directly generate changes in 
vascular tone per se, but do suggest that activation of AMPK may play a role in regulating vascular 
function by improving the vasomotor responses generated in response to other vasoactive agonists in 
dysfunctional vessels. Supplementation of obese rats with α-lipoeic acid improves endothelial dysfunction 
in this model by AMPK-dependent mechanisms
[135]
, berberine treatment alleviates high-glucose mediated 
endothelial dysfunction and is associated with AMPK activation in mouse aortic rings
[245]
, and 
administration of metformin in vivo improves ACh-mediated relaxation and reduces endothelium-derived 
contracting factor (EDCF)-mediated contraction in aortic rings isolated from OLEFT rats (a model of type 
II diabetes)
[141]
. “Lifestyle” interventions such as caloric restriction and exercise both improve vascular 
AMPK activation
[20,57,167,206,264,265]
 and vasomotor function 
[51,85,125,183,192,200,262]
; thus AMPK may be one of 
the mechanisms mediating the vascular benefits of these interventions, and is yet another hypothesis that 
should be tested in future studies. Since AMPK is also an important regulator of metabolism, and can be a 
target for improving metabolic abnormalities in conditions such as obesity and diabetes (it is the primary 
target of the most commonly used anti-diabetic drug metformin), therapeutic strategies that target AMPK 
hold particular promise for conditions where cardiovascular and metabolic pathologies co-exist (i.e. 
diabetes mellitus and obesity), and AMPK may be a useful common target for both lifestyle and 
pharmaceutical interventions aimed at co-ordinately improving vascular and metabolic dysregulation. 
Thus, our observations that AMPK-mediated vascular signalling mechanisms are intact in 
dysfunctional arteries indirectly support therapeutic potential for AMPK in arterial disease. The studies 
cited above represent a growing body of evidence that supports a relationship between AMPK activation 




dysfunction (an area of research that virtually untouched) to evaluate the efficacy of AMPK activation on 
vasomotor function. It will also be important to determine an efficacious level of AMPK activation, as 
another line of evidence that has recently emerged in the literature demonstrating that sustained hyper-
activation of AMPK could also have deleterious effects on cell and tissue function (promoting cell 
senescence and apoptosis) 
[246,269]
. As is the case with many other biological signalling processes, it is 
likely that AMPK activation is also subject to a requirement for balance, with basal or intermittent periods 
of AMPK activation providing benefits, but sustained, excessive activation of AMPK leading to 
undesirable outcomes. This concept may be an important consideration as we continue to interpret data 
and investigate strategies relating to therapeutic intervention and the relationship between AMPK and 
vascular function.  
 
6.3 Limitations 
AMPK remains a difficult signalling system to study due to the multiplicity of its interactions in 
so many cell and whole body processes, and due to the limitations that exists with the research tools 
currently available to study this protein. Clearly new pharmacological tools with improved specificity for 
AMPK and tissue specific AMPK knockout models will aid in confirming and extending the results 





 double knockout models do not exist as they are not viable), 
metabolic dysregulation and other pathophysiological features may limit the use of these models for 
identifying a specific role for vascular AMPK in regulating vascular function (discussed already above). 
Recently developed AMPKβ1 knock out mice may be more useful for providing insight regarding the 
vascular effects of AMPK, as these animals should exhibit major reductions in endothelial AMPK activity 








Another limitation to the overall approach of this thesis is that these experiments mostly represent 
pharmacological manipulation of an isolated tissue system in vitro, and we cannot yet conclude as to 
whether or not the mechanisms and responses elucidated here are intact and contribute to physiological 
responses in vivo. Thus, as is always the case with these types of experiments, on-going investigations 
will be necessary to continue to validate a role for AMPK in regulating vascular tone in a physiological 
context. However, these in vitro pharmacological experiments are valuable for revealing and developing 
potential mechanisms, interactions and responses within a controlled experimental environment that can 
be put forward as working hypotheses for testing in vivo. In the case of AMPK, which regulates multiple 
processes in all cells and body tissues, isolated tissue preparations provide a particular advantage over in 
vivo manipulations, as they are not clouded by the inevitable influence on other potentially confounding 
metabolic processes, and allow for clear resolution of basic effects and mechanisms.  
 
6.4 Final Remarks 
The findings of this thesis contribute to a greater understanding of vasomotor signalling pathways 
by providing insight on a novel regulator of vascular tone in both healthy and dysfunctional arteries. In 
the experiments of this thesis, we have made a significant contribution towards understanding how 
AMPK moderates vascular tone in both healthy and dysfunctional arteries, and shed new insight into the 
mechanisms by which AMPK exerts its function. AMPK-mediated regulation of vascular tone is a new 
topic in vascular biology and we are only beginning to uncover the role of this enzyme, let alone to 
explore the potential physiological applications of this work. It is important that we continue to study the 
basic signalling mechanisms that modulate vascular tone, as understanding the fundamental mechanisms 
of vasomotor signalling pathways and their functional outcomes will allow us to broaden our 
understanding of regulation of vascular tone, blood flow and hemodynamic control, as well as to develop 
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